Compounds and methods for modulating splicing

Abstract

The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

Description

[0001] COMPOUNDS AND METHODS FOR MODULATING SPLICING CLAIM OF PRIORITY This application claims priority to U.S. Application No.63 / 472,590, filed on June 12, 2023. The entire contents of the foregoing application are incorporated herein by reference in their entirety. BACKGROUND Alternative splicing is a major source of protein diversity in higher eukaryotes and is frequently regulated in a tissue-specific or development stage-specific manner. Disease associated alternative splicing patterns in pre-mRNAs are often mapped to changes in splice site signals or sequence motifs and regulatory splicing factors (Faustino and Cooper (2003), Genes Dev 17(4):419-37). Current therapies to modulate RNA expression involve oligonucleotide targeting and gene therapy; however, each of these modalities exhibit unique challenges as currently presented. As such, there is a need for new technologies to modulate RNA expression, including the development of small molecule compounds that target splicing. SUMMARY The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof. In an embodiment, the compounds described herein are compounds of Formula (I) (e.g., a compound of Formulas (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, or stereoisomers thereof. The present disclosure additionally provides methods of using the compounds of the invention (e.g., compounds of Formulas (I), (I-a), (I-b), (I-c), (I-d), (I-e), or (I- f)) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers thereof), and compositions thereof, e.g., to target, and in embodiments bind or form a complex with, a nucleic acid (e.g., a pre-mRNA or nucleic acid component of a small nuclear ribonucleoprotein (snRNP) or spliceosome), a protein (e.g., a protein component of an snRNP or spliceosome, e.g., a member of the splicing machinery, e.g., one or more of the U1, U2, U4, U5, U6, U11, U12, U4atac, U6atac snRNPs), or a combination thereof. In another aspect, the compounds described herein may be used to alter the composition or structure of a nucleic acid (e.g., a pre-mRNA or mRNA (e.g., a pre-mRNA and the mRNA which arises from the pre-mRNA), e.g., by increasing or decreasing splicing at a splice site. In some embodiments, increasing or decreasing splicing results in modulating the level of a gene product (e.g., an RNA or protein) produced. In another aspect, the compounds described herein may be used for the prevention and / or treatment of a disease, disorder, or condition, e.g., a disease, disorder or condition associated with splicing, e.g., alternative splicing. In some embodiments, the compounds described herein (e.g., compounds of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers thereof) and compositions thereof are used for the prevention and / or treatment of a proliferative disease, disorder, or condition (e.g., a disease, disorder, or condition characterized by unwanted cell proliferation, e.g., a cancer or a benign neoplasm) in a subject. In some embodiments, the compounds described herein (e.g., compounds of Formulas (I), (I-a), (I-ai), (I- b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers thereof) and compositions thereof are used for the prevention and / or treatment of a non-proliferative disease, disorder, or condition. In some embodiments, the compounds described herein (e.g., compounds of Formulas ((I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers thereof) and compositions thereof are used for the prevention and / or treatment of a neurological disease or disorder, an autoimmune disease or disorder, immunodeficiency disease or disorder, a lysosomal storage disease or disorder, a cardiovascular disease or disorder, a metabolic disease or disorder, a respiratory disease or disorder, a renal disease or disorder, or an infectious disease in a subject. In one aspect, the present disclosure provides compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, N, or N(R2c); Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N or N(R2c), and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1is C(R2d), C(R2d)(R2e), or N; Z2and Z3are each independently C or N; Z4is C(R2d) or N; Z5is C(R2d), C(R2d)(R2e), N, N(R2c), wherein the bonds within the ring containing Z1, Z2, Z3, Z4, and Z5are single bonds or double bounds depending on valence; L1and L2are each absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, - C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2- C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1- C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or - P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6- haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; wherein each C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, and cycloalkyl is optionally substituted with one or more R9; each R5is independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, cycloalkyl, heterocyclyl, –C(O)RD, or –S(O)xRD; wherein each alkyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or –ORA1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each RD, RE, and RFis independently hydrogen, deuterium, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1- C6alkylene-heteroaryl, or –NRB1RC1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; each R7is independently hydrogen, deuterium, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each R9is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, oxo, –ORA, – NRBRC, –C(O)RD, or –C(O)ORD; each RA1, RB1, and RC1is hydrogen, deuterium, or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In another aspect, the present disclosure provides pharmaceutical compositions comprising a compound of Formula (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I- c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, and optionally a pharmaceutically acceptable excipient. In an embodiment, the pharmaceutical compositions described herein include an effective amount (e.g., a therapeutically effective amount) of a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof. In another aspect, the present disclosure provides methods for modulating splicing, e.g., splicing of a nucleic acid (e.g., a DNA or RNA, e.g., a pre-mRNA) with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I- h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof. In another aspect, the present disclosure provides compositions for use in modulating splicing, e.g., splicing of a nucleic acid (e.g., a DNA or RNA, e.g., a pre-mRNA) with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I- a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof. Modulation of splicing may comprise impacting any step involved in splicing and may include an event upstream or downstream of a splicing event. For example, in some embodiments, the compound of Formula (I) binds to a target, e.g., a target nucleic acid (e.g., DNA or RNA, e.g., a precursor RNA, e.g., a pre-mRNA), a target protein, or combination thereof (e.g., an snRNP and a pre- mRNA). A target may include a splice site in a pre-mRNA or a component of the splicing machinery, such as the U1 snRNP. In some embodiments, the compound of Formula (I) alters a target nucleic acid (e.g., DNA or RNA, e.g., a precursor RNA, e.g., a pre-mRNA), target protein, or combination thereof. In some embodiments, the compound of Formula (I) increases or decreases splicing at a splice site on a target nucleic acid (e.g., an RNA, e.g., a precursor RNA, e.g., a pre-mRNA) by about 0.5% or more (e.g., about 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more), relative to a reference (e.g., the absence of a compound of Formula (I) e.g., in a healthy or diseased cell or tissue). In some embodiments, the presence of a compound of Formula (I) results an increase or decrease of transcription of a target nucleic acid (e.g., an RNA) by about 0.5% or more (e.g., about 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more), relative to a reference (e.g., the absence of a compound of Formula (I), e.g., in a healthy or diseased cell or tissue). In another aspect, the present disclosure provides methods for preventing and / or treating a disease, disorder, or condition in a subject by administering a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or related compositions. In some embodiments, the disease or disorder entails unwanted or aberrant splicing. In some embodiments, the disease or disorder is a proliferative disease, disorder, or condition. Exemplary proliferative diseases include cancer, a benign neoplasm, or angiogenesis. In other embodiments, the present disclosure provides methods for treating and / or preventing a non-proliferative disease, disorder, or condition. In still other embodiments, the present disclosure provides methods for treating and / or preventing a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease. In another aspect, the present disclosure provides methods of down-regulating the expression of (e.g., the level of or the rate of production of) a target protein with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I- h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof in a biological sample or subject. In another aspect, the present disclosure provides methods of up-regulating the expression of (e.g., the level of or the rate of production of) a target protein with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof in a biological sample or subject. In another aspect, the present disclosure provides methods of altering the isoform of a target protein with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof in a biological sample or subject. Another aspect of the disclosure relates to methods of inhibiting the activity of a target protein in a biological sample or subject. In some embodiments, administration of a compound of Formula (I) to a biological sample, a cell, or a subject comprises inhibition of cell growth or induction of cell death. In another aspect, the present disclosure provides compositions for use in preventing and / or treating a disease, disorder, or condition in a subject by administering a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I- h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or related compositions. In some embodiments, the disease or disorder entails unwanted or aberrant splicing. In some embodiments, the disease or disorder is a proliferative disease, disorder, or condition. Exemplary proliferative diseases include cancer, a benign neoplasm, or angiogenesis. In other embodiments, the present disclosure provides methods for treating and / or preventing a non-proliferative disease, disorder, or condition. In still other embodiments, the present disclosure provides methods for treating and / or preventing a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease. In another aspect, the present disclosure provides compositions for use in down-regulating the expression of (e.g., the level of or the rate of production of) a target protein with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof in a biological sample or subject. In another aspect, the present disclosure provides compositions for use in up-regulating the expression of (e.g., the level of or the rate of production of) a target protein with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I- h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof in a biological sample or subject. In another aspect, the present disclosure provides compositions for use in altering the isoform of a target protein with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof in a biological sample or subject. Another aspect of the disclosure relates to compositions for use in inhibiting the activity of a target protein in a biological sample or subject. In some embodiments, administration of a compound of Formula (I) to a biological sample, a cell, or a subject comprises inhibition of cell growth or induction of cell death. In another aspect, the present disclosure features kits comprising a container with a compound of Formulas (I) (e.g., a compound of Formulas (I), (I-a), (I-ai), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j). (I-k), (I-l), (I-m), or (I-n)) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer thereof, or a pharmaceutical composition thereof. In certain embodiments, the kits described herein further include instructions for administering the compound of Formula (I) or the pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer thereof, or the pharmaceutical composition thereof. The details of one or more embodiments of the invention are set forth herein. Other features, objects, and advantages of the invention will be apparent from the Detailed Description, the Examples, and the Claims. DETAILED DESCRIPTION Selected Chemical Definitions Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March’s Advanced Organic Chemistry, 5thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rdEdition, Cambridge University Press, Cambridge, 1987. The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts. When a range of values is listed, it is intended to encompass each value and sub–range within the range. For example “C1-C6alkyl” is intended to encompass, C1, C2, C3, C4, C5, C6, C1- C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6alkyl. The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention. As used herein, “alkyl” refers to a radical of a straight–chain or branched saturated hydrocarbon group having from 1 to 24 carbon atoms (“C1-C24alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-C12alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C1-C8alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C1-C6alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-C6alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C1alkyl”). Examples of C1- C6alkyl groups include methyl (C1), ethyl (C2), n–propyl (C3), isopropyl (C3), n–butyl (C4), tert– butyl (C4), sec–butyl (C4), iso–butyl (C4), n–pentyl (C5), 3–pentanyl (C5), amyl (C5), neopentyl (C5), 3–methyl–2–butanyl (C5), tertiary amyl (C5), and n–hexyl (C6). Additional examples of alkyl groups include n–heptyl (C7), n–octyl (C8) and the like. Each instance of an alkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkyl group is unsubstituted C1–C10alkyl (e.g., –CH3). In certain embodiments, the alkyl group is substituted C1–C6alkyl. As used herein, “alkenyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon–carbon double bonds, and no triple bonds (“C2-C24alkenyl”). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-C10alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2-C8alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2-C6alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C2alkenyl”). The one or more carbon–carbon double bonds can be internal (such as in 2–butenyl) or terminal (such as in 1– butenyl). Examples of C2-C4alkenyl groups include ethenyl (C2), 1–propenyl (C3), 2–propenyl (C3), 1–butenyl (C4), 2–butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6alkenyl groups include the aforementioned C2–4alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Each instance of an alkenyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkenyl group is unsubstituted C1– C10alkenyl. In certain embodiments, the alkenyl group is substituted C2–C6alkenyl. As used herein, the term “alkynyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon–carbon triple bonds (“C2-C24alkenyl”). In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2-C10alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C2-C8alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2-C6alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C2alkynyl”). The one or more carbon– carbon triple bonds can be internal (such as in 2–butynyl) or terminal (such as in 1–butynyl). Examples of C2-C4alkynyl groups include ethynyl (C2), 1–propynyl (C3), 2–propynyl (C3), 1– butynyl (C4), 2–butynyl (C4), and the like. Each instance of an alkynyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkynyl group is unsubstituted C2–10alkynyl. In certain embodiments, the alkynyl group is substituted C2–6alkynyl. As used herein, the term "haloalkyl," refers to a non-cyclic stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one halogen selected from the group consisting of F, Cl, Br, and I. The halogen(s) F, Cl, Br, and I may be placed at any position of the haloalkyl group. Exemplary haloalkyl groups include, but are not limited to: -CF3, -CCl3, -CH2-CF3, -CH2-CCl3, -CH2-CBr3, -CH2-CI3, -CH2-CH2-CH(CF3)-CH3, - CH2-CH2-CH(Br)-CH3, and -CH2-CH=CH-CH2-CF3. Each instance of a haloalkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted haloalkyl”) or substituted (a “substituted haloalkyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent As used herein, the term "heteroalkyl," refers to a non-cyclic stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N, P, S, and Si may be placed at any position of the heteroalkyl group. Exemplary heteroalkyl groups include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH- CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, - CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -O-CH3, and -O-CH2- CH3. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3and -CH2-O-Si(CH3)3. Where "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as –CH2O, –NRCRD, or the like, it will be understood that the terms heteroalkyl and –CH2O or –NRCRDare not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as –CH2O, –NRCRD, or the like. Each instance of a heteroalkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent As used herein, “aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6-C14aryl”). In some embodiments, an aryl group has six ring carbon atoms (“C6aryl”; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“C10aryl”; e.g., naphthyl such as 1–naphthyl and 2–naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“C14aryl”; e.g., anthracyl). An aryl group may be described as, e.g., a C6-C10- membered aryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety. Aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Each instance of an aryl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is unsubstituted C6-C14aryl. In certain embodiments, the aryl group is substituted C6-C14aryl. As used herein, “heteroaryl” refers to a radical of a 5–10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5–10 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl / heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2–indolyl) or the ring that does not contain a heteroatom (e.g., 5–indolyl). A heteroaryl group may be described as, e.g., a 6-10-membered heteroaryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety. Each instance of a heteroaryl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent Exemplary 5–membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5–membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5–membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5–membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6–membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl. Exemplary 6–membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6– membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7–membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6– bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6–bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Other exemplary heteroaryl groups include heme and heme derivatives. As used herein, “cycloalkyl” refers to a radical of a non–aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C3-C10cycloalkyl”) and zero heteroatoms in the non–aromatic ring system. In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C3-C8cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-C6cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-C6cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-C10cycloalkyl”). A cycloalkyl group may be described as, e.g., a C4-C7-membered cycloalkyl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety. Exemplary C3-C6cycloalkyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-C8cycloalkyl groups include, without limitation, the aforementioned C3-C6cycloalkyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), cubanyl (C8), bicyclo[1.1.1]pentanyl (C5), bicyclo[2.2.2]octanyl (C8), bicyclo[2.1.1]hexanyl (C6), bicyclo[3.1.1]heptanyl (C7), and the like. Exemplary C3-C10cycloalkyl groups include, without limitation, the aforementioned C3-C8cycloalkyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro–1H–indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like. As the foregoing examples illustrate, in certain embodiments, the cycloalkyl group is either monocyclic (“monocyclic cycloalkyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic cycloalkyl”) and can be saturated or can be partially unsaturated. “Cycloalkyl” also includes ring systems wherein the cycloalkyl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is on the cycloalkyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the cycloalkyl ring system. Each instance of a cycloalkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is unsubstituted C3-C10cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C3-C10cycloalkyl. “Heterocyclyl” as used herein refers to a radical of a 3– to 16–membered non–aromatic ring system having ring carbon atoms and 1 to 8 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3–16 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is either on the cycloalkyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. A heterocyclyl group may be described as, e.g., a 3-7-membered heterocyclyl, wherein the term “membered” refers to the non- hydrogen ring atoms, i.e., carbon, nitrogen, oxygen, sulfur, boron, phosphorus, and silicon, within the moiety. Each instance of heterocyclyl may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is unsubstituted 3–16 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3–16 membered heterocyclyl. Exemplary 3–membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4–membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5– membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl–2,5–dione. Exemplary 5–membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin–2–one. Exemplary 5–membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6– membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl (e.g., 2,2,6,6-tetramethylpiperidinyl), tetrahydropyranyl, dihydropyridinyl, pyridinonyl (e.g., 1-methylpyridin2-onyl), and thianyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, pyridazinonyl (2-methylpyridazin-3-onyl), pyrimidinonyl (e.g., 1-methylpyrimidin-2-onyl, 3- methylpyrimidin-4-onyl), dithianyl, dioxanyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary 5–membered heterocyclyl groups fused to a C6aryl ring (also referred to herein as a 5,6–bicyclic heterocyclyl ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 5–membered heterocyclyl groups fused to a heterocyclyl ring (also referred to herein as a 5,5–bicyclic heterocyclyl ring) include, without limitation, octahydropyrrolopyrrolyl (e.g., octahydropyrrolo[3,4-c]pyrrolyl), and the like. Exemplary 6-membered heterocyclyl groups fused to a heterocyclyl ring (also referred to as a 4,6-membered heterocyclyl ring) include, without limitation, diazaspirononanyl (e.g., 2,7- diazaspiro[3.5]nonanyl). Exemplary 6–membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6–bicyclic heterocyclyl ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. Exemplary 6–membered heterocyclyl groups fused to a cycloalkyl ring (also referred to herein as a 6,7-bicyclic heterocyclyl ring) include, without limitation, azabicyclooctanyl (e.g., (1,5)-8-azabicyclo[3.2.1]octanyl). Exemplary 6–membered heterocyclyl groups fused to a cycloalkyl ring (also referred to herein as a 6,8-bicyclic heterocyclyl ring) include, without limitation, azabicyclononanyl (e.g., 9- azabicyclo[3.3.1]nonanyl). The terms "alkylene," “alkenylene,” “alkynylene,” “haloalkylene,” “heteroalkylene,” “cycloalkylene,” or “heterocyclylene,” alone or as part of another substituent, mean, unless otherwise stated, a divalent radical derived from an alkyl, alkenyl, alkynyl, haloalkylene, heteroalkylene, cycloalkyl, or heterocyclyl respectively. For example, the term "alkenylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene. An alkylene, alkenylene, alkynylene, haloalkylene, heteroalkylene, cycloalkylene, or heterocyclylene group may be described as, e.g., a C1-C6-membered alkylene, C2-C6-membered alkenylene, C2-C6-membered alkynylene, C1-C6-membered haloalkylene, C1- C6-membered heteroalkylene, C3-C8-membered cycloalkylene, or C3-C8-membered heterocyclylene, wherein the term “membered” refers to the non-hydrogen atoms within the moiety. In the case of heteroalkylene and heterocyclylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula - C(O)2R’- may represent both -C(O)2R’- and –R’C(O)2-. As used herein, the terms “cyano” or “–CN” refer to a substituent having a carbon atom joined to a nitrogen atom by a triple bond, e.g., C≡N. As used herein, the terms “halogen” or “halo” refer to fluorine, chlorine, bromine or iodine. As used herein, the term “hydroxy” refers to –OH. As used herein, the term “nitro” refers to a substitutent having two oxygen atoms bound to a nitrogen atom, e.g., -NO2. As used herein, the term “nucleobase” as used herein, is a nitrogen-containing biological compounds found linked to a sugar within a nucleoside—the basic building blocks of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The primary, or naturally occurring, nucleobases are cytosine (DNA and RNA), guanine (DNA and RNA), adenine (DNA and RNA), thymine (DNA) and uracil (RNA), abbreviated as C, G, A, T, and U, respectively. Because A, G, C, and T appear in the DNA, these molecules are called DNA-bases; A, G, C, and U are called RNA-bases. Adenine and guanine belong to the double-ringed class of molecules called purines (abbreviated as R). Cytosine, thymine, and uracil are all pyrimidines. Other nucleobases that do not function as normal parts of the genetic code, are termed non-naturally occurring. In an embodiment, a nucleobase may be chemically modified, for example, with an alkyl (e.g., methyl), halo, -O-alkyl, or other modification. As used herein, the term “nucleic acid” refers to deoxyribonucleic acids (DNA) or ribonucleic acids (RNA) and polymers thereof in either single- or double-stranded form. The term “nucleic acid” includes a gene, cDNA, pre-mRNA, or an mRNA. In one embodiment, the nucleic acid molecule is synthetic (e.g., chemically synthesized) or recombinant. Unless specifically limited, the term encompasses nucleic acids containing analogues or derivatives of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementarity sequences as well as the sequence explicitly indicated. As used herein, “oxo” refers to a carbonyl, i.e., -C(O)-. The symbol as used herein in relation to a compound of Formula (I) refers to an attachment point to another moiety or functional group within the compound. Alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted. In general, the term “substituted”, whether preceded by the term “optionally” or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds, such as any of the substituents described herein that result in the formation of a stable compound. The present disclosure contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety. Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocyclyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring- forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring- forming substituents are attached to non-adjacent members of the base structure. The compounds provided herein may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to: cis- and trans-forms; E- and Z-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; α- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and half chair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms"). Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and / or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. In an embodiment, the stereochemistry depicted in a compound is relative rather than absolute. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw–Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p.268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). This disclosure additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers. As used herein, a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form. The term “enantiomerically pure” or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 99% by weight, more than 99.5% by weight, or more than 99.9% by weight, of the enantiomer. In certain embodiments, the weights are based upon total weight of all enantiomers or stereoisomers of the compound. In the compositions provided herein, an enantiomerically pure compound can be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising an enantiomerically pure R–compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R–compound. In certain embodiments, the enantiomerically pure R–compound in such compositions can, for example, comprise, at least about 95% by weight R–compound and at most about 5% by weight S–compound, by total weight of the compound. For example, a pharmaceutical composition comprising an enantiomerically pure S– compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S–compound. In certain embodiments, the enantiomerically pure S–compound in such compositions can, for example, comprise, at least about 95% by weight S–compound and at most about 5% by weight R–compound, by total weight of the compound. In some embodiments, a diastereomerically pure compound can be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising a diastereometerically pure exo compound can comprise, for example, about 90% excipient and about 10% diastereometerically pure exo compound. In certain embodiments, the diastereometerically pure exo compound in such compositions can, for example, comprise, at least about 95% by weight exo compound and at most about 5% by weight endo compound, by total weight of the compound. For example, a pharmaceutical composition comprising a diastereometerically pure endo compound can comprise, for example, about 90% excipient and about 10% diastereometerically pure endo compound. In certain embodiments, the diastereometerically pure endo compound in such compositions can, for example, comprise, at least about 95% by weight endo compound and at most about 5% by weight exo compound, by total weight of the compound. In some embodiments, an isomerically pure compound can be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising a isomerically pure exo compound can comprise, for example, about 90% excipient and about 10% isomerically pure exo compound. In certain embodiments, the isomerically pure exo compound in such compositions can, for example, comprise, at least about 95% by weight exo compound and at most about 5% by weight endo compound, by total weight of the compound. For example, a pharmaceutical composition comprising an isomerically pure endo compound can comprise, for example, about 90% excipient and about 10% isomerically pure endo compound. In certain embodiments, the isomerically pure endo compound in such compositions can, for example, comprise, at least about 95% by weight endo compound and at most about 5% by weight exo compound, by total weight of the compound. In certain embodiments, the active ingredient can be formulated with little or no excipient or carrier. Compound described herein may also comprise one or more isotopic substitutions. For example, H may be in any isotopic form, including1H,2H (D or deuterium), and3H (T or tritium); C may be in any isotopic form, including12C,13C, and14C; O may be in any isotopic form, including16O and18O; N may be in any isotopic form, including14N and15N; F may be in any isotopic form, including18F,19F, and the like. The term "pharmaceutically acceptable salt" is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al, Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. These salts may be prepared by methods known to those skilled in the art. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention. In addition to salt forms, the present disclosure provides compounds in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. The term “solvate” refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds of Formula (I) may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. “Solvate” encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates, and methanolates. The term “hydrate” refers to a compound which is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R·x H2O, wherein R is the compound and wherein x is a number greater than 0. A given compound may form more than one type of hydrates, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates ( R·0.5 H2O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates ( R·2 H2O) and hexahydrates ( R·6 H2O)). The term “tautomer” refers to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane that are likewise formed by treatment with acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest. Other Definitions The following definitions are more general terms used throughout the present disclosure. The articles “a” and “an” refer to one or more than one (e.g., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. The term “and / or” means either “and” or “or” unless indicated otherwise. The term “about” is used herein to mean within the typical ranges of tolerances in the art. For example, “about” can be understood as about 2 standard deviations from the mean. In certain embodiments, about means ±10%. In certain embodiments, about means ±5%. When about is present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range. “Acquire” or “acquiring” as used herein, refer to obtaining possession of a value, e.g., a numerical value, or image, or a physical entity (e.g., a sample), by “directly acquiring” or “indirectly acquiring” the value or physical entity. “Directly acquiring” means performing a process (e.g., performing an analytical method or protocol) to obtain the value or physical entity. “Indirectly acquiring” refers to receiving the value or physical entity from another party or source (e.g., a third-party laboratory that directly acquired the physical entity or value). Directly acquiring a value or physical entity includes performing a process that includes a physical change in a physical substance or the use of a machine or device. Examples of directly acquiring a value include obtaining a sample from a human subject. Directly acquiring a value includes performing a process that uses a machine or device, e.g., mass spectrometer to acquire mass spectrometry data. The terms “administer,” “administering,” or “administration,” as used herein refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing an inventive compound, or a pharmaceutical composition thereof. As used herein, the terms “condition,” “disease,” and “disorder” are used interchangeably. An “effective amount” of a compound of Formula (I) refers to an amount sufficient to elicit the desired biological response, i.e., treating the condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound of Formula (I) may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. An effective amount encompasses therapeutic and prophylactic treatment. For example, in treating cancer, an effective amount of an inventive compound may reduce the tumor burden or stop the growth or spread of a tumor. A “therapeutically effective amount” of a compound of Formula (I) is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. In some embodiments, a therapeutically effective amount is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of the condition, or enhances the therapeutic efficacy of another therapeutic agent. The terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprised therein. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Prevention,” “prevent,” and “preventing” as used herein refers to a treatment that comprises administering a therapy, e.g., administering a compound described herein (e.g., a compound of Formula (I)) prior to the onset of a disease, disorder, or condition in order to preclude the physical manifestation of said disease, disorder, or condition. In some embodiments, “prevention,” “prevent,” and “preventing” require that signs or symptoms of the disease, disorder, or condition have not yet developed or have not yet been observed. In some embodiments, treatment comprises prevention and in other embodiments it does not. A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle–aged adult, or senior adult)) and / or other non–human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and / or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and / or turkeys). In certain embodiments, the animal is a mammal. The animal may be a male or female and at any stage of development. A non–human animal may be a transgenic animal. As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of one or more of a symptom, manifestation, or underlying cause of a disease, disorder, or condition (e.g., as described herein), e.g., by administering a therapy, e.g., administering a compound described herein (e.g., a compound of Formula (I)). In an embodiment, treating comprises reducing, reversing, alleviating, delaying the onset of, or inhibiting the progress of a symptom of a disease, disorder, or condition. In an embodiment, treating comprises reducing, reversing, alleviating, delaying the onset of, or inhibiting the progress of a manifestation of a disease, disorder, or condition. In an embodiment, treating comprises reducing, reversing, alleviating, reducing, or delaying the onset of, an underlying cause of a disease, disorder, or condition. In some embodiments, “treatment,” “treat,” and “treating” require that signs or symptoms of the disease, disorder, or condition have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease or condition, e.g., in preventive treatment. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence. Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence. In some embodiments, treatment comprises prevention and in other embodiments it does not. A “proliferative disease” refers to a disease that occurs due to abnormal extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). A proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis; or 5) evasion of host immune surveillance and elimination of neoplastic cells. Exemplary proliferative diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, and angiogenesis. A “non-proliferative disease” refers to a disease that does not primarily extend through the abnormal multiplication of cells. A non-proliferative disease may be associated with any cell type or tissue type in a subject. Exemplary non-proliferative diseases include neurological diseases or disorders (e.g., a repeat expansion disease); autoimmune disease or disorders; immunodeficiency diseases or disorders; lysosomal storage diseases or disorders; inflammatory diseases or disorders; cardiovascular conditions, diseases, or disorders; metabolic diseases or disorders; respiratory conditions, diseases, or disorders; renal diseases or disorders; and infectious diseases. Compounds The present disclosure features a compound of Formula (I): or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, N, or N(R2c); Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N or N(R2c), and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1is C(R2d), C(R2d)(R2e), or N; Z2and Z3are each independently C or N; Z4is C(R2d) or N; Z5is C(R2d), C(R2d)(R2e), N, N(R2c), wherein the bonds within the ring containing Z1, Z2, Z3, Z4, and Z5are single bonds or double bounds depending on valence; L1and L2are each absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, - C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2- C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1- C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or - P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6- haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; wherein each C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, and cycloalkyl is optionally substituted with one or more R9; each R5is independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, cycloalkyl, heterocyclyl, –C(O)RD, or –S(O)xRD; wherein each alkyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or –ORA1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each RD, RE, and RFis independently hydrogen, deuterium, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1- C6alkylene-heteroaryl, or –NRB1RC1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; each R7is independently hydrogen, deuterium, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each R9is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, oxo, –ORA, – NRBRC, –C(O)RD, or –C(O)ORD; each RA1, RB1, and RC1is hydrogen, deuterium, or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3.

[0002] As generally described herein, A and B, are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1. In some embodiments, each of A and B are independently a monocyclic ring, e.g., monocyclic cycloalkyl, monocyclic heterocyclyl, monocyclic aryl, or monocyclic heteroaryl. The monocyclic ring may be saturated, partially unsaturated, or fully unsaturated (e.g., aromatic). In some embodiments, A or B are independently a monocyclic ring comprising between 3 and 10 ring atoms (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms). In some embodiments, A is a 4-membered monocyclic ring. In some embodiments, B is a 4-membered monocyclic ring. In some embodiments, A is a 5-membered monocyclic ring. In some embodiments, B is a 5-membered monocyclic ring. In some embodiments, A is a 6-membered monocyclic ring. In some embodiments, B is a 6-membered monocyclic ring. In some embodiments, A is a 7-membered monocyclic ring. In some embodiments, B is a 7-membered monocyclic ring. In some embodiments, A is an 8-membered monocyclic ring. In some embodiments, B is an 8-membered monocyclic ring. In some embodiments, A or B are independently a monocyclic ring optionally substituted with one or more R1. In some embodiments, A or B are independently a bicyclic ring, e.g., bicyclic cycloalkyl, bicyclic heterocyclyl, bicyclic aryl, or bicyclic heteroaryl. The bicyclic ring may be saturated, partially unsaturated, or fully unsaturated (e.g., aromatic). In some embodiments, A or B are independently a bicyclic ring comprising a fused, bridged, or spiro ring system. In some embodiments, A or B are independently a bicyclic ring comprising between 4 and 18 ring atoms (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 ring atoms). In some embodiments, A is a 6-membered bicyclic ring. In some embodiments, B is a 6-membered bicyclic ring. In some embodiments, A is a 7-membered bicyclic ring. In some embodiments, B is a 7-membered bicyclic ring. In some embodiments, A is an 8-membered bicyclic ring. In some embodiments, B is an 8-membered bicyclic ring. In some embodiments, A is a 9-membered bicyclic ring. In some embodiments, B is a 9-membered bicyclic ring. In some embodiments, A is a 10-membered bicyclic ring. In some embodiments, B is a 10-membered bicyclic ring. In some embodiments, A is an 11-membered bicyclic ring. In some embodiments, B is an 11-membered bicyclic ring. In some embodiments, A is a 12-membered bicyclic ring. In some embodiments, B is a 12- membered bicyclic ring. In some embodiments, A or B are independently a bicyclic ring optionally substituted with one or more R1. In some embodiments, A or B are independently a tricyclic ring, e.g., tricyclic cycloalkyl, tricyclic heterocyclyl, tricyclic aryl, or tricyclic heteroaryl. The tricyclic ring may be saturated, partially unsaturated, or fully unsaturated (e.g., aromatic). In some embodiments, A or B are independently a tricyclic ring that comprises a fused, bridged, or spiro ring system, or a combination thereof. In some embodiments, A or B are independently a tricyclic ring comprising between 6 and 24 ring atoms (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 ring atoms). In some embodiments, A is an 8-membered tricyclic ring. In some embodiments, B is an 8-membered tricyclic ring. In some embodiments, A is a 9-membered tricyclic ring. In some embodiments, B is a 9-membered tricyclic ring. In some embodiments, A is a 10-membered tricyclic ring. In some embodiments, B is a 10-membered tricyclic ring. In some embodiments, A or B are independently a tricyclic ring optionally substituted with one or more R1. In some embodiments, A or B are independently monocyclic cycloalkyl, monocyclic heterocyclyl, monocyclic aryl, or monocyclic heteroaryl. In some embodiments, A or B are independently bicyclic cycloalkyl, bicyclic heterocyclyl, bicyclic aryl, or bicyclic heteroaryl. In some embodiments, A or B are independently tricyclic cycloalkyl, tricyclic heterocyclyl, tricyclic aryl, or tricyclic heteroaryl. In some embodiments, A is monocyclic heterocyclyl. In some embodiments, B is monocyclic heterocyclyl. In some embodiments, A is bicyclic heterocyclyl. In some embodiments, B is bicyclic heterocyclyl. In some embodiments, A is monocyclic heteroaryl. In some embodiments, B is monocyclic heteroaryl. In some embodiments, A is bicyclic heteroaryl. In some embodiments, B is bicyclic heteroaryl. In some embodiments, A or B are independently a nitrogen-containing heterocyclyl, e.g., heterocyclyl comprising one or more nitrogen atom. The one or more nitrogen atom of the nitrogen-containing heterocyclyl may be at any position of the ring. In some embodiments, the nitrogen-containing heterocyclyl is monocyclic, bicyclic, or tricyclic. In some embodiments, A or B are independently heterocyclyl comprising at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 nitrogen atoms. In some embodiments, A is heterocyclyl comprising 1 nitrogen atom. In some embodiments, B is heterocyclyl comprising 1 nitrogen atom. In some embodiments, A is heterocyclyl comprising 2 nitrogen atoms. In some embodiments, B is heterocyclyl comprising 2 nitrogen atoms. In some embodiments, A is heterocyclyl comprising 3 nitrogen atoms. In some embodiments, B is heterocyclyl comprising 3 nitrogen atoms. In some embodiments, A is heterocyclyl comprising 4 nitrogen atoms. In some embodiments, B is heterocyclyl comprising 4 nitrogen atoms. In some embodiments, A or B are independently a nitrogen-containing heterocyclyl comprising one or more additional heteroatoms, e.g., one or more of oxygen, sulfur, boron, silicon, or phosphorus. In some embodiments, the one or more nitrogen of the nitrogen-containing heterocyclyl is substituted, e.g., with R1. In some embodiments, A or B are independently a nitrogen-containing heteroaryl, e.g., heteroaryl comprising one or more nitrogen atom. The one or more nitrogen atom of the nitrogen-containing heteroaryl may be at any position of the ring. In some embodiments, the nitrogen-containing heteroaryl is monocyclic, bicyclic, or tricyclic. In some embodiments, A or B are independently heteroaryl comprising at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 nitrogen atoms. In some embodiments, A is heteroaryl comprising 1 nitrogen atom. In some embodiments, B is heteroaryl comprising 1 nitrogen atom. In some embodiments, A is heteroaryl comprising 2 nitrogen atoms. In some embodiments, B is heteroaryl comprising 2 nitrogen atoms. In some embodiments, A is heteroaryl comprising 3 nitrogen atoms. In some embodiments, B is heteroaryl comprising 3 nitrogen atoms. In some embodiments, A is heteroaryl comprising 4 nitrogen atoms. In some embodiments, B is heteroaryl comprising 4 nitrogen atoms. In some embodiments, A or B are independently a nitrogen-containing heteroaryl comprising one or more additional heteroatoms, e.g., one or more of oxygen, sulfur, boron, silicon, or phosphorus. In some embodiments, the one or more nitrogen of the nitrogen- containing heteroaryl is substituted, e.g., with R1. In some embodiments, A is a 6-membered nitrogen-containing heterocyclyl, e.g., a 6- membered heterocyclyl comprising one or more nitrogen. In some embodiments, A is a 6- membered heterocyclyl comprising 1 nitrogen atom. In some embodiments, A is a 6-membered heterocyclyl comprising 2 nitrogen atoms. In some embodiments, A is a 6-membered heterocyclyl comprising 3 nitrogen atoms. In some embodiments, A is a 6-membered heterocyclyl comprising 4 nitrogen atoms. The one or more nitrogen atom of the 6-membered nitrogen-containing heterocyclyl may be at any position of the ring. In some embodiments, A is a 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R1. In some embodiments, the one or more nitrogen of the 6-membered nitrogen-containing heterocyclyl is substituted, e.g., with R1. In some embodiments, A is a 6-membered nitrogen- containing heterocyclyl comprising one or more additional heteroatoms, e.g., one or more of oxygen, sulfur, boron, silicon, or phosphorus. In some embodiments, B is a 5-membered nitrogen-containing heterocyclyl or heteroaryl, e.g., a 5-membered heterocyclyl or heteroaryl comprising one or more nitrogen. In some embodiments, B is a 5-membered heterocyclyl comprising 1 nitrogen atom. In some embodiments, B is a 5-membered heteroaryl comprising 1 nitrogen atom. In some embodiments, B is a 5-membered heterocyclyl comprising 2 nitrogen atoms. In some embodiments, B is a 5- membered heteroaryl comprising 2 nitrogen atoms. In some embodiments, B is a 5-membered heterocyclyl comprising 3 nitrogen atoms. In some embodiments, B is a 5-membered heteroaryl comprising 3 nitrogen atoms. The one or more nitrogen atom of the 5-membered nitrogen- containing heterocyclyl or heteroaryl may be at any position of the ring. In some embodiments, B is a 5-membered nitrogen-containing heterocyclyl optionally substituted with one or more R1. In some embodiments, B is a 5-membered nitrogen-containing heteroaryl optionally substituted with one or more R1. In some embodiments, the one or more nitrogen of the 5-membered nitrogen-containing heterocyclyl or heteroaryl is substituted, e.g., with R1. In some embodiments, B is a 5-membered nitrogen-containing heterocyclyl or heteroaryl comprising one or more additional heteroatoms, e.g., one or more of oxygen, sulfur, boron, silicon, or phosphorus. In some embodiments, B is a nitrogen-containing bicyclic heteroaryl (e.g., a 9-membered nitrogen-containing bicyclic heteroaryl), that is optionally substituted with one or more R1. In some embodiments, B is a 9-membered bicyclic heteroaryl comprising 1 nitrogen atom. In some embodiments, B is a 9-membered bicyclic heteroaryl comprising 2 nitrogen atoms. In some embodiments, B is a 9-membered bicyclic heteroaryl comprising 3 nitrogen atoms. In some embodiments, B is a 9-membered bicyclic heteroaryl comprising 4 nitrogen atoms. The one or more nitrogen atom of the 9-membered bicyclic heteroaryl may be at any position of the ring. In some embodiments, B is a 9-membered bicyclic heteroaryl substituted with one or more R1. In some embodiments, each of A and B are independently selected from:

[0003] each R1is as defined herein. In an embodiment, A and B are each independently a saturated, partially saturated, or unsaturated (e.g., aromatic) derivative of one of the rings described above. In an embodiment, A and B are each independently a stereoisomer of one of the rings described above. In some embodiments, each of A and B are independently selected from:

[0004] herein. In an embodiment, A and B are each independently a saturated, partially saturated, or unsaturated (e.g., aromatic) derivative of one of the rings described above. In an embodiment, A and B are each independently a stereoisomer of one of the rings described above. In some embodiments, one of A and B is independently a monocyclic heteroaryl or bicyclic heteroaryl, each of which is optionally substituted with one or more R1. In some embodiments, one of A and B is independently a bicyclic heteroaryl optionally substituted with one or more R1. In some embodiments, one of A and B is independently a nitrogen-containing heteroaryl optionally substituted with one or more R1. In some embodiments, one of A and B is independently selected from In some embodiments, one of A and B is independently selected from independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, one of A and B is independently independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, one of A and B is independently independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, one of A and B is independently independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, one of A and B is independently independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, one of A and B is independently independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, A is , wherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, A is each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, A is , wherein each R1ais independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, A is wherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, A is1a , wherein R e iasch independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, B is selected from

[0005] C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, B is , wherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, B is each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, B is , wherein each R1ais independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, B is wherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, B is Ra , wherein each1is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7. In some embodiments, one of A and B is independently selected from

[0006] In some embodiments, one of A and B is independently selected from

[0007] In some embodiments, one of A and B is independently selected from

[0008] In some embodiments, one of A and B is independently a monocyclic heterocyclyl or bicyclic heterocyclyl, each of which is optionally substituted with one or more R1. In some embodiments, one of A and B is independently a nitrogen-containing heterocyclyl optionally substituted with one or more R1. In some embodiments, one of A and B is independently a 4-8 membered heterocyclyl optionally substituted with one or more R1. In some embodiments, one In some embodiments, A is a monocyclic heterocyclyl or bicyclic heterocyclyl, each of which is optionally substituted with one or more R1. In some embodiments, A is a nitrogen- containing heterocyclyl optionally substituted with one or more R1. In some embodiments, A is a 4-8 membered heterocyclyl optionally substituted with one or more R1. In some embodiments, A In some embodiments, B is a monocyclic heterocyclyl or bicyclic heterocyclyl, each of which is optionally substituted with one or more R1. In some embodiments, B is a nitrogen- containing heterocyclyl optionally substituted with one or more R1. In some embodiments, B is a 4-8 membered heterocyclyl optionally substituted with one or more R1. In some embodiments, B

[0009] In some embodiments, of Formula (I), A is heteroaryl optionally substituted with 1-3 R1; B is heterocyclyl optionally substituted with 1-2 R1; X is C(R2a), N, or S; Y is C(R2a), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C or N; Z1is C(R2d), C(R2d)(R2e), or N; Z2is C or N; Z3C or N; Z4is C(R2d) or N; Z5is C(R2d) or N; wherein the bonds within the ring containing Z1, Z2, Z3, Z4, and Z5are single bonds or double bounds depending on valence; L1is absent, C1-C6-alkylene, -O-, -C(O)-, or -N(R3)- , wherein each alkylene is optionally substituted with one or more R4; L1is absent, -O-, or -N(R3)-; each R1is independently hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, – ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, -OC(O)RD, – S(O)xRD, , wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a cyclopropyl group optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, – C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen or C1-C6-alkyl; each R4is independently C1-C6- alkyl or cycloalkyl; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, or – NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. As generally described herein, L1and L2are each independently absent, or refer to a C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)- group, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4. In some embodiments, L1and L2are each independently absent, -N(R3)-, -O-, -N(R3)C(O)-, or - C(O)N(R3)-. In some embodiments, one of L1and L2is absent, -N(R3)-, -O-, -N(R3)C(O)-, or - C(O)N(R3)-. In some embodiments, one of L1and L2is absent. In some embodiments, one of L1and L2is -N(R3)-. In some embodiments, one of L1and L2is -O-. In some embodiments, one of L1and L2is -N(R3)C(O)-. In some embodiments, one of L1and L2is -C(O)N(R3)-. In some embodiments, L1is -N(R3)- and L2is absent. In some embodiments, L1is absent, C1-C6-alkylene, C1-C6-heteroalkylene, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4. In some embodiments, L1is absent, -N(R3)-, -O-, -N(R3)C(O)-, or -C(O)N(R3)-. In some embodiments, L1is absent or N(R3)- (e.g., -NH or -NCH3). In some embodiments, L1is absent. In some embodiments, L1is C1-C6-alkylene (e.g., C1- alkylene, C2-alkylene, C3-alkylene, C4-alkylene, C5-alkylene, or C6-alkylene). In some embodiments, L1is unsubstituted C1-C6alkylene. In some embodiments, L1is substituted C1-C6- alkylene, e.g., C1-C6alkylene substituted with one or more R4. In some embodiments, L1is C1- alkylene substituted with one R4. In some embodiments, L1is -CH2- (or methylene). In some embodiments, L1is -C(O)- (or carbonyl). In some embodiments, L1is C1-C6-heteroalkylene (e.g., C1-heteroalkylene, C2- heteroalkylene, C3-heteroalkylene, C4-heteroalkylene, C5-heteroalkylene, or C6-heteroalkylene). In some embodiments, L1is unsubstituted C1-C6heteroalkylene. In some embodiments, L1is C1- C6-heteroalkylene substituted with one or more R4. In some embodiments, the heteroalkylene comprises 1 or more heteroatoms. In some embodiments, the heteroalkylene comprises one or more of oxygen, sulfur, nitrogen, boron, silicon, or phosphorus. In some embodiments, L1is - N(R3)C(O)-. In some embodiments, L1is -C(O)N(R3)-. In some embodiments, L1is oxygen. In some embodiments, L1is nitrogen, which may be substituted with R3. In some embodiments, L1is nitrogen substituted with one R3. In some embodiments, L1is -N(R3)-. In some embodiments, L1is -N(CH3)-. In some embodiments, L1is -NH-. In some embodiments, L1is -O-. In some embodiments, L2is absent, C1-C6-alkylene, C1-C6-heteroalkylene, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4. In some embodiments, L2is absent, -N(R3)-, -O-, -N(R3)C(O)-, or -C(O)N(R3)-. In some embodiments, L2is absent or N(R3)- (e.g., -NH or -NCH3). In some embodiments, L2is absent. In some embodiments, L2is C1-C6-alkylene (e.g., C1- alkylene, C2-alkylene, C3-alkylene, C4-alkylene, C5-alkylene, or C6-alkylene). In some embodiments, L2is unsubstituted C1-C6alkylene. In some embodiments, L2is substituted C1-C6- alkylene, e.g., C1-C6alkylene substituted with one or more R4. In some embodiments, L2is C1- alkylene substituted with one R4. In some embodiments, L2is -CH2- (or methylene). In some embodiments, L2is -C(O)- (or carbonyl). In some embodiments, L2is C1-C6-heteroalkylene (e.g., C1-heteroalkylene, C2- heteroalkylene, C3-heteroalkylene, C4-heteroalkylene, C5-heteroalkylene, or C6-heteroalkylene). In some embodiments, L2is unsubstituted C1-C6heteroalkylene. In some embodiments, L2is C1- C6-heteroalkylene substituted with one or more R4. In some embodiments, the heteroalkylene comprises 1 or more heteroatoms. In some embodiments, the heteroalkylene comprises one or more of oxygen, sulfur, nitrogen, boron, silicon, or phosphorus. In some embodiments, L2is - N(R3)C(O)-. In some embodiments, L2is -C(O)N(R3)-. In some embodiments, L2is oxygen. In some embodiments, L2is nitrogen, which may be substituted with R3. In some embodiments, L2is nitrogen substituted with one R3. In some embodiments, L2is -N(R3)-. In some embodiments, L2is -N(CH3)-. In some embodiments, L2is -NH-. In some embodiments, L2is -O-. As generally described herein, X is selected from C(R2a), O, S, and N; In some embodiments, X is selected from C(R2a) or N. In some embodiments, X is N. In some embodiments, X is C(R2a). In some embodiments, X is oxygen. In some embodiments, X is sulfur. In some embodiments, X is nitrogen. As generally described herein, Y is selected from C(R2a), C(R2a)(R2b), N, N(R2c), O, and S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence. In some embodiments, Y is selected from C(R2a), N, O, and S. In some embodiments, Y is selected from C(R2a) and N. In some embodiments, Y is C(R2a)(R2b). In some embodiments, Y is C(R2a). In some embodiments, Y is N. In some embodiments, Y is N(R2c). In some embodiments, Y is O. In some embodiments, Y is S. In some embodiments, one of X and Y is N and the other of X and Y is C(R2a). In some embodiments, Y is N. In some embodiments, Y is C(R2a). As generally described herein, W is selected from C, C(R2a), and N, wherein R2ais as described herein. In some embodiments, W is selected from C or N. In some embodiments, W is C. In some embodiments, W is N. In some embodiments, R2ais hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5. In some embodiments, R2ais hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cycloalkyl, heterocyclyl, –ORA, –NRBRC, –NRBC(O)RD,–C(O)NRBRC, –C(O)RD, or –C(O)ORD, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5. In some embodiments, R2cis hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5. In some embodiments, R2cis hydrogen, C1-C6-alkyl, cycloalkyl, heterocyclyl,–C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5. In some embodiments, R2cis hydrogen, C1-C6-alkyl,–C(O)RD, or –C(O)ORD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5. As generally described herein, Z1, Z2, Z3, Z4, and Z5are each independently selected from C, C(R2d), and N, wherein R2dis as described herein, depending on valence. In some embodiments, Z1, Z4, and Z5are each independently selected from C(R2d) and N, wherein R2dis as described herein. In some embodiments, Z2and Z3are each independently selected from C and N. In some embodiments, at least one of Z1, Z2, Z3, Z4, and Z5are each independently N. In some embodiments, at least two of Z1, Z2, Z3, Z4, and Z5are each independently N. In some embodiments, Z1is N. In some embodiments, Z1is C(R2d). In some embodiments, Z2is N. In some embodiments, Z2is C. In some embodiments, Z3is N. In some embodiments, Z3is C. In some embodiments, Z4is N. In some embodiments, Z4is C(R2d). In some embodiments, Z5is N. In some embodiments, Z5is C(R2d). In some embodiments, Z1is N and each of Z2, Z3, Z4, and Z5are each independently C(R2d). In some embodiments, Z1, Z2, Z3, Z4, and Z5are each independently C(R2d). In some embodiments, Z1is C(R2d), and R2dis C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, – C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF. As generally described herein, R1is independently selected from hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or - P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5. In some embodiments, R1is hydrogen. In some embodiments, R1is C1-C6-alkyl. In some embodiments, R1is C2-C6-alkenyl. In some embodiments, R1is C2-C6-alkynyl. In some embodiments, R1is C1-C6-heteroalkyl. In some embodiments, R1is C1-C6-haloalkyl (e.g., -CF3). In some embodiments, R1is C1-alkyl (e.g., methyl). In some embodiments, R1is unsubstituted C1-C6-alkyl, unsubstituted C2-C6-alkenyl, unsubstituted C2-C6-alkynyl, unsubstituted C1-C6- heteroalkyl, or unsubstituted C1-C6-haloalkyl. In some embodiments, R1is C1-C6-alkyl substituted with one or more R5. In some embodiments, R1is C2-C6-alkenyl substituted with one or more R5. In some embodiments, R1is C2-C6-alkynyl substituted with one or more R5. In some embodiments, R1is C1-C6-heteroalkyl substituted with one or more R5. In some embodiments, R1is C1-C6-haloalkyl substituted with one or more R5. In some embodiments, R1is methyl. In some embodiments, R1is cycloalkyl (e.g., 3-7 membered cycloalkyl). In some embodiments, R1is heterocyclyl (e.g., 3-7 membered heterocyclyl). In some embodiments, R1is aryl. In some embodiments, R1is C1-C6alkylene-aryl (e.g., benzyl). In some embodiments, R1is C1-C6alkenylene-aryl. In some embodiments, R1is C1-C6alkylene-heteroaryl. In some embodiments, R1is heteroaryl. In some embodiments, R1is unsubstituted cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted C1-C6alkylene-aryl, unsubstituted C1-C6alkenylene-aryl, unsubstituted C1-C6alkylene-heteroaryl, or unsubstituted heteroaryl. In some embodiments, R1is cycloalkyl substituted with one or more R5. In some embodiments, R1is heterocyclyl substituted with one or more R5. In some embodiments, R1is aryl substituted with one or more R5. In some embodiments, R1is C1-C6alkylene-aryl substituted with one or more R5. In some embodiments, R1is C1-C6alkenylene-aryl substituted with one or more R5. In some embodiments, R1is C1-C6alkylene-heteroaryl substituted with one or more R5. In some embodiments, R1is heteroaryl substituted with one or more R5. In some embodiments, R1is –ORA. In some embodiments, R1is –NRBRC(e.g., NH2or NMe2). In some embodiments, R1is –NRBC(O)RD. In some embodiments, R1is–C(O)NRBRC. In some embodiments, R1is –C(O)RD. In some embodiments, R1is –C(O)ORD. In some embodiments, R1is–SRE. In some embodiments, R1is –S(O)xRD. In some embodiments, R1is halo, e.g., fluoro, chloro, bromo, or iodo. In some embodiments, R1is cyano. In some embodiments, R1is nitro (-NO2). In some embodiments, R1is oxo. In some embodiments, two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl. In some embodiments, two R1groups, together with the atoms to which they are attached, form a 3-7-membered heterocyclyl. In some embodiments, two R1groups, together with the atoms to which they are attached, form a 5- or 6-membered aryl. In some embodiments, two R1groups, together with the atoms to which they are attached, form a 5- or 6-membered heteroaryl. The cycloalkyl, heterocyclyl, aryl, or heteroaryl may be substituted with one or more R5. In some embodiments, R3is hydrogen. In some embodiments, R3is C1-C6alkyl. In some embodiments, R3is C1-C6haloalkyl. In some embodiments, R3is methyl. In some embodiments, R5is C1-C6-alkyl. In some embodiments, R5is C2-C6-alkenyl. In some embodiments, R5is C2-C6-alkynyl. In some embodiments, R5is C1-C6-heteroalkyl. In some embodiments, R5is C1-C6-haloalkyl. In some embodiments, R5is unsubstituted C1-C6-alkyl, unsubstituted C2-C6-alkenyl, unsubstituted C2-C6-alkynyl, unsubstituted C1-C6-haloalkyl, or unsubstituted C1-C6-heteroalkyl. In some embodiments, R5is C1-C6-alkyl substituted with one or more R6. In some embodiments, R5is C2-C6-alkenyl substituted with one or more R6. In some embodiments, R5is C2-C6-alkynyl substituted with one or more R6. In some embodiments, R5is C1-C6-haloalkyl substituted with one or more R6. In some embodiments, R5is C1-C6-heteroalkyl substituted with one or more R6. In some embodiments, R5is cycloalkyl. In some embodiments, R5is heterocyclyl. In some embodiments, R5is aryl. In some embodiments, R5is heteroaryl. In some embodiments, R5is unsubstituted cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl. In some embodiments, R5is cycloalkyl substituted with one or more R6. In some embodiments, R5is heterocyclyl substituted with one or more R6. In some embodiments, R5is aryl substituted with one or more R6. In some embodiments, R5is heteroaryl substituted with one or more R6. In some embodiments, R5is halo (e.g., fluoro, chloro, bromo, or iodo). In some embodiments, R5is cyano. In some embodiments, R5is oxo. In some embodiments, R5is –ORA. In some embodiments, R5is –NRBRC. In some embodiments, R5is –NRBC(O)RD. In some embodiments, R5is –NO2. In some embodiments, R5is –C(O)NRBRC. In some embodiments, R5is –C(O)RD. In some embodiments, R5is –C(O)ORD. In some embodiments, R5is –SRE. In some embodiments, R5is –S(O)xRD. In some embodiments, R6is C1-C6-alkyl. In some embodiments, R6is C1-C6-heteroalkyl. In some embodiments, R6is C1-C6-haloalkyl (e.g., –CF3or –CHF2). In some embodiments, R6is cycloalkyl. In some embodiments, R6is heterocyclyl. In some embodiments, R6is aryl. In some embodiments, R6is heteroaryl. In some embodiments, R6is halo. In some embodiments, R6is cyano. In some embodiments, R6is oxo. In some embodiments, R6is –ORA. In some embodiments, RAis hydrogen. In some embodiments, RAis C1-C6alkyl (e.g., methyl). In some embodiments, RAis C1-C6haloalkyl. In some embodiments, RAis aryl. In some embodiments, RAis heteroaryl. In some embodiments, RAis C1-C6alkylene-aryl (e.g., benzyl). In some embodiments, RAis C1-C6alkylene-heteroaryl. In some embodiments, RAis C(O)RD. In some embodiments, RAis –S(O)xRD. In some embodiments, RB, RC, or both are independently hydrogen, C1-C6-alkyl, C1-C6- heteroalkyl, cycloalkyl, heterocyclyl, or –ORA. In some embodiments, each of RBand RCis independently hydrogen. In some embodiments, each of RBand RCis independently C1-C6alkyl. In some embodiments, one of RBand RCis hydrogen, and the other of RBand RCis C1-C6alkyl. In some embodiments, RBand RCtogether with the atom to which they are attached form a 3-7- membered heterocyclyl ring optionally substituted with one or more of R7(e.g., 1, 2, or 3 R7). In some embodiments, RDis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl (e.g., benzyl), or C1-C6alkylene-heteroaryl. In some embodiments, RDis independently hydrogen. In some embodiments, RDis independently C1-C6alkyl. In some embodiments, RDis hydrogen. In some embodiments, RDis C1-C6alkyl (e.g., methyl). In some embodiments, RDis C1-C6heteroalkyl. In some embodiments, RDis C1-C6haloalkyl. In some embodiments, RDis cycloalkyl. In some embodiments, RDis heterocyclyl. In some embodiments, RDis aryl. In some embodiments, RDis heteroaryl. In some embodiments, RDis C1-C6alkylene-aryl (e.g., benzyl). In some embodiments, RDis C1-C6alkylene-heteroaryl. In some embodiments, x is an integer between 0 and 2 (e.g., 0, 1, or 2). In some embodiments, x is 0. In some embodiments, x is 1. In some embodiments, x is 2. In some embodiments, the compound of Formula (I) is a compound of Formula (I-a):

[0010] (I-a), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, or N; Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1is C(R2d), C(R2d)(R2e), or N; Z2and Z3are each ndependently C or N; Z4is C(R2d) or N; Z5is C(R2d), C(R2d)(R2e), N, N(R2c), wherein the bonds within the ring containing Z1, Z2, Z3, Z4, and Z5are single bonds or double bounds depending on valence; L1and L2are each absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, - N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b,R2d, R2eare each independently hydrogen, C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, – C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, – ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, or – NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, the compound of Formula (I) is a compound of Formula (I-ai): (I-ai), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S; Z1, Z4, and Z5are each independently C(R2d) or N; Z2and Z3are each independently C or N; L1and L2are each independently absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene- heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, – C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3- 7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, and R2dare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, cycloalkyl, heterocyclyl, –C(O)RD, or –S(O)xRD; wherein each alkyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or –ORA1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each RD, RE, and RFis independently hydrogen, deuterium, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1- C6alkylene-heteroaryl, or –NRB1RC1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; each R7is independently hydrogen, deuterium, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each R9is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, oxo, –ORA, – NRBRC, –C(O)RD, or –C(O)ORD; each RA1, RB1, and RC1is hydrogen, deuterium, or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments of Formula (I-ai), Z1, Z2, Z3, Z4, and Z5are each independently selected from C, C(R2d), and N, wherein R2dis as described herein, depending on valence. In some embodiments, Z1, Z4, and Z5are each independently selected from C(R2d) and N, wherein R2dis as described herein. In some embodiments, Z2and Z3are each independently selected from C and N. In some embodiments, at least one of Z1, Z2, Z3, Z4, and Z5are each independently N. In some embodiments, at least two of Z1, Z2, Z3, Z4, and Z5are each independently N. In some embodiments of Formula (I-ai), Z1is N. In some embodiments of Formula (I-ai), Z1is C(R2d). In some embodiments of Formula (I-ai), Z2is N. In some embodiments of Formula (I-ai), Z2is C. In some embodiments of Formula (I-ai), Z3is N. In some embodiments of Formula (I-ai), Z3is C. In some embodiments of Formula (I-ai), Z4is N. In some embodiments of Formula (I-ai), Z4is C(R2d). In some embodiments of Formula (I-ai), Z5is N. In some embodiments of Formula (I-ai), Z5is C(R2d). In some embodiments of Formula (I-ai), X is selected from C(R2a) or N. In some embodiments of Formula (I-ai), X is N. In some embodiments of Formula (I-ai), X is C(R2a). In some embodiments of Formula (I-ai), X is oxygen. In some embodiments of Formula (I-ai), X is sulfur. In some embodiments of Formula (I-ai), X is nitrogen. In some embodiments, of Formula (I-a), one of A and B is independently selected from In some embodiments, of Formula (I-a), one of A and B is independently selected from:

[0011]

[0012] 

[0013] In some embodiments, of Formula (I-a), one of A and B is independently selected from

[0014] In some embodiments, of Formula (I-a), one of A and B is independently selected from:

[0015] In some embodiments, of Formula (I-a), one of L1and L2is selected from: C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-a), one of L1and L2is C1-C6-alkyl. In some embodiments, of Formula (I-a), one of L1and L2is C1-C6-heteroalkyl. In some embodiments, of Formula (I-a), one of L1and L2is C1-C6- haloalkyl. In some embodiments, of Formula (I-a), one of L1and L2is -N(R3)-. In some embodiments, of Formula (I-a), one of L1and L2is -O-. In some embodiments, of Formula (I-a), one of L1and L2is -S-. In some embodiments, of Formula (I-a), one of L1and L2is –C(O)RD. In some embodiments of Formula (I-a), R2cis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-a), R2cis hydrogen. In some embodiments of Formula (I-a), R2cis C1-C6-alkyl. In some embodiments of Formula (I-a), R2cis C1-C6- heteroalkyl. In some embodiments of Formula (I-a), R2cis C1-C6-haloalkyl. In some embodiments of Formula (I-a), R2cis halo. In some embodiments of Formula (I-a), R2cis cyano. In some embodiments of Formula (I-a), R2cis cycloalkyl. In some embodiments of Formula (I- a), R2cis heterocyclyl. In some embodiments of Formula (I-a), R2cis aryl. In some embodiments of Formula (I-a), R2cis heteroaryl. In some embodiments of Formula (I-a), R2cis –ORAIn some embodiments of Formula (I-a), R2cis NRBRC. In some embodiments of Formula (I-a), R2cis – NRBC(O)RD. In some embodiments of Formula (I-a), R2cis –NO2. In some embodiments of Formula (I-a), R2cis –C(O)NRBRC. In some embodiments of Formula (I-a), R2cis –C(O)RD. In some embodiments of Formula (I-a), R2cis –C(O)ORD. In some embodiments of Formula (I-a), R2cis –S(O)xRD. In some embodiments of Formula (I-a), R2cis -P(O)yRERF. In some embodiments of Formula (I-a), R2dis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-a), R2dis hydrogen. In some embodiments of Formula (I-a), R2dis C1-C6-alkyl. In some embodiments of Formula (I-a), R2dis C1-C6- heteroalkyl. In some embodiments of Formula (I-a), R2dis C1-C6-haloalkyl. In some embodiments of Formula (I-a), R2dis halo. In some embodiments of Formula (I-a), R2dis cyano. In some embodiments of Formula (I-a), R2dis cycloalkyl. In some embodiments of Formula (I- a), R2dis heterocyclyl. In some embodiments of Formula (I-a), R2dis aryl. In some embodiments of Formula (I-a), R2dis heteroaryl. In some embodiments of Formula (I-a), R2dis –ORAIn some embodiments of Formula (I-a), R2dis NRBRC. In some embodiments of Formula (I-a), R2dis – NRBC(O)RD. In some embodiments of Formula (I-a), R2dis –NO2. In some embodiments of Formula (I-a), R2dis –C(O)NRBRC. In some embodiments of Formula (I-a), R2dis –C(O)RD. In some embodiments of Formula (I-a), R2dis –C(O)ORD. In some embodiments of Formula (I-a), R2dis –S(O)xRD. In some embodiments of Formula (I-a), R2dis -P(O)yRERF. In some embodiments, the compound of Formula (I) is a compound of Formula (I-b): (I-b), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), C(R2a)(R2b), O, S, or N; Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1is C(R2d) or N; L1and L2are each independently absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or - C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, – ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, – ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each R8is independently hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, or –ORA1; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; n is 0, 1, or 2; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments of Formula (I-b), Y is selected from C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-b), Y is C(R2a)(R2b). In some embodiments of Formula (I- b), Y is N(R2c). In some embodiments of Formula (I-b), Y is O. In some embodiments of Formula (I-b), Y is S. In some embodiments of Formula (I-b), X is selected from C(R2a) or N. In some embodiments of Formula (I-b), X is N. In some embodiments of Formula (I-b), X is C(R2a). In some embodiments of Formula (I-b), X is C(R2a)(R2b). In some embodiments of Formula (I-b), X is oxygen. In some embodiments of Formula (I-b), X is sulfur. In some embodiments of Formula (I-b), X is nitrogen. In some embodiments, of Formula (I-b), one of A and B is independently selected from In some embodiments, of Formula (I-b), one of A and B is independently selected from:

[0016] In some embodiments, of Formula (I-b), one of A and B is independently selected from In some embodiments, of Formula (I-b), one of A and B is independently selected from: In some embodiments, of Formula (I-b), one of L1and L2is selected from: C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-b), one of L1and L2is C1-C6-alkyl. In some embodiments, of Formula (I-b), one of L1and L2is C1-C6-heteroalkyl. In some embodiments, of Formula (I-b), one of L1and L2is C1- C6-haloalkyl. In some embodiments, of Formula (I-b), one of L1and L2is -N(R3)-. In some embodiments, of Formula (I-b), one of L1and L2is -O-. In some embodiments, of Formula (I-b), one of L1and L2is -S-. In some embodiments, of Formula (I-b), one of L1and L2is –C(O)RD. In some embodiments of Formula (I-b), R2cis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-b), R2cis hydrogen. In some embodiments of Formula (I-b), R2cis C1-C6-alkyl. In some embodiments of Formula (I-b), R2cis C1-C6- heteroalkyl. In some embodiments of Formula (I-b), R2cis C1-C6-haloalkyl. In some embodiments of Formula (I-b), R2cis halo. In some embodiments of Formula (I-b), R2cis cyano. In some embodiments of Formula (I-b), R2cis cycloalkyl. In some embodiments of Formula (I- b), R2cis heterocyclyl. In some embodiments of Formula (I-b), R2cis aryl. In some embodiments of Formula (I-b), R2cis heteroaryl. In some embodiments of Formula (I-b), R2cis –ORAIn some embodiments of Formula (I-b), R2cis NRBRC. In some embodiments of Formula (I-b), R2cis – NRBC(O)RD. In some embodiments of Formula (I-b), R2cis –NO2. In some embodiments of Formula (I-b), R2cis –C(O)NRBRC. In some embodiments of Formula (I-b), R2cis –C(O)RD. In some embodiments of Formula (I-b), R2cis –C(O)ORD. In some embodiments of Formula (I-b), R2cis –S(O)xRD. In some embodiments of Formula (I-b), R2cis -P(O)yRERF. In some embodiments of Formula (I-b), R2dis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-b), R2dis hydrogen. In some embodiments of Formula (I-b), R2dis C1-C6-alkyl. In some embodiments of Formula (I-b), R2dis C1-C6- heteroalkyl. In some embodiments of Formula (I-b), R2dis C1-C6-haloalkyl. In some embodiments of Formula (I-b), R2dis halo. In some embodiments of Formula (I-b), R2dis cyano. In some embodiments of Formula (I-b), R2dis cycloalkyl. In some embodiments of Formula (I- b), R2dis heterocyclyl. In some embodiments of Formula (I-b), R2dis aryl. In some embodiments of Formula (I-b), R2dis heteroaryl. In some embodiments of Formula (I-b), R2dis –ORAIn some embodiments of Formula (I-b), R2dis NRBRC. In some embodiments of Formula (I-b), R2dis – NRBC(O)RD. In some embodiments of Formula (I-b), R2dis –NO2. In some embodiments of Formula (I-b), R2dis –C(O)NRBRC. In some embodiments of Formula (I-b), R2dis –C(O)RD. In some embodiments of Formula (I-b), R2dis –C(O)ORD. In some embodiments of Formula (I-b), R2dis –S(O)xRD. In some embodiments of Formula (I-b), R2dis -P(O)yRERF. In some embodiments, the compound of Formula (I) is a compound of Formula (I-c): (I-c), or a pharmaceutically a acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; L1and L2are each absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)- , or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2aand R2ais independently hydrogen, deuterium, C1-C6-alkyl, C2-C6- alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6- alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or – C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each R8is independently hydrogen, C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, or –ORA1; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, or – NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; n is 0, 1, or 2; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, of Formula (I-c), one of A and B is independently selected from In some embodiments, of Formula (I-c), one of A and B is independently selected from:

[0017] In some embodiments, of Formula (I-c), one of A and B is independently selected from In some embodiments, of Formula (I-c), one of A and B is independently selected from: In some embodiments, of Formula (I-c), one of L1and L2is selected from: C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-c), one of L1and L2is C1-C6-alkyl. In some embodiments, of Formula (I-c), one of L1and L2is C1-C6-heteroalkyl. In some embodiments, of Formula (I-c), one of L1and L2is C1-C6- haloalkyl. In some embodiments, of Formula (I-c), one of L1and L2is -N(R3)-. In some embodiments, of Formula (I-c), one of L1and L2is -O-. In some embodiments, of Formula (I-c), one of L1and L2is -S-. In some embodiments, of Formula (I-c), one of L1and L2is –C(O)RD. In some embodiments of Formula (I-c), R2cis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-c), R2cis hydrogen. In some embodiments of Formula (I-c), R2cis C1-C6-alkyl. In some embodiments of Formula (I-c), R2cis C1-C6- heteroalkyl. In some embodiments of Formula (I-c), R2cis C1-C6-haloalkyl. In some embodiments of Formula (I-c), R2cis halo. In some embodiments of Formula (I-c), R2cis cyano. In some embodiments of Formula (I-c), R2cis cycloalkyl. In some embodiments of Formula (I- c), R2cis heterocyclyl. In some embodiments of Formula (I-c), R2cis aryl. In some embodiments of Formula (I-c), R2cis heteroaryl. In some embodiments of Formula (I-c), R2cis –ORAIn some embodiments of Formula (I-c), R2cis NRBRC. In some embodiments of Formula (I-c), R2cis – NRBC(O)RD. In some embodiments of Formula (I-c), R2cis –NO2. In some embodiments of Formula (I-c), R2cis –C(O)NRBRC. In some embodiments of Formula (I-c), R2cis –C(O)RD. In some embodiments of Formula (I-c), R2cis –C(O)ORD. In some embodiments of Formula (I-c), R2cis –S(O)xRD. In some embodiments of Formula (I-c), R2cis -P(O)yRERF. In some embodiments of Formula (I-c), R2dis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-c), R2dis hydrogen. In some embodiments of Formula (I-c), R2dis C1-C6-alkyl. In some embodiments of Formula (I-c), R2dis C1-C6- heteroalkyl. In some embodiments of Formula (I-c), R2dis C1-C6-haloalkyl. In some embodiments of Formula (I-c), R2dis halo. In some embodiments of Formula (I-c), R2dis cyano. In some embodiments of Formula (I-c), R2dis cycloalkyl. In some embodiments of Formula (I- c), R2dis heterocyclyl. In some embodiments of Formula (I-c), R2dis aryl. In some embodiments of Formula (I-c), R2dis heteroaryl. In some embodiments of Formula (I-c), R2dis –ORAIn some embodiments of Formula (I-c), R2dis NRBRC. In some embodiments of Formula (I-c), R2dis – NRBC(O)RD. In some embodiments of Formula (I-c), R2dis –NO2. In some embodiments of Formula (I-c), R2dis –C(O)NRBRC. In some embodiments of Formula (I-c), R2dis –C(O)RD. In some embodiments of Formula (I-c), R2dis –C(O)ORD. In some embodiments of Formula (I-c), R2dis –S(O)xRD. In some embodiments of Formula (I-c), R2dis -P(O)yRERF. In some embodiments, the compound of Formula (I) is a compound of Formula (I-d): (I-d), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, or N; Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1is C(R2d) or N; Z2is C or N; L1is absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene- heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, – C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3- 7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, and R2dare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, – C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; n is 0, 1, or 2; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments of Formula (I-d), Y is selected from C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-d), Y is C(R2a)(R2b). In some embodiments of Formula (I- d), Y is N(R2c). In some embodiments of Formula (I-d), Y is O. In some embodiments of Formula (I-d), Y is S. In some embodiments of Formula (I-d), X is selected from C(R2a) or N. In some embodiments of Formula (I-d), X is N. In some embodiments of Formula (I-d), X is C(R2a). In some embodiments of Formula (I-d), X is C(R2a)(R2b). In some embodiments of Formula (I-d), X is oxygen. In some embodiments of Formula (I-d), X is sulfur. In some embodiments of Formula (I-d), X is nitrogen. In some embodiments, of Formula (I-d), one of A and B is independently selected from In some embodiments, of Formula (I-d), one of A and B is independently selected from:

[0018] In some embodiments, of Formula (I-d), one of A and B is independently selected from In some embodiments, of Formula (I-d), one of A and B is independently selected from:

[0019] In some embodiments, of Formula (I-d), one of L1and L2is selected from: C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-d), one of L1and L2is C1-C6-alkyl. In some embodiments, of Formula (I-d), one of L1and L2is C1-C6-heteroalkyl. In some embodiments, of Formula (I-d), one of L1and L2is C1- C6-haloalkyl. In some embodiments, of Formula (I-d), one of L1and L2is -N(R3)-. In some embodiments, of Formula (I-d), one of L1and L2is -O-. In some embodiments, of Formula (I-d), one of L1and L2is -S-. In some embodiments, of Formula (I-d), one of L1and L2is –C(O)RD. In some embodiments of Formula (I-d), R2cis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-d), R2cis hydrogen. In some embodiments of Formula (I-d), R2cis C1-C6-alkyl. In some embodiments of Formula (I-d), R2cis C1-C6- heteroalkyl. In some embodiments of Formula (I-d), R2cis C1-C6-haloalkyl. In some embodiments of Formula (I-d), R2cis halo. In some embodiments of Formula (I-d), R2cis cyano. In some embodiments of Formula (I-d), R2cis cycloalkyl. In some embodiments of Formula (I- d), R2cis heterocyclyl. In some embodiments of Formula (I-d), R2cis aryl. In some embodiments of Formula (I-d), R2cis heteroaryl. In some embodiments of Formula (I-d), R2cis –ORAIn some embodiments of Formula (I-d), R2cis NRBRC. In some embodiments of Formula (I-d), R2cis – NRBC(O)RD. In some embodiments of Formula (I-d), R2cis –NO2. In some embodiments of Formula (I-d), R2cis –C(O)NRBRC. In some embodiments of Formula (I-d), R2cis –C(O)RD. In some embodiments of Formula (I-d), R2cis –C(O)ORD. In some embodiments of Formula (I-d), R2cis –S(O)xRD. In some embodiments of Formula (I-d), R2cis -P(O)yRERF. In some embodiments of Formula (I-d), R2dis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-d), R2dis hydrogen. In some embodiments of Formula (I-d), R2dis C1-C6-alkyl. In some embodiments of Formula (I-d), R2dis C1-C6- heteroalkyl. In some embodiments of Formula (I-d), R2dis C1-C6-haloalkyl. In some embodiments of Formula (I-d), R2dis halo. In some embodiments of Formula (I-d), R2dis cyano. In some embodiments of Formula (I-d), R2dis cycloalkyl. In some embodiments of Formula (I- d), R2dis heterocyclyl. In some embodiments of Formula (I-d), R2dis aryl. In some embodiments of Formula (I-d), R2dis heteroaryl. In some embodiments of Formula (I-d), R2dis –ORAIn some embodiments of Formula (I-d), R2dis NRBRC. In some embodiments of Formula (I-d), R2dis – NRBC(O)RD. In some embodiments of Formula (I-d), R2dis –NO2. In some embodiments of Formula (I-d), R2dis –C(O)NRBRC. In some embodiments of Formula (I-d), R2dis –C(O)RD. In some embodiments of Formula (I-d), R2dis –C(O)ORD. In some embodiments of Formula (I-d), R2dis –S(O)xRD. In some embodiments of Formula (I-d), R2dis -P(O)yRERF. In some embodiments, the compound of Formula (I) is a compound of Formula (I-e): (I-e), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: B is cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, or N; Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1, Z4, and Z5are each independently C(R2d) or N; Z2and Z3are each independently C or N; L1and L2are each absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, - C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2- C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1- C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or - P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; each R1ais independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6- haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, – C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene- aryl, C1-C6alkylene-heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments of Formula (I-e), Z1is N. In some embodiments of Formula (I-e), Z1is C(R2d). In some embodiments of Formula (I-e), Z2is N. In some embodiments of Formula (I-e), Z2is C. In some embodiments of Formula (I-e), Z3is N. In some embodiments of Formula (I-e), Z3is C. In some embodiments of Formula (I-e), Z4is N. In some embodiments of Formula (I-e), Z4is C(R2d). In some embodiments of Formula (I-e), Z5is N. In some embodiments of Formula (I-e), Z5is C(R2d). In some embodiments of Formula (I-e), X is selected from C(R2a) or N. In some embodiments of Formula (I-e), X is N. In some embodiments of Formula (I-e), X is C(R2a). In some embodiments of Formula (I-e), X is oxygen. In some embodiments of Formula (I-e), X is sulfur. In some embodiments of Formula (I-e), X is nitrogen. In some embodiments of Formula (I-e), Y is selected from C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-e), Y is C(R2a)(R2b). In some embodiments of Formula (I-e), Y is N(R2c). In some embodiments of Formula (I-e), Y is O. In some embodiments of Formula (I-e), Y is S. In some embodiments, of Formula (I-e), one of A and B is independently selected from In some embodiments, of Formula (I-e), one of A and B is independently selected from:

[0020] In some embodiments, of Formula (I-e), one of A and B is independently selected from In some embodiments, of Formula (I-e), one of A and B is independently selected from: In some embodiments, of Formula (I-e), one of A and B is independently . In some embodiments, of Formula (I-e), one of A and B is independently . In some

[0021] In some embodiments, of Formula (I-e), one of L1and L2is selected from: C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-e), one of L1and L2is C1-C6-alkyl. In some embodiments, of Formula (I-e), one of L1and L2is C1-C6-heteroalkyl. In some embodiments, of Formula (I-e), one of L1and L2is C1-C6- haloalkyl. In some embodiments, of Formula (I-e), one of L1and L2is -N(R3)-. In some embodiments, of Formula (I-e), one of L1and L2is -O-. In some embodiments, of Formula (I-e), one of L1and L2is -S-. In some embodiments, of Formula (I-e), one of L1and L2is –C(O)RD. In some embodiments of Formula (I-e), R2cis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-e), R2cis hydrogen. In some embodiments of Formula (I-e), R2cis C1-C6-alkyl. In some embodiments of Formula (I-e), R2cis C1-C6- heteroalkyl. In some embodiments of Formula (I-e), R2cis C1-C6-haloalkyl. In some embodiments of Formula (I-e), R2cis halo. In some embodiments of Formula (I-e), R2cis cyano. In some embodiments of Formula (I-e), R2cis cycloalkyl. In some embodiments of Formula (I- e), R2cis heterocyclyl. In some embodiments of Formula (I-e), R2cis aryl. In some embodiments of Formula (I-e), R2cis heteroaryl. In some embodiments of Formula (I-e), R2cis –ORAIn some embodiments of Formula (I-e), R2cis NRBRC. In some embodiments of Formula (I-e), R2cis – NRBC(O)RD. In some embodiments of Formula (I-e), R2cis –NO2. In some embodiments of Formula (I-e), R2cis –C(O)NRBRC. In some embodiments of Formula (I-e), R2cis –C(O)RD. In some embodiments of Formula (I-e), R2cis –C(O)ORD. In some embodiments of Formula (I-e), R2cis –S(O)xRD. In some embodiments of Formula (I-e), R2cis -P(O)yRERF. In some embodiments of Formula (I-e), R2dis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-e), R2dis hydrogen. In some embodiments of Formula (I-e), R2dis C1-C6-alkyl. In some embodiments of Formula (I-e), R2dis C1-C6- heteroalkyl. In some embodiments of Formula (I-e), R2dis C1-C6-haloalkyl. In some embodiments of Formula (I-e), R2dis halo. In some embodiments of Formula (I-e), R2dis cyano. In some embodiments of Formula (I-e), R2dis cycloalkyl. In some embodiments of Formula (I- e), R2dis heterocyclyl. In some embodiments of Formula (I-e), R2dis aryl. In some embodiments of Formula (I-e), R2dis heteroaryl. In some embodiments of Formula (I-e), R2dis –ORAIn some embodiments of Formula (I-e), R2dis NRBRC. In some embodiments of Formula (I-e), R2dis – NRBC(O)RD. In some embodiments of Formula (I-e), R2dis –NO2. In some embodiments of Formula (I-e), R2dis –C(O)NRBRC. In some embodiments of Formula (I-e), R2dis –C(O)RD. In some embodiments of Formula (I-e), R2dis –C(O)ORD. In some embodiments of Formula (I-e), R2dis –S(O)xRD. In some embodiments of Formula (I-e), R2dis -P(O)yRERF. In some embodiments, the compound of Formula (I) is a compound of Formula (I-f): (I-f), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, or N; Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1is C(R2d) or N; L1is absent, C1-C6-alkylene, C1-C6- heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7- membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; each R1ais independently C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6- heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, – NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene- aryl, C1-C6alkylene-heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments of Formula (I-f), Z1is N. In some embodiments of Formula (I-f), Z1is C(R2d). In some embodiments of Formula (I-f), X is selected from C(R2a) or N. In some embodiments of Formula (I-f), X is N. In some embodiments of Formula (I-f), X is C(R2a). In some embodiments of Formula (I-f), X is oxygen. In some embodiments of Formula (I-f), X is sulfur. In some embodiments of Formula (I-f), X is nitrogen. In some embodiments of Formula (I-f), Y is selected from C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-f), Y is C(R2a)(R2b). In some embodiments of Formula (I-f), Y is N(R2c). In some embodiments of Formula (I-f), Y is O. In some embodiments of Formula (I-f), Y is S. In some embodiments, of Formula (I-f), one of A and B is independently selected from In some embodiments, of Formula (I-f), one of A and B is independently selected from:

[0022] In some embodiments, of Formula (I-f), one of A and B is independently selected from In some embodiments, of Formula (I-f), one of A and B is independently selected from: In some embodiments, of Formula (I-f), one of L1and L2is selected from: C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-f), one of L1and L2is C1-C6-alkyl. In some embodiments, of Formula (I-f), one of L1and L2is C1-C6-heteroalkyl. In some embodiments, of Formula (I-f), one of L1and L2is C1-C6- haloalkyl. In some embodiments, of Formula (I-f), one of L1and L2is -N(R3)-. In some embodiments, of Formula (I-f), one of L1and L2is -O-. In some embodiments, of Formula (I-f), one of L1and L2is -S-. In some embodiments, of Formula (I-f), one of L1and L2is –C(O)RD. In some embodiments of Formula (I-f), R2cis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-f), R2cis hydrogen. In some embodiments of Formula (I-f), R2cis C1-C6-alkyl. In some embodiments of Formula (I-f), R2cis C1-C6- heteroalkyl. In some embodiments of Formula (I-f), R2cis C1-C6-haloalkyl. In some embodiments of Formula (I-f), R2cis halo. In some embodiments of Formula (I-f), R2cis cyano. In some embodiments of Formula (I-f), R2cis cycloalkyl. In some embodiments of Formula (I-f), R2cis heterocyclyl. In some embodiments of Formula (I-f), R2cis aryl. In some embodiments of Formula (I-f), R2cis heteroaryl. In some embodiments of Formula (I-f), R2cis –ORAIn some embodiments of Formula (I-f), R2cis NRBRC. In some embodiments of Formula (I-f), R2cis – NRBC(O)RD. In some embodiments of Formula (I-f), R2cis –NO2. In some embodiments of Formula (I-f), R2cis –C(O)NRBRC. In some embodiments of Formula (I-f), R2cis –C(O)RD. In some embodiments of Formula (I-f), R2cis –C(O)ORD. In some embodiments of Formula (I-f), R2cis –S(O)xRD. In some embodiments of Formula (I-f), R2cis -P(O)yRERF. In some embodiments of Formula (I-f), R2dis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-f), R2dis hydrogen. In some embodiments of Formula (I-f), R2dis C1-C6-alkyl. In some embodiments of Formula (I-f), R2dis C1-C6- heteroalkyl. In some embodiments of Formula (I-f), R2dis C1-C6-haloalkyl. In some embodiments of Formula (I-f), R2dis halo. In some embodiments of Formula (I-f), R2dis cyano. In some embodiments of Formula (I-f), R2dis cycloalkyl. In some embodiments of Formula (I-f), R2dis heterocyclyl. In some embodiments of Formula (I-f), R2dis aryl. In some embodiments of Formula (I-f), R2dis heteroaryl. In some embodiments of Formula (I-f), R2dis –ORAIn some embodiments of Formula (I-f), R2dis NRBRC. In some embodiments of Formula (I-f), R2dis – NRBC(O)RD. In some embodiments of Formula (I-f), R2dis –NO2. In some embodiments of Formula (I-f), R2dis –C(O)NRBRC. In some embodiments of Formula (I-f), R2dis –C(O)RD. In some embodiments of Formula (I-f), R2dis –C(O)ORD. In some embodiments of Formula (I-f), R2dis –S(O)xRD. In some embodiments of Formula (I-f), R2dis -P(O)yRERF. In some embodiments, the compound is a compound of Formula (I-g): (I-g), wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), or N; L1is C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD,-OC(O)RD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2cand R2dare each independently hydrogen, C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, – ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, – ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, of Formula (I-g), one of A and B is independently selected from In some embodiments, of Formula (I-g), one of A and B is independently In some embodiments, of Formula (I-g), one of A and B is independently In some embodiments, of Formula (I-g), one of A and B is independently

[0023] In some embodiments, of Formula (I-g), one of A and B is independently selected from In some embodiments, of Formula (I-g), one of A and B is independently selected from: In some embodiments, of Formula (I-g), L1is selected from: C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-g), L1is C1-C6-alkyl. In some embodiments, of Formula (I-g), L1is C1-C6-heteroalkyl. In some embodiments, of Formula (I-g), L1is C1-C6-haloalkyl. In some embodiments, of Formula (I-g), L1is -N(R3)-. In some embodiments, of Formula (I-g), L1is -O-. In some embodiments, of Formula (I-g), L1is -S-. In some embodiments, of Formula (I-g), L1is –C(O)RD. In someembodiments of Formula (I-g), X is C(R2a). In some embodiments of Formula (I-g), X is N.In some embodiments of Formula (I-g), R2cis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-g), R2cis hydrogen. In some embodiments of Formula (I-g), R2cis C1-C6-alkyl. In some embodiments of Formula (I-g), R2cis C1-C6- heteroalkyl. In some embodiments of Formula (I-g), R2cis C1-C6-haloalkyl. In some embodiments of Formula (I-g), R2cis halo. In some embodiments of Formula (I-g), R2cis cyano. In some embodiments of Formula (I-g), R2cis cycloalkyl. In some embodiments of Formula (I- g), R2cis heterocyclyl. In some embodiments of Formula (I-g), R2cis aryl. In some embodiments of Formula (I-g), R2cis heteroaryl. In some embodiments of Formula (I-g), R2cis –ORAIn some embodiments of Formula (I-g), R2cis NRBRC. In some embodiments of Formula (I-g), R2cis – NRBC(O)RD. In some embodiments of Formula (I-g), R2cis –NO2. In some embodiments of Formula (I-g), R2cis –C(O)NRBRC. In some embodiments of Formula (I-g), R2cis –C(O)RD. In some embodiments of Formula (I-g), R2cis –C(O)ORD. In some embodiments of Formula (I-g), R2cis –S(O)xRD. In some embodiments of Formula (I-g), R2cis -P(O)yRERF. In some embodiments of Formula (I-g), R2dis selected from: hydrogen, C1-C6-alkyl, C1- C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5, and wherein each of RA, RB, RC, RD, RE, RF, and R5is as described herein. In some embodiments of Formula (I-g), R2dis hydrogen. In some embodiments of Formula (I-g), R2dis C1-C6-alkyl. In some embodiments of Formula (I-g), R2dis C1-C6- heteroalkyl. In some embodiments of Formula (I-g), R2dis C1-C6-haloalkyl. In some embodiments of Formula (I-g), R2dis halo. In some embodiments of Formula (I-g), R2dis cyano. In some embodiments of Formula (I-g), R2dis cycloalkyl. In some embodiments of Formula (I- g), R2dis heterocyclyl. In some embodiments of Formula (I-g), R2dis aryl. In some embodiments of Formula (I-g), R2dis heteroaryl. In some embodiments of Formula (I-g), R2dis –ORAIn some embodiments of Formula (I-g), R2dis NRBRC. In some embodiments of Formula (I-g), R2dis – NRBC(O)RD. In some embodiments of Formula (I-g), R2dis –NO2. In some embodiments of Formula (I-g), R2dis –C(O)NRBRC. In some embodiments of Formula (I-g), R2dis –C(O)RD. In some embodiments of Formula (I-g), R2dis –C(O)ORD. In some embodiments of Formula (I-g), R2dis –S(O)xRD. In some embodiments of Formula (I-g), R2dis -P(O)yRERF. In some embodiments, the compound is a compound of Formula (I-h): (I-h), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a) or N; Y is C(R2a)(R2b), N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; L1is C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, – C(O)NRBRC, –C(O)RD, –C(O)ORD,-OC(O)RD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, – S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6- alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or – C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, or – NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, of Formula (I-h), one of A and B is independently selected from In some embodiments, of Formula (I-h), one of A and B is independently selected from:

[0024] In some embodiments, of Formula (I-h), one of A and B is independently selected from In some embodiments, of Formula (I-h), one of A and B is independently selected from: In some embodiments, of Formula (I-h), L1is selected from: C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-h), L1is C1-C6-alkyl. In some embodiments, of Formula (I-h), L1is C1-C6-heteroalkyl. In some embodiments, of Formula (I-h), L1is C1-C6-haloalkyl. In some embodiments, of Formula (I-h), L1is -N(R3)-. In some embodiments, of Formula (I-h), L1is -O-. In some embodiments, of Formula (I-h), L1is -S-. In some embodiments, of Formula (I-h), L1is –C(O)RD. In some embodiments of Formula (I-h), Y is selected from one of C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-h), Y is C(R2a)(R2b). In some embodiments of Formula (I-h), Y is N(R2c). In some embodiments of Formula (I-h), Y is O. In some embodiments of Formula (I-h), Y is S. In some embodiments of Formula (I-h), X is C(R2a). In some embodiments of Formula (I-h), X is N. In some embodiments, the compound is a compound of Formula (I-i): (I-i), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, N, or N(R2c); Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; L1is C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, - N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD,-OC(O)RD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, – ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, – ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, of Formula (I-i), one of A and B is independently selected from

[0025] In some embodiments, of Formula (I-i), one of A and B is independently selected from:

[0026] In some embodiments, of Formula (I-i), one of A and B is independently selected from , wherein R1is as described herein. In some embodiments, of Formula (I-i), one of A and B is independently selected from:

[0027] In some embodiments, of Formula (I-i), L1is selected from: C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-i), L1is C1-C6-alkyl. In some embodiments, of Formula (I-i), L1is C1-C6-heteroalkyl. In some embodiments, of Formula (I-i), L1is C1-C6-haloalkyl. In some embodiments, of Formula (I-i), L1is -N(R3)-. In some embodiments, of Formula (I-i), L1is -O-. In some embodiments, of Formula (I-i), L1is -S-. In some embodiments, of Formula (I-i), L1is –C(O)RD. In some embodiments of Formula (I-i), Y is selected from one of C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-i), Y is C(R2a)(R2b). In some embodiments of Formula (I-i), Y is N(R2c). In some embodiments of Formula (I-i), Y is O. In some embodiments of Formula (I-i), Y is S. In some embodiments of Formula (I-i), X is C(R2a). In some embodiments of Formula (I- i), X is N. In some embodiments, the compound is a compound of Formula (I-j): (I-j), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, N, or N(R2c); Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; L1is C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, - N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD,-OC(O)RD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, – ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, – ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, of Formula (I-j), one of A and B is independently selected from In some embodiments, of Formula (I-j), one of A and B is independently selected from:

[0028] In some embodiments, of Formula (I-j), one of A and B is independently selected from In some embodiments, of Formula (I-j), one of A and B is independently selected from: , In some embodiments, of Formula (I-j), L1is selected from: C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-j), L1is C1-C6-alkyl. In some embodiments, of Formula (I-j), L1is C1-C6-heteroalkyl. In some embodiments, of Formula (I-j), L1is C1-C6-haloalkyl. In some embodiments, of Formula (I-j), L1is -N(R3)-. In some embodiments, of Formula (I-j), L1is -O-. In some embodiments, of Formula (I-j), L1is -S-. In some embodiments, of Formula (I-j), L1is –C(O)RD. In some embodiments of Formula (I-j), Y is selected from one of C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-j), Y is C(R2a)(R2b). In some embodiments of Formula (I-j), Y is N(R2c). In some embodiments of Formula (I-j), Y is O. In some embodiments of Formula (I-j), Y is S. In some embodiments of Formula (I-j), X is C(R2a). In some embodiments of Formula (I- j), X is N. In some embodiments, the compound is a compound of Formula (I-k) (I-k), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, N, or N(R2c); Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein one of X and Y is N, and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; L1is C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, - N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD,-OC(O)RD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, – ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RB and RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, – ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, of Formula (I-k), one of A and B is independently selected from In some embodiments, of Formula (I-k), one of A and B is independently selected from In some embodiments, of Formula (I-k), L1is selected from: C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-k), L1is C1-C6-alkyl. In some embodiments, of Formula (I-k), L1is C1-C6-heteroalkyl. In some embodiments, of Formula (I-k), L1is C1-C6-haloalkyl. In some embodiments, of Formula (I-k), L1is -N(R3)-. In some embodiments, of Formula (I-k), L1is -O-. In some embodiments, of Formula (I-k), L1is -S-. In some embodiments, of Formula (I-k), L1is –C(O)RD. In some embodiments of Formula (I-k), Y is selected from one of C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-k), Y is C(R2a)(R2b). In some embodiments of Formula (I-k), Y is N(R2c). In some embodiments of Formula (I-k), Y is O. In some embodiments of Formula (I-k), Y is S. In some embodiments of Formula (I-k), X is C(R2a). In some embodiments of Formula (I- k), X is N. In some embodiments, the compound is a compound of Formula (I-l): (I-l), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A is aryl or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a) or N; and Y is C(R2a), C(R2a)(R2b), N, or N(R2c); each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD,-OC(O)RD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6- alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or – ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, or – NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments of Formula (I-l), U2is selected from C(R1)(R1) and N(R1). In some embodiments of Formula (I-l), U2is C(R1)(R1). In some embodiments of Formula (I-l), U2is N(R1). In some embodiments of Formula (I-l), U1is selected from C(R1) and N. In some embodiments of Formula (I-l), U1is C(R1). In some embodiments of Formula (I-l), U1is N. In some embodiments, of Formula (I-l), A is independently selected from

[0029] In some embodiments, the compound is a compound of Formula (I-m): (I-m), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein B is cycloalkyl or heterocyclyl, each of which is optionally substituted with one or more R1; X is C(R2a) or N; and each of W,Y, and Z is independently C(R2a), C(R2a)(R2b), N, or N(R2c); each R1is independently hydrogen, C1-C6- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD,-OC(O)RD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3- 7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2c, and R2dare each independently hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, – C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or – S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, –ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments of Formula (I-m), U3is selected from C(R1) and N. In some embodiments of Formula (I-m), U4is selected from C(R1)(R1), C(R1), N(R1) and N. In some embodiments of Formula (I-m), U5is selected from C(R1)(R1), C(R1), N(R1) and N. In some embodiments of Formula (I-m), U6is selected from C(R1)(R1), C(R1), N(R1) and N. independently . In some embodiments, of Formula (I-m), B is independently In some embodiments, the compound is a compound of Formula (I-n): (I-n), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; C is 3-5 membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with one or more R1; L1is absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -C(O)-, -N(R3)-, -N(R3)C(O)-, or - C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or two R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2cand R2dare each independently hydrogen, C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, – NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, – ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each R5is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, –C(O)RD, or –S(O)xRD; each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, – ORA1; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each R7is independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or oxo; each RD, RE, and RFis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene- heteroaryl, or –NRB1RC1; each RA1, RB1, and RC1is hydrogen or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3. In some embodiments, of Formula (I-n), one of A, B, and C is independently selected In some embodiments, of Formula (I-n), one of A, B, and C is independently selected from , wherein R1is as described herein. In some embodiments, of Formula (I-n), one of A, B, and C is independently selected from: In some embodiments, of Formula (I-n), L1is selected from: C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, -N(R3)-, -O-, -S-, or –C(O)RD. In some embodiments, of Formula (I-n), L1is C1-C6-alkyl. In some embodiments, of Formula (I-n), L1is C1-C6-heteroalkyl. In some embodiments, of Formula (I-n), L1is C1-C6-haloalkyl. In some embodiments, of Formula (I-n), L1is -N(R3)-. In some embodiments, of Formula (I-n), L1is -O-. In some embodiments, of Formula (I-n), L1is -S-. In some embodiments, of Formula (I-n), L1is –C(O)RD. In some embodiments of Formula (I-n), Y is selected from one of C(R2a)(R2b), N(R2c), O, or S. In some embodiments of Formula (I-n), Y is C(R2a)(R2b). In some embodiments of Formula (I-n), Y is N(R2c). In some embodiments of Formula (I-n), Y is O. In some embodiments of Formula (I-n), Y is S. In some embodiments, the compound of Formula (I) is selected from a compound listed in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof. Table 1. Exemplary compounds of Formula (I). In some embodiments of Formula (I), A is L1is -N(R3) or -C(O)-; L2is absent; R2ais hydrogen; R2cis hydrogen, C1-C6alkyl, -C(O)RDor – C(O)ORD; R2dis hydrogen, halo, or cyano; RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl); R3is hydrogen; and each R1is independently halo or C1-C6alkyl. In some embodiments of Formula (I), ; L1 is -N(R3) or -C(O)-; L2is2a absent; R is hydrogen; R2cis hydrogen, C1-C6alkyl, -C(O)RDor –C(O)ORD; R2dis hydrogen, halo, or cyano; R3is hydrogen; and RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl). In some embodiments of Formula (I),

[0030] , L1is -N(R3) or -C(O)-; L2is absent; R2ais hydrogen; R2cis hydrogen, C1-C6alkyl, -C(O)RDor – C(O)ORD; R2dis hydrogen, halo, or cyano; R3is hydrogen; and RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl). In some embodiments of Formula (I), N(R3) or -C(O)-; L2is absent; R2ais hydrogen; R2cis hydrogen, C1-C6alkyl, -C(O)RDor – C(O)ORD; R2dis hydrogen, halo, or cyano; RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl); R3is hydrogen; and each R1is independently halo or C1-C6alkyl. In some embodiments of Formula (I), ; L1is -N(R3) or -C(O)-; L2is abse2a nt; R is hydrogen; R2cis hydrogen, C1-C6alkyl, -C(O)RDor –C(O)ORD; R2dis hydrogen, halo, or cyano; R3is hydrogen; and RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl). In some embodiments of Formula (I), C(O)-; L2is absent; R2ais hydrogen; R2cis hydrogen, C1-C6alkyl, -C(O)RDor –C(O)ORD; R2dis hydrogen, halo, or cyano; R3is hydrogen; and RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl). In some embodiments of Formula (I), ; ; L1is -C(O)-; L2is absent; R2ais hydrogen; and each R1is independently halo or C1-C6alkyl.

[0031] N(R3); L2is absent; R2cis hydrogen; R2dis hydrogen, halo, or cyano; R3is hydrogen; and each R1is independently halo or C1-C6alkyl.

[0032] N(R3) or -C(O)-; L2is absent; R2cis C1-C6alkyl, -C(O)RDor –C(O)ORD; R2dis hydrogen, halo, or cyano; RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl); R3is hydrogen; and each R1is independently halo or C1-C6alkyl. ; L1is -N(R3)-; L2is absent; R2cis C1-C6alkyl, - C(O)RDor –C(O)ORD; R2dis hydrogen, halo, or cyano; R3is hydrogen; and RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl). In some embodiments of Formula (I), ; L1is -N(R3); L2is absent; R2cis hydrogen, C1-C6 alkyl, -C(O)RD; R2dis hydrogen, halo, or cyano; R3is hydrogen; and RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl). In some embodiments of Formula (I), ; A is N(R3) or -C(O)-; L2is absent; R2cis C1-C6alkyl; R2dis hydrogen, halo, or cyano; and each R1is independently halo or C1-C6alkyl. In some embodiments of Formula (I), ; ; L1 3 2 2c is -N(R )-; L is absent; R is C1-C6alkyl; and R2dis hydrogen, halo, or cyano. In some embodiments of Formula (I), In some embodiments of Formula (I), N(R3); L2is absent; R2cis -C(O)RDor –C(O)ORD; R2dis hydrogen, halo, or cyano; RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl); and each R1is independently halo or C1-C6alkyl. In some embodiments of Formula (I), , , , ; , 32 2c ;L1is -N(R ) or -C(O)-; L is absent; R is - C(O)RDor –C(O)ORD; R2dis hydrogen, halo, or cyano; and RDis C1-C6alkyl or C1-C6cycloalkyl (e.g., cyclopropyl). In some embodiments of Formula (I), L1is -N(R3) or -C(O)-; L2is absent; and R2dis hydrogen, halo, or cyano. In some embodiments, the compound of Formula (I) is Compound 140, Compound 342, Compound 343, Compound 344, Compound 392, Compound 393, Compound 394, Compound 395, Compound 396, Compound 397, Compound 410, Compound 411, Compound 412, Compound 413, Compound 421, Compound 422, Compound 471, Compound 523, Compound 524, Compound 555, Compound 557, Compound 757, Compound 758, Compound 835, Compound 836, Compound 837, Compound 838, Compound 855, Compound 856, Compound 857, Compound 858, Compound 869, Compound 871, Compound 1010, Compound 1011, Compound 1012, Compound 1200, Compound 1203, Compound 1237, Compound 1245, Compound 1247, Compound 1321, Compound 1322, Compound 1356, Compound 1376, Compound 1388, Compound 1389, Compound 1393, Compound 1396, Compound 1402, Compound 1405, Compound 1420, Compound 1421, or Compound 1427. Pharmaceutical Compositions, Kits, and Administration The present invention provides pharmaceutical compositions comprising a compound of Formula (I) e.g., a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer, as described herein, and optionally a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition described herein comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient. In certain embodiments, the compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, is provided in an effective amount in the pharmaceutical composition. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount. Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the compound of Formula (I) (the “active ingredient”) into association with a carrier and / or one or more other accessory ingredients, and then, if necessary and / or desirable, shaping and / or packaging the product into a desired single- or multi-dose unit. Pharmaceutical compositions can be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. As used herein, a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and / or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage. Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and / or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and / or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w / w) active ingredient. The term “pharmaceutically acceptable excipient” refers to a non-toxic carrier, adjuvant, diluent, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable excipients useful in the manufacture of the pharmaceutical compositions of the invention are any of those that are well known in the art of pharmaceutical formulation and include inert diluents, dispersing and / or granulating agents, surface active agents and / or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and / or oils. Pharmaceutically acceptable excipients useful in the manufacture of the pharmaceutical compositions of the invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Compositions of the present invention may be administered orally, parenterally (including subcutaneous, intramuscular, intravenous and intradermal), by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. In some embodiments, provided compounds or compositions are administrable intravenously and / or orally. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraocular, intravitreal, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intraperitoneal intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, subcutaneously, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. In some embodiments, a provided oral formulation is formulated for immediate release or sustained / delayed release. In some embodiments, the composition is suitable for buccal or sublingual administration, including tablets, lozenges and pastilles. A provided compound can also be in micro-encapsulated form. Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs. For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions or in an ointment such as petrolatum. In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and / or perform such modification with ordinary experimentation. Compounds provided herein are typically formulated in dosage unit form, e.g., single unit dosage form, for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts. The exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. The desired dosage can be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage can be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). In certain embodiments, an effective amount of a compound for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form. In certain embodiments, the compounds of Formula (I) or (II) may be at dosage levels sufficient to deliver from about 0.001 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 50 mg / kg, preferably from about 0.1 mg / kg to about 40 mg / kg, preferably from about 0.5 mg / kg to about 30 mg / kg, from about 0.01 mg / kg to about 10 mg / kg, from about 0.1 mg / kg to about 10 mg / kg, and more preferably from about 1 mg / kg to about 25 mg / kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect. It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult. It will be also appreciated that a compound or composition, as described herein, can be administered in combination with one or more additional pharmaceutical agents. The compounds or compositions can be administered in combination with additional pharmaceutical agents that improve their bioavailability, reduce and / or modify their metabolism, inhibit their excretion, and / or modify their distribution within the body. It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder, and / or it may achieve different effects. The compound or composition can be administered concurrently with, prior to, or subsequent to, one or more additional pharmaceutical agents, which may be useful as, e.g., combination therapies. Pharmaceutical agents include therapeutically active agents. Pharmaceutical agents also include prophylactically active agents. Each additional pharmaceutical agent may be administered at a dose and / or on a time schedule determined for that pharmaceutical agent. The additional pharmaceutical agents may also be administered together with each other and / or with the compound or composition described herein in a single dose or administered separately in different doses. The particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional pharmaceutical agents and / or the desired therapeutic and / or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually. Exemplary additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-diabetic agents, anti-inflammatory agents, immunosuppressant agents, and a pain-relieving agent. Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. Also encompassed by the invention are kits (e.g., pharmaceutical packs). The inventive kits may be useful for preventing and / or treating a proliferative disease or a non-proliferative disease, e.g., as described herein. The kits provided may comprise an inventive pharmaceutical composition or compound and a container (e.g., a vial, ampule, bottle, syringe, and / or dispenser package, or other suitable container). In some embodiments, provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive pharmaceutical composition or compound. In some embodiments, the inventive pharmaceutical composition or compound provided in the container and the second container are combined to form one-unit dosage form. Thus, in one aspect, provided are kits including a first container comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition thereof. In certain embodiments, the kit of the disclosure includes a first container comprising a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In certain embodiments, the kits are useful in preventing and / or treating a disease, disorder, or condition described herein in a subject (e.g., a proliferative disease or a non-proliferative disease). In certain embodiments, the kits further include instructions for administering the compound, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition thereof, to a subject to prevent and / or treat a proliferative disease or a non-proliferative disease. Methods of Use Described herein are compounds useful for modulating splicing. In some embodiments, a compound of Formula (I) may be used to alter the amount, structure, or composition of a nucleic acid (e.g., a precursor RNA, e.g., a pre-mRNA, or the resulting mRNA) by increasing or decreasing splicing at a splice site. In some embodiments, increasing or decreasing splicing results in modulating the level or structure of a gene product (e.g., an RNA or protein) produced. In some embodiments, a compound of Formula (I) may modulate a component of the splicing machinery, e.g., by modulating the interaction with a component of the splicing machinery with another entity (e.g., nucleic acid, protein, or a combination thereof). The splicing machinery as referred to herein comprises one or more spliceosome components. Spliceosome components may comprise, for example, one or more of major spliceosome members (U1, U2, U4, U5, U6 snRNPs), or minor spliceosome members (U11, U12, U4atac, U6atac snRNPs) and their accessory splicing factors. In another aspect, the present disclosure features a method of modifying of a target (e.g., a precursor RNA, e.g., a pre-mRNA) through inclusion of a splice site in the target, wherein the method comprises providing a compound of Formula (I). In some embodiments, inclusion of a splice site in a target (e.g., a precursor RNA, e.g., a pre-mRNA, or the resulting mRNA) results in addition or deletion of one or more nucleic acids to the target (e.g., a new exon, e.g. a skipped exon). Addition or deletion of one or more nucleic acids to the target may result in an increase in the levels of a gene product (e.g., RNA, e.g., mRNA, or protein). In another aspect, the present disclosure features a method of modifying a target (e.g., a precursor RNA, e.g., a pre-mRNA, or the resulting mRNA) through exclusion of a splice site in the target, wherein the method comprises providing a compound of Formula (I). In some embodiments, exclusion of a splice site in a target (e.g., a precursor RNA, e.g., a pre-mRNA) results in deletion or addition of one or more nucleic acids from the target (e.g., a skipped exon, e.g. a new exon). Deletion or addition of one or more nucleic acids from the target may result in a decrease in the levels of a gene product (e.g., RNA, e.g., mRNA, or protein). In other embodiments, the methods of modifying a target (e.g., a precursor RNA, e.g., a pre-mRNA, or the resulting mRNA) comprise suppression of splicing at a splice site or enhancement of splicing at a splice site (e.g., by more than about 0.5%, e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more), e.g., as compared to a reference (e.g., the absence of a compound of Formula (I) or (II), or in a healthy or diseased cell or tissue). The methods described herein can be used to modulate splicing, e.g., of a nucleic acid comprising a particular sequence (e.g., a target sequence). Exemplary genes encoding a target sequence (e.g., a target sequence comprising DNA or RNA, e.g., pre-mRNA) include, inter alia, ABCA4, ABCA9, ABCB1, ABCB5, ABCC9, ABCD1, ACADL, ACADM, ACADSB, ACSS2, ACTB, ACTG2, ADA, ADAL, ADAM10, ADAM15, ADAM22, ADAM32, ADAMTS12, ADAMTS13, ADAMTS20, ADAMTS6, ADAMTS9, ADAR, ADCY3, ADCY10, ADCY8, ADNP, ADRBK2, AFP, AGL, AGT, AHCTF1, AHR, AKAP10, AKAP3, AKNA, ALAS1, ALS2CL, ALB, ALDH3A2, ALG6, AMBRA1, ANK3, ANTXR2, ANXA10, ANXA11, ANGPTL3, AP2A2, AP4E1, APC, APOA1, APOB, APOC3, APOH, AR, ARID2, ARID3A, ARID3B, ARFGEF1 , ARFGEF2, ARHGAP1, ARHGAP8, ARHGAP18, ARHGAP26, ARHGEF18, ARHGEF2, ARPC3, ARS2, ASH1L, ASH1L- IT1, ASNSD1, ASPM, ATAD5, ATF1, ATG4A, ATG16L2, ATM, ATN1, ATP11C, ATP6V1G3, ATP13A5, ATP7A, ATP7B, ATR, ATXN2, ATXN3, ATXN7, ATXN10, AXIN1, B2M, B4GALNT3, BBS4, BCL2, BCL2L1, BCL2-like 11 (BIM), BCL11B, BBOX1, BCS1L, BEAN1, BHLHE40, BMPR2, BMP2K, BPTF, BRAF, BRCA1, BRCA2, BRCC3, BRSK1, BRSK2, BTAF1, BTK, C2orf55, C4orf29, C6orf118, C9orf43, C9orf72, C10orf137, C11orf30, C11orf65, C11orf70, C11οrf87, C12orf51, C13orf1, C13orf15, C14orf10l, C14orf118, C15orf29, C15orf42, C15orf60, C16orf33, C16orf38, C16orf48, C18orf8, C19orf42, C1orf107, C1orf114, C1orf130, C1orf149, C1orf27, C1orf71, C1orf94, C1R, C20orf74, C21orf70, C3orf23, C4orf18, C5orf34, C8B, C8orf33, C9orf114, C9orf86, C9orf98, C3, CA11, CAB39, CACHD1, CACNA1A, CACNA1B, CACNA1C, CACNA2D1, CACNA1G, CACNA1H, CALCA, CALCOCO2, CAMK1D, CAMKK1, CAPN3, CAPN9, CAPSL, CARD11, CARKD, CASZ1, CAT, CBLB, CBX1, CBX3, CCDC102B, CCDC11, CCDC15, CCDC18, CCDC5, CCDC81, CCDC131, CCDC146, CD4, CD274, CD1B, CDC14A, CDC16, CDC2L5, CDC42BPB, CDCA8, CDH10, CDH11, CDH24, CDH8, CDH9, CDK5RAP2, CDK6, CDK8, CDK11B, CD33, CD46, CDH1, CDH23, CDK6, CDK11B, CDK13, CEBPZ, CEL, CELSR3, CENPA, CENPI, CENPT, CENTB2, CENTG2, CEP110, CEP170, CEP192, CETP, CFB, CFTR, CFH, CGN, CGNL1, CHAF1A, CHD9, CHIC2, CHL1, CHN1, CHM, CLEC16A, CL1C2, CLCN1, CLINT1, CLK1, CLPB, CLPTM1, CMIP, CMYA5, CNGA3, CNOT1, CNOT7, CNTN6, COG3, COL11A1, COL11A2, COL12A1, COL14A1, COL15A1, COL17A1, COL19A1, COL1A1, COL1A2, COL2A1, COL3A1, COL4A1, COL4A2, COL4A5, COL4A6, COL5A2, COL6A1, COL7A1, COL9A1, COL9A2, COL22A1, COL24A1, COL25A1, COL29A1, COLQ, COMTD1, COPA, COPB2, COPS7B, COPZ2, CPSF2, CPXM2, CR1, CRBN, CRYZ, CREBBP, CRKRS, CSE1L, CSTB, CSTF3, CT45-6, CTNNB1, CUBN, CUL4B, CUL5, CXorf41, CXXC1, CYBB, CYFIP2, CYP3A4, CYP3A43, CYP3A5, CYP4F2, CYP4F3, CYP17, CYP19, CYP24A1, CYP27A1, DAB1, DAZ2, DCBLD1, DCC, DCTN3, DCUN1D4, DDA1, DDEF1, DDX1, DDX24, DDX4, DENND2D, DEPDC2, DES, DGAT2, DHFR, DHRS7, DHRS9, DHX8, DIP2A, DMD, DMTF1, DNAH3, DNAH8, DNAI1, DNAJA4, DNAJC13, DNAJC7, DNMT1, DNTTIP2, DOCK4, DOCK5, DOCK10, DOCK11, DOT1L, DPP3, DPP4, DPY19L2P2, DR1, DSCC1, DVL3, DUX4, DYNC1H1, DYSF, E2F1, E2F3, E2F8, E4F1, EBF1, EBF3, ECM2, EDEM3, EFCAB3, EFCAB4B, EFNA4, EFTUD2, EGFR, EIF3A, ELA1, ELA2A, ELF2, ELF3, ELF4, EMCN, EMD, EML5, ENO3, ENPP3, EP300, EPAS1, EPB41L5, EPHA3, EPHA4, EPHB1, EPHB2, EPHB3, EPS15, ERBB4, ERCC1, ERCC8, ERGIC3, ERMN, ERMP1, ERN1, ERN2, ESR1, ESRRG, ETS2, ETV3, ETV4, ETV5, ETV6, EVC2, EWSR1, EXO1, EXOC4, F3, F11, F13A1, F5, F7, F8, FAH, FAM13A1, FAM13B1, FAM13C1, FAM134A, FAM161A, FAM176B, FAM184A, FAM19A1, FAM20A, FAM23B, FAM65C, FANCA, FANCC, FANCG, FANCM, FANK1, FAR2, FBN1, FBXO15, FBXO18, FBXO38, FCGBP, FECH, FEZ2, FGA, FGD6, FGFR2, FGFR1OP, FGFR1OP2, FGFR2, FGG, FGR, FIX, FKBP3, FLI1, FLJ35848, FLJ36070, FLNA, FN1, FNBP1L, FOLH1, FOSL1, FOSL2, FOXK1, FOXM1, FOXO1, FOXP4, FRAS1, FUT9, FXN, FZD3, FZD6, GAB1, GABPA, GALC, GALNT3, GAPDH, GART, GAS2L3, GATA3, GATAD2A, GBA, GBGT1, GCG, GCGR, GCK, GFI1, GFM1, GH1, GHR, GHV, GJA1, GLA, GLT8D1, GNA11, GNAQ, GNAS, GNB5, GOLGB1, GOLT1A, GOLT1B, GPATCH1, GPR158, GPR160, GPX4, GRAMD3, GRHL1, GRHL2, GRHPR, GRIA1, GRIA3, GRIA4, GRIN2B, GRM3, GRM4, GRN, GSDMB, GSTCD, GSTO2, GTF2I, GTPBP4, HADHA, HAND2, HBA2, HBB, HCK, HDAC3, HDAC5, HDX, HEPACAM2, HERC1, HES7, HEXA, HEXB, HHEX, HIPK3, HLA-DPB1, HLA-G, HLCS, HLTF, HMBS, HMGA1, HMGCL, HNF1A, HNF1B, HNF4A, HNF4G, HNRNPH1, HOXC10, HP1BP3, HPGD, HPRT1, HPRT2, HSF1, HSF4, HSF2BP, HSPA9, HSPG2, HTT, HXA, ICA1, IDH1, IDS, IFI44L, IKBKAP, IKZF1, IKZF3, IL1R2, IL5RA, IL7RA, IMMT, INPP5D, INSR, INTS3, INTU, IP04, IP08, IQGAP2, IRF2, IRF4, IRF8, IRX3, ISL1, ISL2, ITFG1, ITGA6, ITGAL, ITGB1, ITGB2, 1TGB3, ITGB4, ITIH1, ITPR2, IWS1, JAK1, JAK2, JAG1, JMJD1C, JPH3, KALRN, KAT6A, KATNAL2, KCNN2, KCNT2, KDM2A, KIAA0256, KIAA0528, KIAA0564, KIAA0586, KIAA1033, KIAA1166, KIAA1219, KIAA1409, KIAA1622, KIAA1787, KIF3B, KIF15, KIF16B, KIF5A, KIF5B, KIF9, KIN, KIR2DL5B, KIR3DL2, KIR3DL3, KIT, KLF3, KLF5, KLF7, KLF10, KLF12, KLF16, KLHL20, KLK12, KLKB1, KMT2A, KMT2B, KPNA5, KRAS, KREMEN1, KRIT1, KRT5, KRTCAP2, KYNU, L1CAM, L3MBTL, L3MBTL2, LACE1, LAMA1, LAMA2, LAMA3, LAMB1, LARP7, LDLR, LEF1, LENG1, LGALS3, LGMN, LHCGR, LHX3, LHX6, LIMCH1, LIMK2, LIN28B, LIN54, LMBRD1, LMBRD2, LMLN, LMNA, LMO2, LMO7, LOC389634, LOC390110, LPA, LPCAT2, LPL, LRP4, LRPPRC, LRRK2, LRRC19, LRRC42, LRWD1, LUM, LVRN, LYN, LYST, MADD, MAGI1, MAGT1, MALT1, MAP2K1, MAP4K4, MAPK8IP3, MAPK9, MAPT, MARC1, MARCH5, MATN2, MBD3, MCF2L2, MCM6, MDGA2, MDM4, ASXL1, FUS, SPR54, MECOM, MEF2C, MEF2D, MEGF10, MEGF11, MEMO1, MET, MGA, MGAM, MGAT4A, MGAT5, MGC16169, MGC34774, MKKS, MIB1, MIER2, MITF, MKL2, MLANA, MLH1, MLL5, MLX, MME, MPDZ, MPI, MRAP2, MRPL11, MRPL39, MRPS28, MRPS35, MS4A13, MSH2, MSH3, MSMB, MST1R, MTDH, MTERF3, MTF1, MTF2, MTIF2, MTHFR, MUC2, MUT, MVK, MYB, MYBL2, MYC, MYCBP2, MYH2, MYRF, MYT1, MY019, MY03A, MY09B, MYOM2, MYOM3, NAG, NARG1, NARG2, NCOA1, NDC80, NDFIP2, NEB, NEDD4, NEK1, NEK5, ΝΕΚ11, NF1, NF2, NFATC2, NFE2L2, NFIA, NFIB, NFIX, NFKB1, NFKB2, NFKBIL2, NFRKB, NFYA, NFYB, NIPA2, NKAIN2, NKAP, NLRC3, NLRC5, NLRP3, NLRP7, NLRP8, NLRP13, NME1, NME1-NME2, NME2, NME7, NOL10, NOP561, NOS1, NOS2A, NOTCH1, NPAS4, NPM1, NR1D1, NR1H3, NR1H4, NR4A3, NR5A1, NRXN1, NSMAF, NSMCE2, NT5C, NT5C2, NT5C3, NUBP1, NUBPL, NUDT5, NUMA1, NUP88, NUP98, NUP160, NUPL1, OAT, OAZ1, OBFC2A, OBFC2B, OLIG2, OMA1, OPA1, OPN4, OPTN, OSBPL11, OSBPL8, OSGEPL1, OTC, OTX2, OVOL2, OXT, PA2G4, PADI4, PAH, PAN2, PAOX, PAPOLG, PARD3, PARP1, PARVB, PAWR, PAX3, PAX8, PBGD, PBRM1, PBX2, PCBP4, PCCA, PCGF2, PCNX, PCOTH, PDCD4, PDE4D, PDE8B, PDE10A, PD1A3, PDH1, PDLIM5, PDXK, PDZRN3, PELI2, PDK4, PDS5A, PDS5B, PGK1, PGM2, PHACTR4, PHEX, PHKB, PHLDB2, PHOX2B, PHTF1, PIAS1, PIEZO1, PIGF, PIGN, PIGT, PIK3C2G, PIK3CA, PIK3CD, PIK3CG, PIK3RI, PIP5K1A, PITRM1, PIWIL3, PKD1, PKHD1L1, PKD2, PKIB, PKLR, PKM1, PKM2, PLAGL2, PLCB1, PLCB4, PLCG1, PLD1, PLEKHA5, PLEKHA7, PLEKHM1, PLKR, PLXNC1, PMFBP1, POLN, POLR3D, POMT2, POSTN, POU2AF1, POU2F2, POU2F3, PPARA, PPFIA2, PPP1R12A, PPP3CB, PPP4C, PPP4R1L, PPP4R2, PRAME, PRC1, PRDM1, PREX1, PREX2, PRIM1, PRIM2, PRKAR1A, PRKCA, PRKG1, PRMT7, PROC, PROCR, PROSC, PRODH, PROX1, PRPF40B, PRPF4B, PRRG2, PRUNE2, PSD3, PSEN1, PSMAL, PTCH1, PTEN, PTK2, PTK2B, PTPN2, PTPN3, PTPN4, PTPN11, PTPN22, PTPRD, PTPRK, PTPRM, PTPRN2, PTPRT, PUS10, PVRL2, PYGM, QRSL1, RAB11FIP2, RAB23, RAF1, RALBP1, RALGDS, RB1CC1, RBL2, RBM39, RBM45, RBPJ, RBSN, REC8, RELB, RFC4, RFT1, RFTN1, RHOA, RHPN2, RIF1, RIT1, RLN3, RMND5B, RNF11, RNF32, RNFT1, RNGTT, ROCK1, ROCK2, RORA, RP1, RP6KA3, RP11- 265F1, RP13-36C9, RPAP3, RPN1, RPGR, RPL22, RPL22L1, RPS6KA6, RREB1, RRM1, RRP1B, RSK2, RTEL1, RTF1, RUFY1, RUNX1, RUNX2, RXRA, RYR3, SAAL1, SAE1, SALL4, SAT1, SATB2, SBCAD, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCNA, SCN11A, SCO1, SCYL3, SDC1, SDK1, SDK2, SEC24A, SEC24D, SEC31A, SEL1L, SENP3, SENP6, SENP7, SERPINA1, SETD3, SETD4, SETDB1, SEZ6, SFRS12, SGCE, SGOL2, SGPL1, SH2D1A, SH3BGRL2, SH3PXD2A, SH3PXD2B, SH3RF2, SH3TC2, SHOC2, SIPA1L2, SIPA1L3, SIVA1, SKAP1, SKIV2L2, SLC6A11, SLC6A13, SLC6A6, SLC7A2, SLC12A3, SLC13A1, SLC22A17, SLC25A14, SLC28A3, SLC33A1, SLC35F6, SLC38A1, SLC38A4, SLC39A10, SLC4A2, SLC6A8, SMARCA1, SMARCA2, SMARCA5, SMARCC2, SMC5, SMN2, SMOX, SMS, SMTN, SNCAIP, SNORD86, SNRK, SNRP70, SNX5, SNX6, SOD1, SOD10, SOS, SOS2, SOX5, SOX6, SOX8, SP1, SP2, SP3, SP110, SPAG9, SPATA13, SPATA4, SPATS1, SPECC1L, SPDEF, SPI1, SPINK5, SPP2, SPTA1, SRF, SRM, SRP72, SSX3, SSX5, SSX9, STAG1, STAG2, STAMBPLI, STARD6, STAT1, STAT3, STAT5A, STAT5B, STAT6, STK17B, STX3, STXBP1, SUCLG2, SULF2, SUPT6H, SUPT16H, SV2C, SYCP2, SYT6, SYCPI, SYTL3, SYTL5, TAF2, TARDBP, TBC1D3G, TBC1D8B, TBC1D26, TBC1D29, TBCEL, TBK1, TBP, TBPL1, TBR1, TBX, TCEB3, TCF3, TCF4, TCF7L2, TCFL5, TCF12, TCP11L2, TDRD3, TEAD1, TEAD3, TEAD4, TECTB, TEK, TERF1, TERF2, TET2, TFAP2A, TFAP2B, TFAP2C, TFAP4, TFDP1, TFRC, TG, TGM7, TGS1, THAP7, THAP12, THOC2, TIAL1, TIAM2, TIMM50, TLK2, TM4SF20, TM6SF1, TMEM27, TMEM77, TMEM156, TMEM194A, TMF1, TMPRSS6, TNFRSF10A, TNFRSF10B, TNFRSF8, TNK2, TNKS, TNKS2, TOM1L1, TOM1L2, TOP2B, TP53, TP53INP1, TP53BP2, TP53I3, TP63, TRAF3IP3, TRAPPC2, TRIM44, TRIM65, TRIML1, TRIML2, TRPM3, TRPM5, TRPM7, TRPS1, TSC1, TSC2, TSHB, TSPAN7, TTC17, TTF1, TTLL5, TTLL9, TTN, TTPAL, TTR, TUSC3, TXNDC10, UBE3A, UCK1, UGT1A1, UHRF1BP1, UNC45B, UNC5C, USH2A, USF2, USP1, USP6, USP18, USP38, USP39, UTP20, UTP15, UTP18, UTRN, UTX, UTY, UVRAG, UXT, VAPA, VEGFA, VPS29, VPS35, VPS39, VT11A, VT11B, VWA3B, WDFY2, WDR16, WDR17, WDR26, WDR44, WDR67, WDTC1, WRN, WRNIP1, WT1, WWC3, XBP1, XRN1, XRN2, XX-FW88277, YAP1, YARS, YBX1, YGM, YY1, ZBTB18, ZBTB20, ZC3HAV1, ZC3HC1, ZC3H7A, ZDHHC19, ZEB1, ZEB2, ZFPM1, ZFYVE1, ZFX, ZIC2, ZNF37A, ZNF91, ZNF114, ZNF155, ZNF169, ZNF205, ZNF236, ZNF317, ZNF320, ZNF326, ZNF335, ZNF365, ZNF367, ZNF407, ZNF468, ZNF506, ZNF511, ZNF511-PRAP1, ZNF519, ZNF521, ZNF592, ZNF618, ZNF763, and ZWINT. Additional exemplary genes encoding a target sequence (e.g., a target sequence comprising DNA or RNA, e.g., pre-mRNA) include genes include A1CF, A4GALT, AAR2, ABAT, ABCA11P, ZNF721, ABCA5, ABHD10, ABHD13, ABHD2, ABHD6, AC000120.3, KRIT1, AC004076.1, ZNF772, AC004076.9, ZNF772, AC004223.3, RAD51D, AC004381.6, AC006486.1, ERF, AC007390.5, AC007780.1, PRKAR1A, AC007998.2, INO80C, AC009070.1, CMC2, AC009879.2, AC009879.3, ADHFE1, AC010487.3, ZNF816-ZNF321P, ZNF816, AC010328.3, AC010522.1, ZNF587B, AC010547.4, ZNF19, AC012313.3, ZNF497, AC012651.1, CAPN3, AC013489.1, DET1, AC016747.4, C2orf74, AC020907.6, FXYD3, AC021087.5, PDCD6, AHRR, AC022137.3, ZNF761, AC025283.3, NAA60, AC027644.4, RABGEF1, AC055811.2, FLCN, AC069368.3, ANKDD1A, AC073610.3, ARF3, AC074091.1,GPN1, AC079447.1, LIPT1, AC092587.1, AC079594.2, TRIM59, AC091060.1,C18orf21, AC092143.3, MC1R, AC093227.2, ZNF607, AC093512.2, ALDOA, AC098588.1, ANAPC10, AC107871.1, CALML4, AC114490.2, ZMYM6, AC138649.1, NIPA1, AC138894.1, CLN3, AC139768.1, AC242426.2, CHD1L, ACADM, ACAP3, ACKR2,RP11- 141M3.5, KRBOX1, ACMSD, ACOT9, ACP5, ACPL2, ACSBG1, ACSF2, ACSF3, ACSL1, ACSL3, ACVR1, ADAL, ADAM29, ADAMTS10, ADAMTSL5, ADARB1, ADAT2, ADCK3, ADD3, ADGRG1, ADGRG2, ADH1B, ADIPOR1, ADNP, ADPRH, AGBL5, AGPAT1, AGPAT3, AGR2, AGTR1, AHDC1, AHI1, AHNAK, AIFM1, AIFM3, AIMP2, AK4, AKAP1, AKNAD1, CLCC1, AKR1A1, AKT1, AKT1S1, AKT2, AL139011.2, PEX19, AL157935.2, ST6GALNAC6, AL358113.1,TJP2, AL441992.2, KYAT1, AL449266.1,CLCC1, AL590556.3, LINC00339, CDC42, ALAS1, ALB, ALDH16A1, ALDH1B1, ALDH3A1, ALDH3B2, ALDOA, ALKBH2, ALPL, AMD1, AMICA1, AMN1, AMOTL2, AMY1B, AMY2B, ANAPC10, ANAPC11, ANAPC15, ANG, RNASE4, AL163636.2, ANGEL2, ANGPTL1, ANKMY1, ANKRD11, ANKRD28, ANKRD46, ANKRD9, ANKS3, ANKS3,RP11-127I20.7, ANKS6, ANKZF1, ANPEP, ANXA11, ANXA2, ANXA8L2, AL603965.1, AOC3, AP000304.12, CRYZL1, AP000311.1, CRYZL1, AP000893.2,RAB30, AP001267.5, ATP5MG, AP002495.2, AP003175.1, OR2AT4, AP003419.1, CLCF1, AP005263.1, ANKRD12, AP006621.5, AP006621.1, AP1G1, AP3M1, AP3M2, APBA2, APBB1, APLP2, APOA2, APOL1, APOL3, APTX, ARAP1,STARD10, ARF4, ARFIP1, ARFIP2, ARFRP1, ARHGAP11A, ARHGAP33, ARHGAP4, ARHGEF10, ARHGEF3, ARHGEF35, OR2A1-AS1, ARHGEF35, OR2A1-AS1, ARHGEF34P, ARID1B, ARHGEF35, OR2A20P, OR2A1-AS1, ARHGEF9, ARL1, ARL13B, ARL16, ARL6, ARMC6, ARMC8, ARMCX2, ARMCX5, RP4-769N13.6, ARMCX5-GPRASP2, BHLHB9, ARMCX5-GPRASP2,GPRASP1, ARMCX5- GPRASP2,GPRASP2, ARMCX6, ARNT2, ARPP19, ARRB2, ARSA, ART3, ASB3,GPR75-ASB3, ASCC2, ASNS, ASNS, AC079781.5, ASPSCR1, ASS1, ASUN, ATE1, ATF1, ATF7IP2, ATG13, ATG4D, ATG7, ATG9A, ATM, ATOX1, ATP1B3, ATP2C1, ATP5F1A, ATP5G2, ATP5J, ATP5MD, ATP5PF, ATP6AP2, ATP6V0B, ATP6V1C1, ATP6V1D, ATP7B, ATXN1, ATXN1L,IST1, ATXN3, ATXN7L1, AURKA, AURKB, AXDND1, B3GALNT1, B3GALT5, AF064860.1, B3GALT5,AF064860.5, B3GNT5, B4GALT3, B4GALT4, B9D1, BACH1, BAIAP2, BANF1, BANF2, BAX, BAZ2A, BBIP1, BCHE, BCL2L14, BCL6, BCL9L, BCS1L, BDH1, BDKRB2,AL355102.2, BEST1, BEST3, BEX4, BHLHB9, BID, BIN3, BIRC2, BIVM, BIVM- ERCC5, BIVM, BLCAP, BLK, BLOC1S1, RP11-644F5.10, BLOC1S6, AC090527.2, BLOC1S6, RP11-96O20.4, BLVRA, BMF, BOLA1, BORCS8-MEF2B, BORCS8, BRCA1, BRD1, BRDT, BRINP3, BROX, BTBD10, BTBD3, BTBD9, BTD, BTF3L4, BTNL9, BUB1B-PAK6, PAK6, BUB3, C10orf68, C11orf1, C11orf48, C11orf54, C11orf54,AP001273.2, C11orf57, C11orf63, C11orf82, C12orf23, C12orf4, C12orf65, C12orf79, C14orf159, C14orf93, C17orf62, C18orf21, C19orf12, C19orf40, C19orf47, C19orf48, C19orf54, C1D, C1GALT1, C1QB, C1QTNF1, C1S, C1orf101, C1orf112, C1orf116, C1orf159, C1orf63, C2, C2,CFB, C20orf27, C21orf58, C2CD4D, C2orf15, LIPT1, MRPL30, C2orf80, C2orf81, C3orf14, C3orf17, C3orf18, C3orf22, C3orf33,AC104472.3, C4orf33, C5orf28, C5orf34, C6orf118, C6orf203, C6orf211, C6orf48, C7orf50, C7orf55, C7orf55-LUC7L2, LUC7L2, C8orf44-SGK3,C8orf44, C8orf59, C9,DAB2, C9orf153, C9orf9, CA5BP1,CA5B, CABYR, CALCA, CALCOCO1, CALCOCO2, CALM1, CALM3, CALML4, RP11-315D16.2, CALN1, CALU, CANT1, CANX, CAP1, CAPN12, CAPS2, CARD8, CARHSP1, CARNS1, CASC1, CASP3, CASP7, CBFA2T2, CBS, CBY1, CCBL1, CCBL2, RBMXL1, CCDC12, CCDC126, CCDC14, CCDC149, CCDC150, CCDC169-SOHLH2, CCDC169, CCDC171, CCDC37, CCDC41, CCDC57, CCDC63, CCDC7, CCDC74B, CCDC77, CCDC82, CCDC90B, CCDC91, CCDC92, CCNE1, CCHCR1, CCL28, CCNB1IP1, CCNC, CCND3, CCNG1, CCP110, CCR9, CCT7, CCT8, CD151, CD1D, CD200, CD22, CD226, CD276, CD36, CD59, CDC26, CDC42, CDC42SE1, CDC42SE2, CDHR3, CDK10, CDK16, CDK4, CDKAL1, CDKL3,CTD-2410N18.4, CDKN1A, CDKN2A, CDNF, CEBPZOS, CELF1, CEMIP, CENPK, CEP170B, CEP250, CEP57, CEP57L1, CEP63, CERS4, CFL1, CFL2, CFLAR, CGNL1, CHCHD7, CHD1L, CHD8, CHFR,ZNF605, CHIA, CHID1, CHL1, CHM, CHMP1A, CHMP3, RNF103-CHMP3, CHRNA2, CIDEC, CIRBP, CITED1, CKLF-CMTM1, CMTM1, CKMT1B, CLDN12,CTB-13L3.1, CLDND1,AC021660.3, CLDND1,CPOX, CLHC1, CLIP1, CLUL1, CMC4, MTCP1, CNDP2, CNFN, CNOT1, CNOT6, CNOT7, CNOT8, CNR1, CNR2, CNTFR, CNTRL, COA1, COASY, COCH, COL8A1, COLCA1, COLEC11, COMMD3- BMI1, BMI1, COPS5, COPS7B, COQ8A, CORO6, COTL1, COX14,RP4-605O3.4, COX7A2, COX7A2L, COX7B2, CPA4, CPA5, CPEB1, CPNE1, AL109827.1, RBM12, CPNE1, RP1- 309K20.6, RBM12, CPNE3, CPSF3L, CPT1C, CREB3L2, CREM, CRP, CRYZ, CS,AC073896.1, CS, RP11-977G19.10, CSAD, CSDE1, CSF2RA, CSGALNACT1, CSK, CSNK2A1, CSRNP2, CT45A4, CT45A4,CT45A5, CT45A6, CTBP2, CTCFL, CTD-2116N17.1, KIAA0101, CTD- 2349B8.1, SYT17, CTD-2528L19.4, ZNF607, CTD-2619J13.8, ZNF497, CTNNA1, CTNNBIP1, CTNND1, CTPS2, CTSB, CTSL, CTTN, CUL2, CUL9, CWC15, CXorf40B, CYB561A3, CYBC1, CYLD, CYP11A1, CYP2R1, CYP4B1, CYP4F22, DAG1, DAGLB,KDELR2, DARS, DBNL, DCAF11, DCAF8,PEX19, DCLRE1C, DCTD, DCTN1, DCTN4, DCUN1D2, DDR1, DDX11, DDX19B, AC012184.2, DDX19B, RP11-529K1.3, DDX25, DDX39B, ATP6V1G2-DDX39B, SNORD84, DDX42, DDX60L, DEDD, DEDD2, DEFA1, DEFA1B, DEFA1B, DEFA3, DENND1C, DENND2A, DENND4B, DET1, DGKA, DGKZ, DGLUCY, DHRS4L2, DHRS9, DHX40, DIABLO, AC048338.1, DIAPH1, DICER1, DKKL1, DLG1, DLG3, DLST, DMC1, DMKN, DMTF1, DMTN, DNAJC14, DNAJC19, DNAL1, DNASE1L1, DNMT3A, DOC2A, DOCK8, DOK1, DOPEY1, DPAGT1, DPP8, DRAM2, DRD2, DROSHA, DSN1, DTNA, DTX2, DTX3, DUOX1, DUOXA1, DUS2, DUSP10, DUSP13, DUSP18, DUSP22, DYDC1, DYDC2, DYNLL1, DYNLT1, DYRK1A, DYRK2, DYRK4, RP11-500M8.7, DZIP1L, E2F6, ECHDC1, ECSIT, ECT2, EDC3, EDEM1, EDEM2, MMP24-AS1, RP4-614O4.11, EEF1AKNMT, EEF1D, EFEMP1, EFHC1, EGFL7, EHF, EI24, EIF1AD, EIF2B5, EIF4G1, EIF2B5, POLR2H, EIF3E, EIF3K, EIF4E3, EIF4G1, ELF1, ELMO2, ELMOD1, AP000889.3, ELMOD3, ELOC, ELOF1, ELOVL1, ELOVL7, ELP1, ELP6, EML3, EMP3, ENC1, ENDOV, ENO1, ENPP5, ENTHD2, ENTPD6, EP400NL, EPB41L1, EPDR1,NME8, EPHX1, EPM2A, EPN1, EPN2, EPN3, EPS8L2, ERBB3, ERC1, ERCC1, ERG, ERI2, ERI2, DCUN1D3, ERLIN2, ERMARD, ERRFI1, ESR2,RP11-544I20.2, ESRRA, ESRRB, ESRRG, ETFA, ETFRF1, ETV1, ETV4, ETV7, EVA1A, EVC2, EVX1, EXD2, EXO5, EXOC1, EXOC2, FAAP24, FABP6, FADS1, FADS2, FAHD2B, FAM107B, FAM111A, FAM111B, FAM114A1, FAM114A2, FAM115C, FAM115C,FAM115D, FAM120B, FAM133B, FAM135A, FAM153A, FAM153B, FAM154B, FAM156A, FAM156B, FAM168B, FAM172A, FAM182B, FAM192A, FAM19A2, FAM200B, FAM220A, FAM220A, AC009412.1, FAM222B, FAM227B, FAM234A, AC004754.1, FAM3C, FAM45A, FAM49B, FAM60A, FAM63A, FAM81A, FAM86B1, FAM86B2, FANCI, FANK1, FAR2, FAXC, FAXDC2, FBF1, FBH1, FBXL4, FBXO18, FBXO22, FBXO31, FBXO41, FBXO44, FBXO45, FBXW9, FCHO1, FCHSD2, FDFT1, FDPS, FER, FETUB, FGD4, FGF1, FGFR1, FGFRL1, FGL1, FHL2, FIBCD1, FIGNL1, FIGNL1,DDC, FKBP5, FKRP, FLRT2, FLRT3, FMC1, LUC7L2, FMC1-LUC7L2, FNDC3B, FOLH1, FOLR1, FOXP1, FOXK1, FOXM1, FOXO1, FOXP4, AC097634.4, FOXRED1, FPR1, FPR2, FRG1B, FRS2, FTO, FTSJ1, FUK, FUT10, FUT3, FUT6, FXYD3, FZD3, G2E3, GAA, GABARAPL1, GABPB1, GABRA5, GAL3ST1, GALE, GALNT11, GALNT14, GALNT6, GAPVD1, GARNL3, GAS2L3, GAS8, GATA1, GATA2, GATA4, GBA, GCNT1, GDPD2, GDPD5, GEMIN7,MARK4, GEMIN8, GGA3, GGACT, AL356966.1, GGPS1, GHRL, GID8, GIGYF2, GIMAP8, GIPC1, GJB1, GJB6, GLB1L, GLI1, GLT8D1, GMFG, GMPR2, GNAI2, GNAQ,GNB1, GNB2, GNE, GNG2, GNGT2, GNPDA1, GNPDA2, GOLGA3,CHFR, GOLGA4, GOLPH3L, GOLT1B, GPBP1L1, GPER1, GPR116, GPR141,EPDR1, GPR155, GPR161, GPR56, GPR63, GPR75-ASB3,ASB3, GPR85, GPSM2, GRAMD1B, GRB10, GRB7, GREM2, GRIA2, GSDMB, GSE1, GSN, GSTA4, GSTZ1, GTDC1, GTF2H1, GTF2H4, VARS2, GTF3C2, GUCY1A3, GUCY1B3, GUK1, GULP1, GYPC, GYS1, GZF1, HAGH, HAO2, HAPLN3, HAVCR1, HAX1, HBG2, AC104389.4, HBG2, AC104389.4, HBE1, HBG2, AC104389.4, HBE1,OR51B5, HBG2,HBE1, AC104389.28, HBS1L, HCFC1R1, HCK, HDAC2, HDAC6, HDAC7, HDLBP, HEATR4, HECTD4, HEXIM2, HHAT, HHATL, CCDC13, HINFP, HIRA, C22orf39, HIVEP3, HJV, HKR1, HLF, HMBOX1, HMGA1, HMGB3, HMGCR, HMGN4, HMOX2, HNRNPC, HNRNPD, HNRNPH1, HNRNPH3, HNRNPR, HOMER3, HOPX, HOXA3, HOXB3, HOXB3,HOXB4, HOXC4, HOXD3, HOXD3,HOXD4, HPCAL1, HPS4, HPS5, HRH1, HS3ST3A1, HSH2D, HSP90AA1, HSPD1, HTT, HUWE1, HYOU1, IAH1, ICA1L, ICAM2, ICE2, ICK, IDH2, IDH3G, IDS, IFI27, IFI44, IFT20, IFT22, IFT88, IGF2, INS-IGF2, IGF2BP3, IGFBP6, IKBKAP, IKBKB, IL11, IL18BP, IL18RAP, IL1RAP, IL1RL1, IL18R1, IL1RN, IL32, IL4I1,NUP62,AC011452.1, IL4I1,NUP62,CTC- 326K19.6, IL6ST, ILVBL, IMMP1L, IMPDH1, INCA1, ING1, INIP, INPP1, INPP5J, INPP5K, INSIG2, INTS11, INTS12, INTS14, IP6K2, IP6K3, IPO11, LRRC70, IQCE, IQGAP3, IRAK4, IRF3, IRF5, IRF6, ISG20, IST1, ISYNA1, ITFG2, ITGB1BP1, ITGB7, ITIH4, RP5-966M1.6, ITPRIPL1, JADE1, JAK2, JARID2, JDP2, KANK1, KANK1,RP11-31F19.1, KANK2, KANSL1L, KAT6A, KBTBD2, KBTBD3, KCNAB2, KCNE3, KCNG1, KCNJ16, KCNJ9, KCNMB2,AC117457.1,LINC01014, KCTD20, KCTD7,RABGEF1, KDM1B, KDM4A,AL451062.3, KHNYN, KIAA0040, KIAA0125, KIAA0196, KIAA0226L, PPP1R2P4, KIAA0391, KIAA0391, AL121594.1, KIAA0391, PSMA6, KIAA0753, KIAA0895, KIAA0895L, KIAA1191, KIAA1407, KIAA1841, C2orf74, KIF12, KIF14, KIF27, KIF9, KIFC3, KIN, KIRREL1, KITLG, KLC1, APOPT1, AL139300.1, KLC4, KLHDC4, KLHDC8A, KLHL13, KLHL18, KLHL2, KLHL24, KLHL7, KLK11, KLK2, KLK5, KLK6, KLK7, KNOP1, KRBA2, AC135178.2, KRBA2, RP11-849F2.7, KRIT1, KRT15, KRT8, KTN1, KXD1, KYAT3, RBMXL1, KYNU, L3MBTL1, LACC1, LARGE, LARP4, LARP7, LAT2, LBHD1, LCA5, LCA5L, LCTL, LEPROTL1, LGALS8, LGALS9C, LGMN, LHFPL2, LIG4, LIMCH1, LIMK2, LIMS2, LINC00921, ZNF263, LIPF, LLGL2, LMAN2L, LMCD1, LMF1, RP11-161M6.2, LMO1, LMO3, LOXHD1, LPAR1, LPAR2, LPAR4, LPAR5, LPAR6, LPHN1, LPIN2, LPIN3, LPP, LRFN5, LRIF1, LRMP, LRRC14, LRRC20, LRRC24, C8orf82, LRRC39, LRRC42, LRRC48, LRRC4C, LRRC8A, LRRC8B, LRRD1, LRTOMT, LRTOMT, AP000812.5, LSM7, LTB4R, LTBP3, LUC7L2, FMC1-LUC7L2, LUC7L3, LUZP1, LYG1, LYL1, LYPD4, LYPD6B, LYRM1, LYRM5, LYSMD4, MACC1, MAD1L1, MAD1L1, AC069288.1, MAEA, MAFF, MAFG, MAFK, MAGEA12,CSAG4, MAGEA2, MAGEA2B, MAGEA4, MAGEB1, MAGOHB, MAN2A2, MANBAL, MAOB, MAP2K3, MAP3K7CL, MAP3K8, MAP7, MAP9, MAPK6, MAPK7, MAPK8, MAPKAP1, 10-Mar, 7-Mar, 8-Mar, MARK2, MASP1, MATK, MATR3, MATR3,SNHG4, MB, MBD5, MBNL1, MBOAT7, MCC, MCFD2, MCM9, MCOLN3, MCRS1, MDC1, MDGA2, MDH2, MDM2, ME1, MEAK7, MECR, MED4, MEF2A, MEF2B,BORCS8-MEF2B, MEF2BNB- MEF2B, MEF2B, MEF2BNB, MEF2C, MEF2D, MEGF10, MEI1, MEIS2, MELK, MET, METTL13, METTL23, MFF, MFN2, MFSD2A, MGST3, MIB2, MICAL1, MICAL3, MICOS10, NBL1,MICOS10-NBL1, MID1, MINA, MINOS1-NBL1,MINOS1, MIOS, MIPOL1, MIS12, MKLN1, MKNK1, MKNK1,MOB3C, MLF2, MLH1, MMP17, MOBP, MOCS1, MOGS, MOK, MORF4L1, MPC1, MPC2, MPG, MPI, MPP1, MPP2, MPPE1, MPST, MRAS, MRO, MROH1, MROH7-TTC4, MROH7, MRPL14, MRPL24, MRPL33,BABAM2, MRPL33, BRE, MRPL47, MRPL48, MRPL55, MRRF, MRTFA, MRTFB, MRVI1, MS4A1, MS4A15, MS4A3, MS4A6E,MS4A7,MS4A14, MSANTD3, MSANTD4, MSH5,MSH5-SAPCD1, MSL2, MSRB3, MSS51, MTCP1,CMC4, MTERF, MTERF1, MTERF3, MTERFD2, MTERFD3, MTF2, MTG2, MTHFD2, MTHFD2L, MTIF2, MTIF3, MTMR10, MTRF1, MTRR, MTUS2, MUTYH, MVK, MX1, MX2, MYH10, MYL12A, MYB, MYD88, MYL5, MYLIP, MYNN, MYO15A, MYO1B, MYOM2, MZF1, N4BP2L2, NAA60, NAB1, NAE1, NAGK, NAP1L1, NAP1L4, NAPG, NARFL, NARG2, NAT1, NAT10, NBPF11, WI2-3658N16.1, NBPF12, NBPF15, NBPF24, NBPF6, NBPF9, NBR1, NCAPG2, NCBP2, NCEH1, NCOA1, NCOA4, NDC1, NDRG1, NDRG2, NDRG4, NDST1, NDUFAF6, NDUFB2, NDUFC1, NDUFS1, NDUFS8, NDUFV1, NEDD1, NEIL1, NEIL2, NEK10, NEK11, NEK6, NEK9, NELFA, NEU4, NFAT5, NFE2, NFE2L2, AC019080.1, NFRKB, NFYA, NFYC, NIF3L1, NIPA2, NKIRAS1, NKX2-1, NLRC3, NME1,NME1-NME2,NME2, NME1-NME2, NME2, NME4, NME6, NME9, NOD1, NOL10, NOL8, NONO, NPAS1, NPIPA8, RP11-1212A22.1, NPIPB3, NPIPB4, NPIPB9, NPL, NPM1, NPPA, NQO2, NR1H3, NR2C2, NR2F2, NR4A1, NRDC, NREP, NRF1, NRG4, NRIP1, NSD2, NSDHL, NSG1, NSMCE2, NSRP1, NT5C2, NTF4, NTMT1, NTNG2, NUBP2, NUCB2, NUDT1, NUDT2, NUDT4, NUF2, NUMBL, NUP50, NUP54, NUP85, NVL, NXF1, NXPE1, NXPE3, OARD1, OAT, OAZ2, OCIAD1, OCLN, ODF2, OGDHL, OGFOD2, AC026362.1, OGFOD2, RP11-197N18.2, OLA1, OPRL1, OPTN, OR2H1, ORAI2, ORMDL1, ORMDL2, ORMDL3, OSBPL2, OSBPL3, OSBPL5, OSBPL9, OSER1, OSGIN1, OSR2, P2RX4, P2RY2, P2RY6, P4HA2, PABPC1, PACRGL, PACSIN3, PADI1, PAIP2, PAK1, PAK3, PAK4, PAK7, PALB2, PANK2, PAQR6, PARP11, PARVG, PASK, PAX6, PBRM1, PBXIP1, PCBP3, PCBP4,AC115284.1, PCBP4, RP11-155D18.14, RP11-155D18.12, PCGF3, PCGF5, PCNP, PCSK9, PDCD10, PDCD6, AHRR, PDDC1, PDGFRB, PDIA6, PDIK1L, PDLIM7, PDP1, PDPK1, PDPN, PDZD11, PEA15, PEX2, PEX5, PEX5L, PFKM, PFN4, PGAP2, PGAP2, AC090587.2, PGAP3, PGM3, PGPEP1, PHB, PHC2, PHF20, PHF21A, PHF23, PHKB, PHLDB1, PHOSPHO1, PHOSPHO2, KLHL23, PI4KB, PIAS2, PICALM, PIF1, PIGN, PIGO, PIGT, PIK3CD, PILRB, STAG3L5P-PVRIG2P-PILRB, PIP5K1B, PIR, PISD, PIWIL4,FUT4, PKD2, PKIA, PKIG, PKM, PKN2, PLA1A, PLA2G2A, PLA2G5, PLA2G7, PLAC8, PLAGL1, PLD1, PLD3, PLEKHA1, PLEKHA2, PLEKHA6, PLEKHG5, PLIN1, PLS1, PLS3, PLSCR1, PLSCR2, PLSCR4, PLXNB1, PLXNB2, PMP22, PMS1, PNISR, PNKP,AKT1S1, PNMT, PNPLA4, PNPLA8, PNPO, PNRC1, POC1B, POFUT1, POLB, POLD1, POLH, POLI, POLL, POLR1B, POM121, POM121C,AC006014.7, POM121C, AC211429.1, POMC, POMT1, POP1, PORCN, POU5F1, PSORS1C3, PPARD, PPARG, PPHLN1, PPIL3, PPIL4, PPM1A, PPM1B,AC013717.1, PPP1CB, PPP1R11, PPP1R13L, PPP1R26, PPP1R9A, PPP2R2B, PPP3CA, PPP6R1, PPP6R3, PPT2,PPT2-EGFL8, EGFL8, PPWD1, PRDM2, PRDM8, PRELID3A, PREPL, PRICKLE1, PRKAG1, PRMT2, PRMT5, PRMT7, PROM1, PRPS1, PRPSAP2, PRR14L, PRR15L, PRR5,PRR5-ARHGAP8, PRR5L, PRR7, PRRC2B, PRRT4, PRSS50, PRSS45, PRSS44, PRUNE, PRUNE1, PSEN1, PSMA2, PSMF1, PSORS1C1, PSPH, PSRC1, PTBP3, PTHLH, PTK2, PTPDC1, PTPRM, PUF60, PUM2, PUS1, PUS10, PXN, PXYLP1, PYCR1, QRICH1, R3HCC1L, R3HDM2, RAB17, RAB23, RAB3A, RAB3D,TMEM205, RAB4B-EGLN2, EGLN2, AC008537.1, RAB5B, RAB7L1, RABL2A, RABL2B, RABL5, RACGAP1, RAD17, RAD51L3-RFFL, RAD51D, RAD52, RAE1, RAI14, RAI2, RALBP1, RAN, RANGAP1, RAP1A, RAP1B, RAP1GAP, RAPGEF4, RAPGEFL1, RASGRP2, RASSF1, RBCK1, RBM12B, RBM14, RBM4, RBM14-RBM4, RBM23, RBM4, RBM14-RBM4, RBM47, RBM7,AP002373.1, RBM7, RP11-212D19.4, RBMS2, RBMY1E, RBPJ, RBPMS, RBSN, RCBTB2, RCC1, RCC1, SNHG3, RCCD1, RECQL, RELL2, REPIN1, AC073111.3, REPIN1, ZNF775, RER1, RERE, RFWD3, RFX3, RGL2, RGMB, RGS11, RGS3, RGS5, AL592435.1, RHBDD1, RHNO1, TULP3, RHOC, AL603832.3, RHOC,RP11-426L16.10, RHOH, RIC8B, RIMKLB, RIN1, RIPK2, RIT1, RLIM, RNASE4,ANG,AL163636.6, RNASEK, RNASEK-C17orf49, RNF111, RNF123, RNF13, RNF14, RNF185, RNF216, RNF24, RNF32, RNF34, RNF38, RNF4, RNF44, RNH1, RNMT, RNPS1, RO60, ROPN1, ROPN1B, ROR2, RP1-102H19.8, C6orf163, RP1-283E3.8,CDK11A, RP11-120M18.2,PRKAR1A, RP11-133K1.2, PAK6, RP11- 164J13.1,CAPN3, RP11-21J18.1, ANKRD12, RP11-322E11.6,INO80C, RP11- 337C18.10,CHD1L, RP11-432B6.3, TRIM59, RP11-468E2.4,IRF9, RP11-484M3.5,UPK1B, RP11-517H2.6, CCR6, RP11-613M10.9, SLC25A51, RP11-659G9.3, RAB30, RP11- 691N7.6,CTNND1, RP11-849H4.2, RP11-896J10.3, NKX2-1, RP11-96O20.4,SQRDL, RP11- 986E7.7, SERPINA3, RP4-769N13.6, GPRASP1, RP4-769N13.6,GPRASP2, RP4-798P15.3, SEC16B, RP5-1021I20.4, ZNF410, RP6-109B7.3, FLJ27365, RPE, RPH3AL, RPL15, RPL17, RPL17-C18orf32,RPL17, RPL23A, RPL36,HSD11B1L, RPP38, RPS20, RPS27A, RPS3A, RPS6KA3, RPS6KC1, RPS6KL1, RPUSD1, RRAGD, RRAS2, RRBP1, RSL1D1, RSRC2, RSRP1, RUBCNL, RUNX1T1, RUVBL2, RWDD1, RWDD4, S100A13,AL162258.1, S100A13,RP1- 178F15.5, S100A16, S100A4, S100A3, S100A6, S100PBP, SAA1, SACM1L, SAMD4B, SAR1A, SARAF, SARNP,RP11-762I7.5, SCAMP5, SCAP, SCAPER, SCFD1, SCGB3A2, SCIN, SCML1, SCNN1D, SCO2, SCOC, SCRN1, SDC2, SDC4, SEC13, SEC14L1, SEC14L2, SEC22C, SEC23B, SEC24C, SEC61G, SEMA4A, SEMA4C, SEMA4D, SEMA6C, SENP7, SEPP1, 11-Sep, 2-Sep, SERGEF, AC055860.1, SERP1, SERPINA1, SERPINA5, SERPINB6, SERPING1, SERPINH1, SERTAD3, SETD5, SFMBT1, AC096887.1, SFTPA1, SFTPA2, SFXN2, SGCD, SGCE, SGK3, SGK3,C8orf44, SH2B1, SH2D6, SH3BP1,Z83844.3, SH3BP2, SH3BP5, SH3D19, SH3YL1, SHC1, SHISA5, SHMT1, SHMT2, SHOC2, SHROOM1, SIGLEC5,SIGLEC14, SIL1, SIN3A, SIRT2, SIRT6, SKP1, STAT4, AC104109.3, SLAIN1, SLC10A3, SLC12A9, SLC14A1, SLC16A6, SLC1A2, SLC1A6, SLC20A2, SLC25A18, SLC25A19, SLC25A22, SLC25A25, SLC25A29, SLC25A30, SLC25A32, SLC25A39, SLC25A44, SLC25A45, SLC25A53, SLC26A11, SLC26A4, SLC28A1, SLC29A1, SLC2A14, SLC2A5, SLC2A8, SLC35B2, SLC35B3, SLC35C2, SLC37A1, SLC38A1, SLC38A11, SLC39A13, SLC39A14, SLC41A3, SLC44A3, SLC4A7, SLC4A8, SLC5A10, SLC5A11, SLC6A1, SLC6A12, SLC6A9, SLC7A2, SLC7A6, SLC7A7, SLCO1A2, SLCO1C1, SLCO2B1, SLFN11, SLFN12, SLFNL1, SLMO1, SLTM, SLU7, SMAD2, SMAP2, SMARCA2, SMARCE1, AC073508.2, SMARCE1, KRT222, SMC6, SMG7, SMIM22, SMOX, SMPDL3A, SMTN, SMU1, SMUG1, SNAP25, SNCA, SNRK, SNRPC, SNRPD1, SNRPD2, SNRPN, SNRPN,SNURF, SNUPN, SNX11, SNX16, SNX17, SOAT1, SOHLH2,CCDC169- SOHLH2,CCDC169, SORBS1, SORBS2, SOX5, SP2, SPART, SPATA20, SPATA21, SPATS2, SPATS2L, SPDYE2, SPECC1, SPECC1L,SPECC1L-ADORA2A, SPECC1L-ADORA2A, ADORA2A, SPEG, SPG20, SPG21, SPIDR, SPIN1, SPOCD1, SPOP, SPRR2A, SPRR2B, SPRR2E, SPRR2B, SPRR2F, SPRR2D, SPRR3, SPRY1, SPRY4, SPTBN2, SRC, SRGAP1, SRP68, SRSF11, SSX1, SSX2IP, ST3GAL4, ST3GAL6, ST5, ST6GALNAC6, ST7L, STAC3, STAG1, STAG2, STAMBP, STAMBPL1, STARD3NL, STAT6, STAU1, STAU2, AC022826.2, STAU2, RP11-463D19.2, STEAP2, STEAP3, STIL, STK25, STK33, STK38L, STK40, STMN1, STON1,STON1-GTF2A1L, STRAP, STRBP, STRC, AC011330.5, STRC, CATSPER2, STRC, CATSPER2, AC011330.5, STRC,STRCP1, STT3A, STX16-NPEPL1, NPEPL1, STX5, STX6, STX8, STXBP6, STYK1, SULT1A1, SULT1A2, SUMF2, SUN1, SUN2, SUN2, DNAL4, SUOX, SUPT6H, SUV39H2, SV2B, SYBU, SYNCRIP, SYNJ2, SYT1, SYTL4, TAB2, TACC1, TADA2B, TAF1C, TAF6,AC073842.2, TAF6, RP11-506M12.1, TAF9, TAGLN, TANK, TAPSAR1,PSMB9, TAPT1, TATDN1, TAZ, TBC1D1, TBC1D12, HELLS, TBC1D15, TBC1D3H,TBC1D3G, TBC1D5, TBC1D5,SATB1, TBCA, TBCEL, TBCEL, AP000646.1, TBL1XR1, TBP, TBX5, TBXAS1, TCAF1, TCEA2, TCEAL4, TCEAL8, TCEAL9, TCEANC, TCEB1, TCF19, TCF25, TCF4, TCP1, TCP10L, AP000275.65, TCP11, TCP11L2, TCTN1, TDG, TDP1, TDRD7, TEAD2, TECR, TENC1, TENT4A, TEX264, TEX30, TEX37, TFDP1, TFDP2, TFEB, TFG, TFP1,TF, TFPI, TGIF1, THAP6, THBS3, THOC5, THRAP3, THUMPD3, TIAL1, TIMM9, TIMP1, TIRAP, TJAP1, TJP2, TK2, TLDC1, TLE3, TLE6, TLN1, TLR10, TM9SF1, TMBIM1, TMBIM4, TMBIM6, TMC6, TMCC1, TMCO4, TMEM126A, TMEM139, TMEM150B, TMEM155, TMEM161B, TMEM164, TMEM168, TMEM169, TMEM175, TMEM176B, TMEM182, TMEM199,CTB-96E2.3, TMEM216, TMEM218, TMEM230, TMEM263, TMEM45A, TMEM45B, TMEM62, TMEM63B, TMEM66, TMEM68, TMEM98, TMEM9B, TMPRSS11D, TMPRSS5, TMSB15B, TMTC4, TMUB2, TMX2-CTNND1, RP11-691N7.6,CTNND1, TNFAIP2, TNFAIP8L2, SCNM1, TNFRSF10C, TNFRSF19, TNFRSF8, TNFSF12-TNFSF13, TNFSF12, TNFSF13, TNFSF12-TNFSF13, TNFSF13, TNIP1, TNK2, TNNT1, TNRC18, TNS3, TOB2, TOM1L1, TOP1MT, TOP3B, TOX2, TP53,RP11-199F11.2, TP53I11, TP53INP2, TPCN1, TPM3P9,AC022137.3, TPT1, TRA2B, TRAF2, TRAF3, TRAPPC12, TRAPPC3, TREH, TREX1, TREX2, TRIB2, TRIM3, TRIM36, TRIM39, TRIM46, TRIM6, TRIM6-TRIM34, TRIM6-TRIM34, TRIM34, TRIM66, TRIM73, TRIT1, TRMT10B, TRMT2B, TRMT2B-AS1, TRNT1, TRO, TROVE2, TRPS1, TRPT1, TSC2, TSGA10, TSPAN14, TSPAN3, TSPAN4, TSPAN5, TSPAN6, TSPAN9, TSPO, TTC12, TTC23, TTC3, TTC39A, TTC39C, TTLL1, TTLL7, TTPAL, TUBD1, TWNK, TXNL4A, TXNL4B, TXNRD1, TYK2, U2AF1, UBA2, UBA52, UBAP2, UBE2D2, UBE2D3, UBE2E3, UBE2I, UBE2J2, UBE3A, UBL7, UBXN11, UBXN7, UGDH, UGGT1, UGP2, UMAD1,AC007161.3, UNC45A, UQCC1, URGCP-MRPS24,URGCP, USMG5, USP16, USP21, USP28, USP3, USP33, USP35, USP54, USP9Y, USPL1, UTP15, VARS2, VASH2, VAV3, VDAC1, VDAC2, VDR, VEZT, VGF, VIL1, VILL, VIPR1, VPS29, VPS37C, VPS8, VPS9D1, VRK2, VWA1, VWA5A, WARS, WASF1, WASHC5, WBP5, WDHD1, WDPCP, WDR37, WDR53, WDR6, WDR72, WDR74, WDR81, WDR86, WDYHV1, WFDC3, WHSC1, WIPF1, WSCD2, WWP2, XAGE1A, XAGE1B, XKR9, XPNPEP1, XRCC3, XRN2, XXYLT1, YIF1A, YIF1B, YIPF1, YIPF5, YPEL5, YWHAB, YWHAZ, YY1AP1, ZBTB1, ZBTB14, ZBTB18, ZBTB20, ZBTB21, ZBTB25, ZBTB33, ZBTB34, ZBTB38, ZBTB43, ZBTB49, ZBTB7B, ZBTB7C, ZBTB8OS, ZC3H11A, ZBED6, ZC3H13, ZCCHC17, ZCCHC7, ZDHHC11, ZDHHC13, ZEB2, ZFAND5, ZFAND6, ZFP1, ZFP62, ZFX, ZFYVE16, ZFYVE19, ZFYVE20, ZFYVE27, ZHX2, AC016405.1, ZHX3, ZIK1, ZIM2,PEG3, ZKSCAN1, ZKSCAN3, ZKSCAN8, ZMAT3, ZMAT5, ZMIZ2, ZMYM6, ZMYND11, ZNF10,AC026786.1, ZNF133, ZNF146, ZNF16, ZNF177, ZNF18, ZNF200, ZNF202, ZNF211, ZNF219, ZNF226, ZNF227, ZNF23, AC010547.4, ZNF23, AC010547.9, ZNF239, ZNF248, ZNF25, ZNF253, ZNF254, ZNF254, AC092279.1, ZNF263, ZNF274, ZNF275, ZNF28,ZNF468, ZNF283, ZNF287, ZNF3, ZNF320, ZNF322, ZNF324B, ZNF331, ZNF334, ZNF34, ZNF350, ZNF385A, ZNF395, FBXO16, ZNF415, ZNF418, ZNF43, ZNF433-AS1, AC008770.4, ZNF438, ZNF444, ZNF445, ZNF467, ZNF480, ZNF493, ZNF493,CTD-2561J22.3, ZNF502, ZNF507, ZNF512, AC074091.1, ZNF512,RP11-158I13.2, ZNF512B, ZNF512B, SAMD10, ZNF521, ZNF532, ZNF544, AC020915.5, ZNF544, CTD- 3138B18.4, ZNF559,ZNF177, ZNF562, ZNF567, ZNF569, ZNF570, ZNF571-AS1,ZNF540, ZNF577, ZNF580,ZNF581, ZNF580, ZNF581,CCDC106, ZNF600, ZNF611, ZNF613, ZNF615, ZNF619,ZNF620, ZNF639, ZNF652, ZNF665, ZNF667, ZNF668, ZNF671, ZNF682, ZNF687, ZNF691, ZNF696, ZNF701, ZNF706, ZNF707, ZNF714, ZNF717, ZNF718, ZNF720, ZNF721, ZNF730, ZNF763, ZNF780B, AC005614.5, ZNF782, ZNF786, ZNF79, ZNF791, ZNF81, ZNF83, ZNF837, ZNF839, ZNF84, ZNF845, ZNF846, ZNF865, ZNF91, ZNF92, ZNHIT3, ZSCAN21, ZSCAN25, ZSCAN30, and ZSCAN32. In some embodiments, the gene encoding a target sequence comprises the HTT gene. In some embodiments, the gene encoding a target sequence comprises the MYB gene. In some embodiments, the gene encoding a target sequence comprises the SMN2 gene. In some embodiments, the gene encoding a target sequence comprises the FOXM1 gene. Exemplary genes that may be modulated by the compounds of Formula (I) or (II) described herein may also include, inter alia, AC005258.1, AC005943.1, AC007849.1, AC008770.2, AC010487.3, AC011477.4, AC012651.1, AC012531.3, AC034102.2, AC073896.4, AC104472.3, AL109811.3, AL133342.1, AL137782.1, AL157871.5, AF241726.2, AL355336.1, AL358113.1, AL360181.3, AL445423.2, AL691482.3, AP001267.5, RF01169, and RF02271. The compounds described herein may further be used to modulate a sequence comprising a particular splice site sequence, e.g., an RNA sequence (e.g., a pre-mRNA sequence). In some embodiments, the splice site sequence comprises a 5’ splice site sequence. In some embodiments, the splice site sequence comprises a 3’ splice site sequence. Exemplary gene sequences and splice site sequences (e.g., 5’ splice site sequences) include AAAgcaaguu (SEQ ID NO: 1), AAAguaaaaa (SEQ ID NO: 2), AAAguaaaau (SEQ ID NO: 3), AAAguaaagu (SEQ ID NO: 4), AAAguaaaua (SEQ ID NO: 5), AAAguaaaug (SEQ ID NO: 6), AAAguaaauu (SEQ ID NO: 7), AAAguaacac (SEQ ID NO: 8), AAAguaacca (SEQ ID NO: 9), AAAguaacuu (SEQ ID NO: 10), AAAguaagaa (SEQ ID NO: 11), AAAguaagac (SEQ ID NO: 12), AAAguaagag (SEQ ID NO: 13), AAAguaagau (SEQ ID NO: 14), AAAguaagca (SEQ ID NO: 15), AAAguaagcc (SEQ ID NO: 16), AAAguaagcu (SEQ ID NO: 17), AAAguaagga (SEQ ID NO: 18), AAAguaaggg (SEQ ID NO: 19), AAAguaaggu (SEQ ID NO: 20), AAAguaagua (SEQ ID NO: 21), AAAguaaguc (SEQ ID NO: 22), AAAguaagug (SEQ ID NO: 23), AAAguaaguu (SEQ ID NO: 24), AAAguaaucu (SEQ ID NO: 25), AAAguaauua (SEQ ID NO: 26), AAAguacaaa (SEQ ID NO: 27), AAAguaccgg (SEQ ID NO: 28), AAAguacuag (SEQ ID NO: 29), AAAguacugg (SEQ ID NO: 30), AAAguacuuc (SEQ ID NO: 31), AAAguacuug (SEQ ID NO: 32), AAAguagcuu (SEQ ID NO: 33), AAAguaggag (SEQ ID NO: 34), AAAguaggau (SEQ ID NO: 35), AAAguagggg (SEQ ID NO: 36), AAAguaggua (SEQ ID NO: 37), AAAguaguaa (SEQ ID NO: 38), AAAguauauu (SEQ ID NO: 39), AAAguauccu (SEQ ID NO: 40), AAAguaucuc (SEQ ID NO: 41), AAAguaugga (SEQ ID NO: 42), AAAguaugua (SEQ ID NO: 43), AAAguaugug (SEQ ID NO: 44), AAAguauguu (SEQ ID NO: 45), AAAguauugg (SEQ ID NO: 46), AAAguauuuu (SEQ ID NO: 47), AAAgucagau (SEQ ID NO: 48), AAAgucugag (SEQ ID NO: 49), AAAgugaaua (SEQ ID NO: 50), AAAgugagaa (SEQ ID NO: 51), AAAgugagac (SEQ ID NO: 52), AAAgugagag (SEQ ID NO: 53), AAAgugagau (SEQ ID NO: 54), AAAgugagca (SEQ ID NO: 55), AAAgugagcu (SEQ ID NO: 56), AAAgugaggg (SEQ ID NO: 57), AAAgugagua (SEQ ID NO: 58), AAAgugaguc (SEQ ID NO: 59), AAAgugagug (SEQ ID NO: 60), AAAgugaguu (SEQ ID NO: 61), AAAgugcguc (SEQ ID NO: 62), AAAgugcuga (SEQ ID NO: 63), AAAguggguc (SEQ ID NO: 64), AAAguggguu (SEQ ID NO: 65), AAAgugguaa (SEQ ID NO: 66), AAAguguaug (SEQ ID NO: 67), AAAgugugug (SEQ ID NO: 68), AAAguguguu (SEQ ID NO: 69), AAAguuaagu (SEQ ID NO: 70), AAAguuacuu (SEQ ID NO: 71), AAAguuagug (SEQ ID NO: 72), AAAguuaugu (SEQ ID NO: 73), AAAguugagu (SEQ ID NO: 74), AAAguuugua (SEQ ID NO: 75), AACguaaaac (SEQ ID NO: 76), AACguaaagc (SEQ ID NO: 77), AACguaaagg (SEQ ID NO: 78), AACguaagca (SEQ ID NO: 79), AACguaaggg (SEQ ID NO: 80), AACguaaguc (SEQ ID NO: 81), AACguaagug (SEQ ID NO: 82), AACguaaugg (SEQ ID NO: 83), AACguaguga (SEQ ID NO: 84), AACguaugua (SEQ ID NO: 85), AACguauguu (SEQ ID NO: 86), AACgugagca (SEQ ID NO: 87), AACgugagga (SEQ ID NO: 88), AACgugauuu (SEQ ID NO: 89), AACgugggau (SEQ ID NO: 90), AACgugggua (SEQ ID NO: 91), AACguguguu (SEQ ID NO: 92), AACguuggua (SEQ ID NO: 93), AAGgcaaauu (SEQ ID NO: 94), AAGgcaagag (SEQ ID NO: 95), AAGgcaagau (SEQ ID NO: 96), AAGgcaagcc (SEQ ID NO: 97), AAGgcaagga (SEQ ID NO: 98), AAGgcaaggg (SEQ ID NO: 99), AAGgcaagug (SEQ ID NO: 100), AAGgcaaguu (SEQ ID NO: 101), AAGgcacugc (SEQ ID NO: 102), AAGgcagaaa (SEQ ID NO: 103), AAGgcaggau (SEQ ID NO: 104), AAGgcaggca (SEQ ID NO: 105), AAGgcaggga (SEQ ID NO: 106), AAGgcagggg (SEQ ID NO: 107), AAGgcaggua (SEQ ID NO: 108), AAGgcaggug (SEQ ID NO: 109), AAGgcaucuc (SEQ ID NO: 110), AAGgcaugcu (SEQ ID NO: 111), AAGgcaugga (SEQ ID NO: 112), AAGgcauguu (SEQ ID NO: 113), AAGgcauuau (SEQ ID NO: 114), AAGgcgagcu (SEQ ID NO: 115), AAGgcgaguc (SEQ ID NO: 116), AAGgcgaguu (SEQ ID NO: 117), AAGgcuagcc (SEQ ID NO: 118), AAGguaaaaa (SEQ ID NO: 119), AAGguaaaac (SEQ ID NO: 120), AAGguaaaag (SEQ ID NO: 121), AAGguaaaau (SEQ ID NO: 122), AAGguaaaca (SEQ ID NO: 123), AAGguaaacc (SEQ ID NO: 124), AAGguaaacu (SEQ ID NO: 125), AAGguaaaga (SEQ ID NO: 126), AAGguaaagc (SEQ ID NO: 127), AAGguaaagg (SEQ ID NO: 128), AAGguaaagu (SEQ ID NO: 129), AAGguaaaua (SEQ ID NO: 130), AAGguaaauc (SEQ ID NO: 131), AAGguaaaug (SEQ ID NO: 132), AAGguaaauu (SEQ ID NO: 133), AAGguaacaa (SEQ ID NO: 134), AAGguaacau (SEQ ID NO: 135), AAGguaaccc (SEQ ID NO: 136), AAGguaacua (SEQ ID NO: 137), AAGguaacuc (SEQ ID NO: 138), AAGguaacug (SEQ ID NO: 139), AAGguaacuu (SEQ ID NO: 140), AAGguaagaa (SEQ ID NO: 141), AAGguaagac (SEQ ID NO: 142), AAGguaagag (SEQ ID NO: 143), AAGguaagau (SEQ ID NO: 144), AAGguaagca (SEQ ID NO: 145), AAGguaagcc (SEQ ID NO: 146), AAGguaagcg (SEQ ID NO: 147), AAGguaagcu (SEQ ID NO: 148), AAGguaagga (SEQ ID NO: 149), AAGguaaggc (SEQ ID NO: 150), AAGguaaggg (SEQ ID NO: 151), AAGguaaggu (SEQ ID NO: 152), AAGguaagua (SEQ ID NO: 153), AAGguaaguc (SEQ ID NO: 154), AAGguaagug (SEQ ID NO: 155), AAGguaaguu (SEQ ID NO: 156), AAGguaauaa (SEQ ID NO: 157), AAGguaauac (SEQ ID NO: 158), AAGguaauag (SEQ ID NO: 159), AAGguaauau (SEQ ID NO: 160), AAGguaauca (SEQ ID NO: 161), AAGguaaucc (SEQ ID NO: 162), AAGguaaucu (SEQ ID NO: 163), AAGguaauga (SEQ ID NO: 164), AAGguaaugc (SEQ ID NO: 165), AAGguaaugg (SEQ ID NO: 166), AAGguaaugu (SEQ ID NO: 167), AAGguaauua (SEQ ID NO: 168), AAGguaauuc (SEQ ID NO: 169), AAGguaauug (SEQ ID NO: 170), AAGguaauuu (SEQ ID NO: 171), AAGguacaaa (SEQ ID NO: 172), AAGguacaag (SEQ ID NO: 173), AAGguacaau (SEQ ID NO: 174), AAGguacacc (SEQ ID NO: 175), AAGguacacu (SEQ ID NO: 176), AAGguacagg (SEQ ID NO: 177), AAGguacagu (SEQ ID NO: 178), AAGguacaua (SEQ ID NO: 179), AAGguacaug (SEQ ID NO: 180), AAGguacauu (SEQ ID NO: 181), AAGguaccaa (SEQ ID NO: 182), AAGguaccag (SEQ ID NO: 183), AAGguaccca (SEQ ID NO: 184), AAGguacccu (SEQ ID NO: 185), AAGguaccuc (SEQ ID NO: 186), AAGguaccug (SEQ ID NO: 187), AAGguaccuu (SEQ ID NO: 188), AAGguacgaa (SEQ ID NO: 189), AAGguacggg (SEQ ID NO: 190), AAGguacggu (SEQ ID NO: 191), AAGguacguc (SEQ ID NO: 192), AAGguacguu (SEQ ID NO: 193), AAGguacuaa (SEQ ID NO: 194), AAGguacuau (SEQ ID NO: 195), AAGguacucu (SEQ ID NO: 196), AAGguacuga (SEQ ID NO: 197), AAGguacugc (SEQ ID NO: 198), AAGguacugu (SEQ ID NO: 199), AAGguacuuc (SEQ ID NO: 200), AAGguacuug (SEQ ID NO: 201), AAGguacuuu (SEQ ID NO: 202), AAGguagaaa (SEQ ID NO: 203), AAGguagaac (SEQ ID NO: 204), AAGguagaca (SEQ ID NO: 205), AAGguagacc (SEQ ID NO: 206), AAGguagacu (SEQ ID NO: 207), AAGguagagu (SEQ ID NO: 208), AAGguagaua (SEQ ID NO: 209), AAGguagcaa (SEQ ID NO: 210), AAGguagcag (SEQ ID NO: 211), AAGguagcca (SEQ ID NO: 212), AAGguagccu (SEQ ID NO: 213), AAGguagcua (SEQ ID NO: 214), AAGguagcug (SEQ ID NO: 215), AAGguagcuu (SEQ ID NO: 216), AAGguaggaa (SEQ ID NO: 217), AAGguaggag (SEQ ID NO: 218), AAGguaggau (SEQ ID NO: 219), AAGguaggca (SEQ ID NO: 220), AAGguaggcc (SEQ ID NO: 221), AAGguaggcu (SEQ ID NO: 222), AAGguaggga (SEQ ID NO: 223), AAGguagggc (SEQ ID NO: 224), AAGguagggg (SEQ ID NO: 225), AAGguagggu (SEQ ID NO: 226), AAGguaggua (SEQ ID NO: 227), AAGguagguc (SEQ ID NO: 228), AAGguaggug (SEQ ID NO: 229), AAGguagguu (SEQ ID NO: 230), AAGguaguaa (SEQ ID NO: 231), AAGguaguag (SEQ ID NO: 232), AAGguagucu (SEQ ID NO: 233), AAGguagugc (SEQ ID NO: 234), AAGguagugg (SEQ ID NO: 235), AAGguaguuc (SEQ ID NO: 236), AAGguaguuu (SEQ ID NO: 237), AAGguauaaa (SEQ ID NO: 238), AAGguauaau (SEQ ID NO: 239), AAGguauaca (SEQ ID NO: 240), AAGguauacu (SEQ ID NO: 241), AAGguauaua (SEQ ID NO: 242), AAGguauauc (SEQ ID NO: 243), AAGguauaug (SEQ ID NO: 244), AAGguauauu (SEQ ID NO: 245), AAGguaucac (SEQ ID NO: 246), AAGguaucag (SEQ ID NO: 247), AAGguauccc (SEQ ID NO: 248), AAGguauccu (SEQ ID NO: 249), AAGguaucuc (SEQ ID NO: 250), AAGguaucug (SEQ ID NO: 251), AAGguaucuu (SEQ ID NO: 252), AAGguaugaa (SEQ ID NO: 253), AAGguaugac (SEQ ID NO: 254), AAGguaugag (SEQ ID NO: 255), AAGguaugau (SEQ ID NO: 256), AAGguaugca (SEQ ID NO: 257), AAGguaugcc (SEQ ID NO: 258), AAGguaugcu (SEQ ID NO: 259), AAGguaugga (SEQ ID NO: 260), AAGguauggc (SEQ ID NO: 261), AAGguauggg (SEQ ID NO: 262), AAGguaugua (SEQ ID NO: 263), AAGguauguc (SEQ ID NO: 264), AAGguaugug (SEQ ID NO: 265), AAGguauguu (SEQ ID NO: 266), AAGguauuaa (SEQ ID NO: 267), AAGguauuac (SEQ ID NO: 268), AAGguauuag (SEQ ID NO: 269), AAGguauuau (SEQ ID NO: 270), AAGguauucc (SEQ ID NO: 271), AAGguauuga (SEQ ID NO: 272), AAGguauugu (SEQ ID NO: 273), AAGguauuua (SEQ ID NO: 274), AAGguauuuc (SEQ ID NO: 275), AAGguauuug (SEQ ID NO: 276), AAGguauuuu (SEQ ID NO: 277), AAGgucaaau (SEQ ID NO: 278), AAGgucaaga (SEQ ID NO: 279), AAGgucaagu (SEQ ID NO: 280), AAGgucacag (SEQ ID NO: 281), AAGgucagaa (SEQ ID NO: 282), AAGgucagac (SEQ ID NO: 283), AAGgucagag (SEQ ID NO: 284), AAGgucagca (SEQ ID NO: 285), AAGgucagcc (SEQ ID NO: 286), AAGgucagcg (SEQ ID NO: 287), AAGgucagcu (SEQ ID NO: 288), AAGgucagga (SEQ ID NO: 289), AAGgucaggc (SEQ ID NO: 290), AAGgucaggg (SEQ ID NO: 291), AAGgucaggu (SEQ ID NO: 292), AAGgucagua (SEQ ID NO: 293), AAGgucaguc (SEQ ID NO: 294), AAGgucagug (SEQ ID NO: 295), AAGgucaguu (SEQ ID NO: 296), AAGgucauag (SEQ ID NO: 297), AAGgucaucu (SEQ ID NO: 298), AAGguccaca (SEQ ID NO: 299), AAGguccaga (SEQ ID NO: 300), AAGguccaua (SEQ ID NO: 301), AAGgucccag (SEQ ID NO: 302), AAGgucccuc (SEQ ID NO: 303), AAGguccuuc (SEQ ID NO: 304), AAGgucgagg (SEQ ID NO: 305), AAGgucuaau (SEQ ID NO: 306), AAGgucuacc (SEQ ID NO: 307), AAGgucuaua (SEQ ID NO: 308), AAGgucuccu (SEQ ID NO: 309), AAGgucucug (SEQ ID NO: 310), AAGgucucuu (SEQ ID NO: 311), AAGgucugaa (SEQ ID NO: 312), AAGgucugag (SEQ ID NO: 313), AAGgucugga (SEQ ID NO: 314), AAGgucuggg (SEQ ID NO: 315), AAGgucugua (SEQ ID NO: 316), AAGgucuguu (SEQ ID NO: 317), AAGgucuucu (SEQ ID NO: 318), AAGgucuuuu (SEQ ID NO: 319), AAGgugaaac (SEQ ID NO: 320), AAGgugaaag (SEQ ID NO: 321), AAGgugaaau (SEQ ID NO: 322), AAGgugaacu (SEQ ID NO: 323), AAGgugaagc (SEQ ID NO: 324), AAGgugaagg (SEQ ID NO: 325), AAGgugaagu (SEQ ID NO: 326), AAGgugaaua (SEQ ID NO: 327), AAGgugaaug (SEQ ID NO: 328), AAGgugaauu (SEQ ID NO: 329), AAGgugacaa (SEQ ID NO: 330), AAGgugacag (SEQ ID NO: 331), AAGgugacau (SEQ ID NO: 332), AAGgugacug (SEQ ID NO: 333), AAGgugacuu (SEQ ID NO: 334), AAGgugagaa (SEQ ID NO: 335), AAGgugagac (SEQ ID NO: 336), AAGgugagag (SEQ ID NO: 337), AAGgugagau (SEQ ID NO: 338), AAGgugagca (SEQ ID NO: 339), AAGgugagcc (SEQ ID NO: 340), AAGgugagcg (SEQ ID NO: 341), AAGgugagcu (SEQ ID NO: 342), AAGgugagga (SEQ ID NO: 343), AAGgugaggc (SEQ ID NO: 344), AAGgugaggg (SEQ ID NO: 345), AAGgugaggu (SEQ ID NO: 346), AAGgugagua (SEQ ID NO: 347), AAGgugaguc (SEQ ID NO: 348), AAGgugagug (SEQ ID NO: 349), AAGgugaguu (SEQ ID NO: 350), AAGgugauaa (SEQ ID NO: 351), AAGgugauca (SEQ ID NO: 352), AAGgugaucc (SEQ ID NO: 353), AAGgugauga (SEQ ID NO: 354), AAGgugaugc (SEQ ID NO: 355), AAGgugaugu (SEQ ID NO: 356), AAGgugauua (SEQ ID NO: 357), AAGgugauug (SEQ ID NO: 358), AAGgugauuu (SEQ ID NO: 359), AAGgugcaca (SEQ ID NO: 360), AAGgugcauc (SEQ ID NO: 361), AAGgugcccu (SEQ ID NO: 362), AAGgugccug (SEQ ID NO: 363), AAGgugcgug (SEQ ID NO: 364), AAGgugcguu (SEQ ID NO: 365), AAGgugcucc (SEQ ID NO: 366), AAGgugcuga (SEQ ID NO: 367), AAGgugcugc (SEQ ID NO: 368), AAGgugcugg (SEQ ID NO: 369), AAGgugcuua (SEQ ID NO: 370), AAGgugcuuu (SEQ ID NO: 371), AAGguggaua (SEQ ID NO: 372), AAGguggcua (SEQ ID NO: 373), AAGguggcug (SEQ ID NO: 374), AAGguggcuu (SEQ ID NO: 375), AAGgugggaa (SEQ ID NO: 376), AAGgugggag (SEQ ID NO: 377), AAGgugggau (SEQ ID NO: 378), AAGgugggca (SEQ ID NO: 379), AAGgugggcc (SEQ ID NO: 380), AAGgugggcg (SEQ ID NO: 381), AAGgugggga (SEQ ID NO: 382), AAGguggggu (SEQ ID NO: 383), AAGgugggua (SEQ ID NO: 384), AAGgugggug (SEQ ID NO: 385), AAGguggguu (SEQ ID NO: 386), AAGgugguaa (SEQ ID NO: 387), AAGgugguac (SEQ ID NO: 388), AAGgugguau (SEQ ID NO: 389), AAGguggugg (SEQ ID NO: 390), AAGgugguua (SEQ ID NO: 391), AAGgugguuc (SEQ ID NO: 392), AAGgugguuu (SEQ ID NO: 393), AAGguguaag (SEQ ID NO: 394), AAGgugucaa (SEQ ID NO: 395), AAGgugucag (SEQ ID NO: 396), AAGgugucug (SEQ ID NO: 397), AAGgugugaa (SEQ ID NO: 398), AAGgugugag (SEQ ID NO: 399), AAGgugugca (SEQ ID NO: 400), AAGgugugga (SEQ ID NO: 401), AAGguguggu (SEQ ID NO: 402), AAGgugugua (SEQ ID NO: 403), AAGguguguc (SEQ ID NO: 404), AAGgugugug (SEQ ID NO: 405), AAGguguguu (SEQ ID NO: 406), AAGguguucu (SEQ ID NO: 407), AAGguguugc (SEQ ID NO: 408), AAGguguugg (SEQ ID NO: 409), AAGguguuug (SEQ ID NO: 410), AAGguuaaaa (SEQ ID NO: 411), AAGguuaaca (SEQ ID NO: 412), AAGguuaagc (SEQ ID NO: 413), AAGguuaauu (SEQ ID NO: 414), AAGguuacau (SEQ ID NO: 415), AAGguuagaa (SEQ ID NO: 416), AAGguuagau (SEQ ID NO: 417), AAGguuagca (SEQ ID NO: 418), AAGguuagcc (SEQ ID NO: 419), AAGguuagga (SEQ ID NO: 420), AAGguuaggc (SEQ ID NO: 421), AAGguuagua (SEQ ID NO: 422), AAGguuaguc (SEQ ID NO: 423), AAGguuagug (SEQ ID NO: 424), AAGguuaguu (SEQ ID NO: 425), AAGguuauag (SEQ ID NO: 426), AAGguuauga (SEQ ID NO: 427), AAGguucaaa (SEQ ID NO: 428), AAGguucaag (SEQ ID NO: 429), AAGguuccuu (SEQ ID NO: 430), AAGguucggc (SEQ ID NO: 431), AAGguucguu (SEQ ID NO: 432), AAGguucuaa (SEQ ID NO: 433), AAGguucuga (SEQ ID NO: 434), AAGguucuua (SEQ ID NO: 435), AAGguugaau (SEQ ID NO: 436), AAGguugacu (SEQ ID NO: 437), AAGguugagg (SEQ ID NO: 438), AAGguugagu (SEQ ID NO: 439), AAGguugaua (SEQ ID NO: 440), AAGguugcac (SEQ ID NO: 441), AAGguugcug (SEQ ID NO: 442), AAGguuggaa (SEQ ID NO: 443), AAGguuggca (SEQ ID NO: 444), AAGguuggga (SEQ ID NO: 445), AAGguugggg (SEQ ID NO: 446), AAGguuggua (SEQ ID NO: 447), AAGguugguc (SEQ ID NO: 448), AAGguuggug (SEQ ID NO: 449), AAGguugguu (SEQ ID NO: 450), AAGguuguaa (SEQ ID NO: 451), AAGguugucc (SEQ ID NO: 452), AAGguugugc (SEQ ID NO: 453), AAGguuguua (SEQ ID NO: 454), AAGguuuacc (SEQ ID NO: 455), AAGguuuaua (SEQ ID NO: 456), AAGguuuauu (SEQ ID NO: 457), AAGguuuccu (SEQ ID NO: 458), AAGguuucgu (SEQ ID NO: 459), AAGguuugag (SEQ ID NO: 460), AAGguuugca (SEQ ID NO: 461), AAGguuugcc (SEQ ID NO: 462), AAGguuugcu (SEQ ID NO: 463), AAGguuugga (SEQ ID NO: 464), AAGguuuggu (SEQ ID NO: 465), AAGguuugua (SEQ ID NO: 466), AAGguuuguc (SEQ ID NO: 467), AAGguuugug (SEQ ID NO: 468), AAGguuuuaa (SEQ ID NO: 469), AAGguuuuca (SEQ ID NO: 470), AAGguuuucg (SEQ ID NO: 471), AAGguuuugc (SEQ ID NO: 472), AAGguuuugu (SEQ ID NO: 473), AAGguuuuuu (SEQ ID NO: 474), AAUgcaagua (SEQ ID NO: 475), AAUgcaaguc (SEQ ID NO: 476), AAUguaaaca (SEQ ID NO: 477), AAUguaaaua (SEQ ID NO: 478), AAUguaaauc (SEQ ID NO: 479), AAUguaaaug (SEQ ID NO: 480), AAUguaaauu (SEQ ID NO: 481), AAUguaacua (SEQ ID NO: 482), AAUguaagaa (SEQ ID NO: 483), AAUguaagag (SEQ ID NO: 484), AAUguaagau (SEQ ID NO: 485), AAUguaagcc (SEQ ID NO: 486), AAUguaagcu (SEQ ID NO: 487), AAUguaagga (SEQ ID NO: 488), AAUguaagua (SEQ ID NO: 489), AAUguaaguc (SEQ ID NO: 490), AAUguaagug (SEQ ID NO: 491), AAUguaaguu (SEQ ID NO: 492), AAUguaauca (SEQ ID NO: 493), AAUguaauga (SEQ ID NO: 494), AAUguaaugu (SEQ ID NO: 495), AAUguacauc (SEQ ID NO: 496), AAUguacaug (SEQ ID NO: 497), AAUguacgau (SEQ ID NO: 498), AAUguacgua (SEQ ID NO: 499), AAUguacguc (SEQ ID NO: 500), AAUguacgug (SEQ ID NO: 501), AAUguacucu (SEQ ID NO: 502), AAUguaggca (SEQ ID NO: 503), AAUguagguu (SEQ ID NO: 504), AAUguaucua (SEQ ID NO: 505), AAUguaugaa (SEQ ID NO: 506), AAUguaugua (SEQ ID NO: 507), AAUguaugug (SEQ ID NO: 508), AAUguauguu (SEQ ID NO: 509), AAUgucagag (SEQ ID NO: 510), AAUgucagau (SEQ ID NO: 511), AAUgucagcu (SEQ ID NO: 512), AAUgucagua (SEQ ID NO: 513), AAUgucaguc (SEQ ID NO: 514), AAUgucagug (SEQ ID NO: 515), AAUgucaguu (SEQ ID NO: 516), AAUgucggua (SEQ ID NO: 517), AAUgucuguu (SEQ ID NO: 518), AAUgugagaa (SEQ ID NO: 519), AAUgugagca (SEQ ID NO: 520), AAUgugagcc (SEQ ID NO: 521), AAUgugagga (SEQ ID NO: 522), AAUgugagua (SEQ ID NO: 523), AAUgugaguc (SEQ ID NO: 524), AAUgugagug (SEQ ID NO: 525), AAUgugaguu (SEQ ID NO: 526), AAUgugauau (SEQ ID NO: 527), AAUgugcaua (SEQ ID NO: 528), AAUgugcgua (SEQ ID NO: 529), AAUgugcguc (SEQ ID NO: 530), AAUgugggac (SEQ ID NO: 531), AAUguggguc (SEQ ID NO: 532), AAUgugggug (SEQ ID NO: 533), AAUgugguuu (SEQ ID NO: 534), AAUgugugua (SEQ ID NO: 535), AAUguuaagu (SEQ ID NO: 536), AAUguuagaa (SEQ ID NO: 537), AAUguuagau (SEQ ID NO: 538), AAUguuagua (SEQ ID NO: 539), AAUguuggug (SEQ ID NO: 540), ACAgcaagua (SEQ ID NO: 541), ACAguaaaua (SEQ ID NO: 542), ACAguaaaug (SEQ ID NO: 543), ACAguaagaa (SEQ ID NO: 544), ACAguaagca (SEQ ID NO: 545), ACAguaagua (SEQ ID NO: 546), ACAguaaguc (SEQ ID NO: 547), ACAguaagug (SEQ ID NO: 548), ACAguaaguu (SEQ ID NO: 549), ACAguacgua (SEQ ID NO: 550), ACAguaggug (SEQ ID NO: 551), ACAguauaac (SEQ ID NO: 552), ACAguaugua (SEQ ID NO: 553), ACAgucaguu (SEQ ID NO: 554), ACAgugagaa (SEQ ID NO: 555), ACAgugagcc (SEQ ID NO: 556), ACAgugagcu (SEQ ID NO: 557), ACAgugagga (SEQ ID NO: 558), ACAgugaggu (SEQ ID NO: 559), ACAgugagua (SEQ ID NO: 560), ACAgugaguc (SEQ ID NO: 561), ACAgugagug (SEQ ID NO: 562), ACAgugaguu (SEQ ID NO: 563), ACAgugggua (SEQ ID NO: 564), ACAguggguu (SEQ ID NO: 565), ACAguguaaa (SEQ ID NO: 566), ACAguuaagc (SEQ ID NO: 567), ACAguuaagu (SEQ ID NO: 568), ACAguuaugu (SEQ ID NO: 569), ACAguugagu (SEQ ID NO: 570), ACAguuguga (SEQ ID NO: 571), ACCguaagua (SEQ ID NO: 572), ACCgugagaa (SEQ ID NO: 573), ACCgugagca (SEQ ID NO: 574), ACCgugaguu (SEQ ID NO: 575), ACCgugggug (SEQ ID NO: 576), ACGguaaaac (SEQ ID NO: 577), ACGguaacua (SEQ ID NO: 578), ACGguaagua (SEQ ID NO: 579), ACGguaagug (SEQ ID NO: 580), ACGguaaguu (SEQ ID NO: 581), ACGguaauua (SEQ ID NO: 582), ACGguaauuu (SEQ ID NO: 583), ACGguacaau (SEQ ID NO: 584), ACGguacagu (SEQ ID NO: 585), ACGguaccag (SEQ ID NO: 586), ACGguacggu (SEQ ID NO: 587), ACGguacgua (SEQ ID NO: 588), ACGguaggaa (SEQ ID NO: 589), ACGguaggag (SEQ ID NO: 590), ACGguaggug (SEQ ID NO: 591), ACGguaguaa (SEQ ID NO: 592), ACGguauaau (SEQ ID NO: 593), ACGguaugac (SEQ ID NO: 594), ACGguaugcg (SEQ ID NO: 595), ACGguaugua (SEQ ID NO: 596), ACGguauguc (SEQ ID NO: 597), ACGgugaaac (SEQ ID NO: 598), ACGgugaagu (SEQ ID NO: 599), ACGgugaauc (SEQ ID NO: 600), ACGgugacag (SEQ ID NO: 601), ACGgugacca (SEQ ID NO: 602), ACGgugagaa (SEQ ID NO: 603), ACGgugagau (SEQ ID NO: 604), ACGgugagcc (SEQ ID NO: 605), ACGgugagua (SEQ ID NO: 606), ACGgugagug (SEQ ID NO: 607), ACGgugaguu (SEQ ID NO: 608), ACGgugcgug (SEQ ID NO: 609), ACGguggcac (SEQ ID NO: 610), ACGguggggc (SEQ ID NO: 611), ACGgugggug (SEQ ID NO: 612), ACGguguagu (SEQ ID NO: 613), ACGgugucac (SEQ ID NO: 614), ACGgugugua (SEQ ID NO: 615), ACGguguguu (SEQ ID NO: 616), ACGguuagug (SEQ ID NO: 617), ACGguuaguu (SEQ ID NO: 618), ACGguucaau (SEQ ID NO: 619), ACUguaaaua (SEQ ID NO: 620), ACUguaagaa (SEQ ID NO: 621), ACUguaagac (SEQ ID NO: 622), ACUguaagca (SEQ ID NO: 623), ACUguaagcu (SEQ ID NO: 624), ACUguaagua (SEQ ID NO: 625), ACUguaaguc (SEQ ID NO: 626), ACUguaaguu (SEQ ID NO: 627), ACUguacguu (SEQ ID NO: 628), ACUguacugc (SEQ ID NO: 629), ACUguaggcu (SEQ ID NO: 630), ACUguaggua (SEQ ID NO: 631), ACUguauauu (SEQ ID NO: 632), ACUguaugaa (SEQ ID NO: 633), ACUguaugcu (SEQ ID NO: 634), ACUguaugug (SEQ ID NO: 635), ACUguauucc (SEQ ID NO: 636), ACUgucagcu (SEQ ID NO: 637), ACUgucagug (SEQ ID NO: 638), ACUgugaacg (SEQ ID NO: 639), ACUgugagca (SEQ ID NO: 640), ACUgugagcg (SEQ ID NO: 641), ACUgugagcu (SEQ ID NO: 642), ACUgugagua (SEQ ID NO: 643), ACUgugaguc (SEQ ID NO: 644), ACUgugagug (SEQ ID NO: 645), ACUgugaguu (SEQ ID NO: 646), ACUgugggua (SEQ ID NO: 647), ACUgugugug (SEQ ID NO: 648), ACUguuaagu (SEQ ID NO: 649), AGAgcaagua (SEQ ID NO: 650), AGAguaaaac (SEQ ID NO: 651), AGAguaaacg (SEQ ID NO: 652), AGAguaaaga (SEQ ID NO: 653), AGAguaaagu (SEQ ID NO: 654), AGAguaaauc (SEQ ID NO: 655), AGAguaaaug (SEQ ID NO: 656), AGAguaacau (SEQ ID NO: 657), AGAguaacua (SEQ ID NO: 658), AGAguaagaa (SEQ ID NO: 659), AGAguaagac (SEQ ID NO: 660), AGAguaagag (SEQ ID NO: 661), AGAguaagau (SEQ ID NO: 662), AGAguaagca (SEQ ID NO: 663), AGAguaagcu (SEQ ID NO: 664), AGAguaagga (SEQ ID NO: 665), AGAguaaggc (SEQ ID NO: 666), AGAguaaggg (SEQ ID NO: 667), AGAguaaggu (SEQ ID NO: 668), AGAguaaguc (SEQ ID NO: 669), AGAguaagug (SEQ ID NO: 670), AGAguaaguu (SEQ ID NO: 671), AGAguaauaa (SEQ ID NO: 672), AGAguaaugu (SEQ ID NO: 673), AGAguaauuc (SEQ ID NO: 674), AGAguaauuu (SEQ ID NO: 675), AGAguacacc (SEQ ID NO: 676), AGAguaccug (SEQ ID NO: 677), AGAguacgug (SEQ ID NO: 678), AGAguacucu (SEQ ID NO: 679), AGAguacuga (SEQ ID NO: 680), AGAguacuuu (SEQ ID NO: 681), AGAguagcug (SEQ ID NO: 682), AGAguaggaa (SEQ ID NO: 683), AGAguaggga (SEQ ID NO: 684), AGAguagggu (SEQ ID NO: 685), AGAguagguc (SEQ ID NO: 686), AGAguaggug (SEQ ID NO: 687), AGAguagguu (SEQ ID NO: 688), AGAguauaua (SEQ ID NO: 689), AGAguauauu (SEQ ID NO: 690), AGAguaugaa (SEQ ID NO: 691), AGAguaugac (SEQ ID NO: 692), AGAguaugau (SEQ ID NO: 693), AGAguauguc (SEQ ID NO: 694), AGAguaugug (SEQ ID NO: 695), AGAguauguu (SEQ ID NO: 696), AGAguauuaa (SEQ ID NO: 697), AGAguauuau (SEQ ID NO: 698), AGAgucagug (SEQ ID NO: 699), AGAgugagac (SEQ ID NO: 700), AGAgugagag (SEQ ID NO: 701), AGAgugagau (SEQ ID NO: 702), AGAgugagca (SEQ ID NO: 703), AGAgugagua (SEQ ID NO: 704), AGAgugaguc (SEQ ID NO: 705), AGAgugagug (SEQ ID NO: 706), AGAgugaguu (SEQ ID NO: 707), AGAgugcguc (SEQ ID NO: 708), AGAgugggga (SEQ ID NO: 709), AGAgugggug (SEQ ID NO: 710), AGAgugugug (SEQ ID NO: 711), AGAguguuuc (SEQ ID NO: 712), AGAguuagua (SEQ ID NO: 713), AGAguugaga (SEQ ID NO: 714), AGAguugagu (SEQ ID NO: 715), AGAguugguu (SEQ ID NO: 716), AGAguuugau (SEQ ID NO: 717), AGCguaagcu (SEQ ID NO: 718), AGCguaagug (SEQ ID NO: 719), AGCgugagcc (SEQ ID NO: 720), AGCgugagug (SEQ ID NO: 721), AGCguuguuc (SEQ ID NO: 722), AGGgcagagu (SEQ ID NO: 723), AGGgcagccu (SEQ ID NO: 724), AGGgcuagua (SEQ ID NO: 725), AGGguaaaga (SEQ ID NO: 726), AGGguaaaua (SEQ ID NO: 727), AGGguaaauc (SEQ ID NO: 728), AGGguaaauu (SEQ ID NO: 729), AGGguaacca (SEQ ID NO: 730), AGGguaacug (SEQ ID NO: 731), AGGguaacuu (SEQ ID NO: 732), AGGguaagaa (SEQ ID NO: 733), AGGguaagag (SEQ ID NO: 734), AGGguaagau (SEQ ID NO: 735), AGGguaagca (SEQ ID NO: 736), AGGguaagga (SEQ ID NO: 737), AGGguaaggc (SEQ ID NO: 738), AGGguaaggg (SEQ ID NO: 739), AGGguaagua (SEQ ID NO: 740), AGGguaaguc (SEQ ID NO: 741), AGGguaagug (SEQ ID NO: 742), AGGguaaguu (SEQ ID NO: 743), AGGguaauac (SEQ ID NO: 744), AGGguaauga (SEQ ID NO: 745), AGGguaauua (SEQ ID NO: 746), AGGguaauuu (SEQ ID NO: 747), AGGguacacc (SEQ ID NO: 748), AGGguacagu (SEQ ID NO: 749), AGGguacggu (SEQ ID NO: 750), AGGguaggac (SEQ ID NO: 751), AGGguaggag (SEQ ID NO: 752), AGGguaggca (SEQ ID NO: 753), AGGguaggcc (SEQ ID NO: 754), AGGguaggga (SEQ ID NO: 755), AGGguagggu (SEQ ID NO: 756), AGGguagguc (SEQ ID NO: 757), AGGguaggug (SEQ ID NO: 758), AGGguagguu (SEQ ID NO: 759), AGGguauaua (SEQ ID NO: 760), AGGguaugac (SEQ ID NO: 761), AGGguaugag (SEQ ID NO: 762), AGGguaugau (SEQ ID NO: 763), AGGguaugca (SEQ ID NO: 764), AGGguaugcu (SEQ ID NO: 765), AGGguauggg (SEQ ID NO: 766), AGGguauggu (SEQ ID NO: 767), AGGguaugua (SEQ ID NO: 768), AGGguauguc (SEQ ID NO: 769), AGGguaugug (SEQ ID NO: 770), AGGguauuac (SEQ ID NO: 771), AGGguauucu (SEQ ID NO: 772), AGGguauuuc (SEQ ID NO: 773), AGGgucagag (SEQ ID NO: 774), AGGgucagca (SEQ ID NO: 775), AGGgucagga (SEQ ID NO: 776), AGGgucaggg (SEQ ID NO: 777), AGGgucagug (SEQ ID NO: 778), AGGgucaguu (SEQ ID NO: 779), AGGguccccu (SEQ ID NO: 780), AGGgucggga (SEQ ID NO: 781), AGGgucugca (SEQ ID NO: 782), AGGgucuguu (SEQ ID NO: 783), AGGgugaaga (SEQ ID NO: 784), AGGgugacua (SEQ ID NO: 785), AGGgugagaa (SEQ ID NO: 786), AGGgugagac (SEQ ID NO: 787), AGGgugagag (SEQ ID NO: 788), AGGgugagca (SEQ ID NO: 789), AGGgugagcc (SEQ ID NO: 790), AGGgugagcu (SEQ ID NO: 791), AGGgugagga (SEQ ID NO: 792), AGGgugaggg (SEQ ID NO: 793), AGGgugaggu (SEQ ID NO: 794), AGGgugagua (SEQ ID NO: 795), AGGgugaguc (SEQ ID NO: 796), AGGgugagug (SEQ ID NO: 797), AGGgugaguu (SEQ ID NO: 798), AGGgugggga (SEQ ID NO: 799), AGGguggggu (SEQ ID NO: 800), AGGgugggua (SEQ ID NO: 801), AGGgugggug (SEQ ID NO: 802), AGGgugugua (SEQ ID NO: 803), AGGgugugug (SEQ ID NO: 804), AGGguuaaug (SEQ ID NO: 805), AGGguuagaa (SEQ ID NO: 806), AGGguuaguu (SEQ ID NO: 807), AGGguuggug (SEQ ID NO: 808), AGGguuugug (SEQ ID NO: 809), AGGguuuguu (SEQ ID NO: 810), AGUguaaaag (SEQ ID NO: 811), AGUguaaaua (SEQ ID NO: 812), AGUguaaauu (SEQ ID NO: 813), AGUguaagaa (SEQ ID NO: 814), AGUguaagag (SEQ ID NO: 815), AGUguaagau (SEQ ID NO: 816), AGUguaagca (SEQ ID NO: 817), AGUguaagcc (SEQ ID NO: 818), AGUguaagua (SEQ ID NO: 819), AGUguaagug (SEQ ID NO: 820), AGUguaaguu (SEQ ID NO: 821), AGUguaauug (SEQ ID NO: 822), AGUguaggac (SEQ ID NO: 823), AGUguagguc (SEQ ID NO: 824), AGUguaugag (SEQ ID NO: 825), AGUguaugua (SEQ ID NO: 826), AGUguauguu (SEQ ID NO: 827), AGUguauugu (SEQ ID NO: 828), AGUguauuua (SEQ ID NO: 829), AGUgucaguc (SEQ ID NO: 830), AGUgugagag (SEQ ID NO: 831), AGUgugagca (SEQ ID NO: 832), AGUgugagcc (SEQ ID NO: 833), AGUgugagcu (SEQ ID NO: 834), AGUgugagua (SEQ ID NO: 835), AGUgugaguc (SEQ ID NO: 836), AGUgugagug (SEQ ID NO: 837), AGUgugaguu (SEQ ID NO: 838), AGUgugggua (SEQ ID NO: 839), AGUgugggug (SEQ ID NO: 840), AGUgugugua (SEQ ID NO: 841), AGUguuccua (SEQ ID NO: 842), AGUguugggg (SEQ ID NO: 843), AGUguuucag (SEQ ID NO: 844), AUAguaaaua (SEQ ID NO: 845), AUAguaagac (SEQ ID NO: 846), AUAguaagau (SEQ ID NO: 847), AUAguaagca (SEQ ID NO: 848), AUAguaagua (SEQ ID NO: 849), AUAguaagug (SEQ ID NO: 850), AUAguaaguu (SEQ ID NO: 851), AUAguaggua (SEQ ID NO: 852), AUAguauguu (SEQ ID NO: 853), AUAgucucac (SEQ ID NO: 854), AUAgugagac (SEQ ID NO: 855), AUAgugagag (SEQ ID NO: 856), AUAgugagau (SEQ ID NO: 857), AUAgugagcc (SEQ ID NO: 858), AUAgugaggc (SEQ ID NO: 859), AUAgugagua (SEQ ID NO: 860), AUAgugaguc (SEQ ID NO: 861), AUAgugagug (SEQ ID NO: 862), AUAgugcguc (SEQ ID NO: 863), AUAgugugua (SEQ ID NO: 864), AUAguucagu (SEQ ID NO: 865), AUCguaagcc (SEQ ID NO: 866), AUCguaaguu (SEQ ID NO: 867), AUCguauucc (SEQ ID NO: 868), AUCgugagua (SEQ ID NO: 869), AUGgcaagcg (SEQ ID NO: 870), AUGgcaagga (SEQ ID NO: 871), AUGgcaaguu (SEQ ID NO: 872), AUGgcaggua (SEQ ID NO: 873), AUGgcaugug (SEQ ID NO: 874), AUGgcgccau (SEQ ID NO: 875), AUGgcuugug (SEQ ID NO: 876), AUGguaaaac (SEQ ID NO: 877), AUGguaaaau (SEQ ID NO: 878), AUGguaaacc (SEQ ID NO: 879), AUGguaaaga (SEQ ID NO: 880), AUGguaaaua (SEQ ID NO: 881), AUGguaaaug (SEQ ID NO: 882), AUGguaaauu (SEQ ID NO: 883), AUGguaacag (SEQ ID NO: 884), AUGguaacau (SEQ ID NO: 885), AUGguaacua (SEQ ID NO: 886), AUGguaacuc (SEQ ID NO: 887), AUGguaacuu (SEQ ID NO: 888), AUGguaagaa (SEQ ID NO: 889), AUGguaagac (SEQ ID NO: 890), AUGguaagag (SEQ ID NO: 891), AUGguaagau (SEQ ID NO: 892), AUGguaagca (SEQ ID NO: 893), AUGguaagcc (SEQ ID NO: 894), AUGguaagcu (SEQ ID NO: 895), AUGguaagga (SEQ ID NO: 896), AUGguaaggg (SEQ ID NO: 897), AUGguaagua (SEQ ID NO: 898), AUGguaaguc (SEQ ID NO: 899), AUGguaagug (SEQ ID NO: 900), AUGguaaguu (SEQ ID NO: 901), AUGguaauaa (SEQ ID NO: 902), AUGguaauau (SEQ ID NO: 903), AUGguaauga (SEQ ID NO: 904), AUGguaaugg (SEQ ID NO: 905), AUGguaauug (SEQ ID NO: 906), AUGguaauuu (SEQ ID NO: 907), AUGguacagc (SEQ ID NO: 908), AUGguacauc (SEQ ID NO: 909), AUGguaccag (SEQ ID NO: 910), AUGguaccug (SEQ ID NO: 911), AUGguacgag (SEQ ID NO: 912), AUGguacggu (SEQ ID NO: 913), AUGguagauc (SEQ ID NO: 914), AUGguagcag (SEQ ID NO: 915), AUGguagcug (SEQ ID NO: 916), AUGguaggaa (SEQ ID NO: 917), AUGguaggau (SEQ ID NO: 918), AUGguaggca (SEQ ID NO: 919), AUGguaggcu (SEQ ID NO: 920), AUGguagggg (SEQ ID NO: 921), AUGguagggu (SEQ ID NO: 922), AUGguaggua (SEQ ID NO: 923), AUGguaggug (SEQ ID NO: 924), AUGguaguuu (SEQ ID NO: 925), AUGguauagu (SEQ ID NO: 926), AUGguauaua (SEQ ID NO: 927), AUGguaucag (SEQ ID NO: 928), AUGguaucuu (SEQ ID NO: 929), AUGguaugau (SEQ ID NO: 930), AUGguaugca (SEQ ID NO: 931), AUGguaugcc (SEQ ID NO: 932), AUGguaugcg (SEQ ID NO: 933), AUGguaugcu (SEQ ID NO: 934), AUGguaugga (SEQ ID NO: 935), AUGguauggc (SEQ ID NO: 936), AUGguaugug (SEQ ID NO: 937), AUGguauguu (SEQ ID NO: 938), AUGguauuau (SEQ ID NO: 939), AUGguauuga (SEQ ID NO: 940), AUGguauuug (SEQ ID NO: 941), AUGgucaggg (SEQ ID NO: 942), AUGgucaguc (SEQ ID NO: 943), AUGgucagug (SEQ ID NO: 944), AUGgucauuu (SEQ ID NO: 945), AUGgugaaaa (SEQ ID NO: 946), AUGgugaaac (SEQ ID NO: 947), AUGgugaaau (SEQ ID NO: 948), AUGgugaacu (SEQ ID NO: 949), AUGgugaaga (SEQ ID NO: 950), AUGgugacgu (SEQ ID NO: 951), AUGgugagaa (SEQ ID NO: 952), AUGgugagac (SEQ ID NO: 953), AUGgugagag (SEQ ID NO: 954), AUGgugagca (SEQ ID NO: 955), AUGgugagcc (SEQ ID NO: 956), AUGgugagcg (SEQ ID NO: 957), AUGgugagcu (SEQ ID NO: 958), AUGgugaggc (SEQ ID NO: 959), AUGgugaggg (SEQ ID NO: 960), AUGgugagua (SEQ ID NO: 961), AUGgugaguc (SEQ ID NO: 962), AUGgugagug (SEQ ID NO: 963), AUGgugaguu (SEQ ID NO: 964), AUGgugauuu (SEQ ID NO: 965), AUGgugcgau (SEQ ID NO: 966), AUGgugcgug (SEQ ID NO: 967), AUGgugggua (SEQ ID NO: 968), AUGgugggug (SEQ ID NO: 969), AUGguggguu (SEQ ID NO: 970), AUGgugguua (SEQ ID NO: 971), AUGguguaag (SEQ ID NO: 972), AUGgugugaa (SEQ ID NO: 973), AUGgugugua (SEQ ID NO: 974), AUGgugugug (SEQ ID NO: 975), AUGguuacuc (SEQ ID NO: 976), AUGguuagca (SEQ ID NO: 977), AUGguuaguc (SEQ ID NO: 978), AUGguuagug (SEQ ID NO: 979), AUGguuaguu (SEQ ID NO: 980), AUGguucagu (SEQ ID NO: 981), AUGguucguc (SEQ ID NO: 982), AUGguuggua (SEQ ID NO: 983), AUGguugguc (SEQ ID NO: 984), AUGguugguu (SEQ ID NO: 985), AUGguuguuu (SEQ ID NO: 986), AUGguuugca (SEQ ID NO: 987), AUGguuugua (SEQ ID NO: 988), AUUgcaagua (SEQ ID NO: 989), AUUguaaaua (SEQ ID NO: 990), AUUguaagau (SEQ ID NO: 991), AUUguaagca (SEQ ID NO: 992), AUUguaagga (SEQ ID NO: 993), AUUguaaggc (SEQ ID NO: 994), AUUguaagua (SEQ ID NO: 995), AUUguaaguc (SEQ ID NO: 996), AUUguaaguu (SEQ ID NO: 997), AUUguaauua (SEQ ID NO: 998), AUUguaauuu (SEQ ID NO: 999), AUUguacaaa (SEQ ID NO: 1000), AUUguaccuc (SEQ ID NO: 1001), AUUguacgug (SEQ ID NO: 1002), AUUguacuug (SEQ ID NO: 1003), AUUguaggua (SEQ ID NO: 1004), AUUguaugag (SEQ ID NO: 1005), AUUguaugua (SEQ ID NO: 1006), AUUgucuguu (SEQ ID NO: 1007), AUUgugagcu (SEQ ID NO: 1008), AUUgugagua (SEQ ID NO: 1009), AUUgugaguc (SEQ ID NO: 1010), AUUgugaguu (SEQ ID NO: 1011), AUUgugcgug (SEQ ID NO: 1012), AUUgugggug (SEQ ID NO: 1013), AUUguuagug (SEQ ID NO: 1014), CAAguaaaaa (SEQ ID NO: 1015), CAAguaaaua (SEQ ID NO: 1016), CAAguaaauc (SEQ ID NO: 1017), CAAguaaaug (SEQ ID NO: 1018), CAAguaaccc (SEQ ID NO: 1019), CAAguaacua (SEQ ID NO: 1020), CAAguaacug (SEQ ID NO: 1021), CAAguaagaa (SEQ ID NO: 1022), CAAguaagac (SEQ ID NO: 1023), CAAguaagau (SEQ ID NO: 1024), CAAguaaggu (SEQ ID NO: 1025), CAAguaagua (SEQ ID NO: 1026), CAAguaaguc (SEQ ID NO: 1027), CAAguaagug (SEQ ID NO: 1028), CAAguaaguu (SEQ ID NO: 1029), CAAguaaucc (SEQ ID NO: 1030), CAAguaaucu (SEQ ID NO: 1031), CAAguaauua (SEQ ID NO: 1032), CAAguaauuc (SEQ ID NO: 1033), CAAguaauug (SEQ ID NO: 1034), CAAguaauuu (SEQ ID NO: 1035), CAAguacaca (SEQ ID NO: 1036), CAAguacguu (SEQ ID NO: 1037), CAAguacuuu (SEQ ID NO: 1038), CAAguagcug (SEQ ID NO: 1039), CAAguaggau (SEQ ID NO: 1040), CAAguaggua (SEQ ID NO: 1041), CAAguagguc (SEQ ID NO: 1042), CAAguaggug (SEQ ID NO: 1043), CAAguagguu (SEQ ID NO: 1044), CAAguaguuu (SEQ ID NO: 1045), CAAguauaac (SEQ ID NO: 1046), CAAguauaug (SEQ ID NO: 1047), CAAguaucuu (SEQ ID NO: 1048), CAAguaugag (SEQ ID NO: 1049), CAAguaugua (SEQ ID NO: 1050), CAAguauguc (SEQ ID NO: 1051), CAAguaugug (SEQ ID NO: 1052), CAAguauguu (SEQ ID NO: 1053), CAAguauuga (SEQ ID NO: 1054), CAAguauuuc (SEQ ID NO: 1055), CAAgucagac (SEQ ID NO: 1056), CAAgucagua (SEQ ID NO: 1057), CAAgucuaua (SEQ ID NO: 1058), CAAgucugau (SEQ ID NO: 1059), CAAgugacuu (SEQ ID NO: 1060), CAAgugagaa (SEQ ID NO: 1061), CAAgugagac (SEQ ID NO: 1062), CAAgugagca (SEQ ID NO: 1063), CAAgugaggc (SEQ ID NO: 1064), CAAgugaggg (SEQ ID NO: 1065), CAAgugagua (SEQ ID NO: 1066), CAAgugaguc (SEQ ID NO: 1067), CAAgugagug (SEQ ID NO: 1068), CAAgugaucc (SEQ ID NO: 1069), CAAgugaucu (SEQ ID NO: 1070), CAAgugauuc (SEQ ID NO: 1071), CAAgugauug (SEQ ID NO: 1072), CAAgugauuu (SEQ ID NO: 1073), CAAgugccuu (SEQ ID NO: 1074), CAAgugggua (SEQ ID NO: 1075), CAAguggguc (SEQ ID NO: 1076), CAAgugggug (SEQ ID NO: 1077), CAAgugugag (SEQ ID NO: 1078), CAAguuaaaa (SEQ ID NO: 1079), CAAguuaagu (SEQ ID NO: 1080), CAAguuaauc (SEQ ID NO: 1081), CAAguuagaa (SEQ ID NO: 1082), CAAguuaguu (SEQ ID NO: 1083), CAAguucaag (SEQ ID NO: 1084), CAAguuccgu (SEQ ID NO: 1085), CAAguuggua (SEQ ID NO: 1086), CAAguuuagu (SEQ ID NO: 1087), CAAguuucca (SEQ ID NO: 1088), CAAguuuguu (SEQ ID NO: 1089), CACguaagag (SEQ ID NO: 1090), CACguaagca (SEQ ID NO: 1091), CACguaauug (SEQ ID NO: 1092), CACguaggac (SEQ ID NO: 1093), CACguaucga (SEQ ID NO: 1094), CACgucaguu (SEQ ID NO: 1095), CACgugagcu (SEQ ID NO: 1096), CACgugaguc (SEQ ID NO: 1097), CACgugagug (SEQ ID NO: 1098), CAGgcaagaa (SEQ ID NO: 1099), CAGgcaagac (SEQ ID NO: 1100), CAGgcaagag (SEQ ID NO: 1101), CAGgcaagga (SEQ ID NO: 1102), CAGgcaagua (SEQ ID NO: 1103), CAGgcaagug (SEQ ID NO: 1104), CAGgcaaguu (SEQ ID NO: 1105), CAGgcacgca (SEQ ID NO: 1106), CAGgcagagg (SEQ ID NO: 1107), CAGgcaggug (SEQ ID NO: 1108), CAGgcaucau (SEQ ID NO: 1109), CAGgcaugaa (SEQ ID NO: 1110), CAGgcaugag (SEQ ID NO: 1111), CAGgcaugca (SEQ ID NO: 1112), CAGgcaugcg (SEQ ID NO: 1113), CAGgcaugug (SEQ ID NO: 1114), CAGgcgagag (SEQ ID NO: 1115), CAGgcgccug (SEQ ID NO: 1116), CAGgcgugug (SEQ ID NO: 1117), CAGguaaaaa (SEQ ID NO: 1118), CAGguaaaag (SEQ ID NO: 1119), CAGguaaaca (SEQ ID NO: 1120), CAGguaaacc (SEQ ID NO: 1121), CAGguaaaga (SEQ ID NO: 1122), CAGguaaagc (SEQ ID NO: 1123), CAGguaaagu (SEQ ID NO: 1124), CAGguaaaua (SEQ ID NO: 1125), CAGguaaauc (SEQ ID NO: 1126), CAGguaaaug (SEQ ID NO: 1127), CAGguaaauu (SEQ ID NO: 1128), CAGguaacag (SEQ ID NO: 1129), CAGguaacau (SEQ ID NO: 1130), CAGguaacca (SEQ ID NO: 1131), CAGguaaccg (SEQ ID NO: 1132), CAGguaacgu (SEQ ID NO: 1133), CAGguaacua (SEQ ID NO: 1134), CAGguaacuc (SEQ ID NO: 1135), CAGguaacug (SEQ ID NO: 1136), CAGguaacuu (SEQ ID NO: 1137), CAGguaagaa (SEQ ID NO: 1138), CAGguaagac (SEQ ID NO: 1139), CAGguaagag (SEQ ID NO: 1140), CAGguaagau (SEQ ID NO: 1141), CAGguaagcc (SEQ ID NO: 1142), CAGguaagga (SEQ ID NO: 1143), CAGguaaggc (SEQ ID NO: 1144), CAGguaaggg (SEQ ID NO: 1145), CAGguaaggu (SEQ ID NO: 1146), CAGguaagua (SEQ ID NO: 1147), CAGguaagug (SEQ ID NO: 1148), CAGguaaguu (SEQ ID NO: 1149), CAGguaauaa (SEQ ID NO: 1150), CAGguaauau (SEQ ID NO: 1151), CAGguaaucc (SEQ ID NO: 1152), CAGguaaugc (SEQ ID NO: 1153), CAGguaaugg (SEQ ID NO: 1154), CAGguaaugu (SEQ ID NO: 1155), CAGguaauua (SEQ ID NO: 1156), CAGguaauuc (SEQ ID NO: 1157), CAGguaauug (SEQ ID NO: 1158), CAGguaauuu (SEQ ID NO: 1159), CAGguacaaa (SEQ ID NO: 1160), CAGguacaag (SEQ ID NO: 1161), CAGguacaau (SEQ ID NO: 1162), CAGguacaca (SEQ ID NO: 1163), CAGguacacg (SEQ ID NO: 1164), CAGguacaga (SEQ ID NO: 1165), CAGguacagg (SEQ ID NO: 1166), CAGguacagu (SEQ ID NO: 1167), CAGguacaua (SEQ ID NO: 1168), CAGguacaug (SEQ ID NO: 1169), CAGguacauu (SEQ ID NO: 1170), CAGguaccac (SEQ ID NO: 1171), CAGguaccca (SEQ ID NO: 1172), CAGguacccg (SEQ ID NO: 1173), CAGguacccu (SEQ ID NO: 1174), CAGguaccgc (SEQ ID NO: 1175), CAGguaccgg (SEQ ID NO: 1176), CAGguaccuc (SEQ ID NO: 1177), CAGguaccug (SEQ ID NO: 1178), CAGguaccuu (SEQ ID NO: 1179), CAGguacgag (SEQ ID NO: 1180), CAGguacgca (SEQ ID NO: 1181), CAGguacgcc (SEQ ID NO: 1182), CAGguacggu (SEQ ID NO: 1183), CAGguacgua (SEQ ID NO: 1184), CAGguacgug (SEQ ID NO: 1185), CAGguacuaa (SEQ ID NO: 1186), CAGguacuag (SEQ ID NO: 1187), CAGguacuau (SEQ ID NO: 1188), CAGguacucc (SEQ ID NO: 1189), CAGguacucu (SEQ ID NO: 1190), CAGguacuga (SEQ ID NO: 1191), CAGguacugc (SEQ ID NO: 1192), CAGguacugu (SEQ ID NO: 1193), CAGguacuua (SEQ ID NO: 1194), CAGguacuuu (SEQ ID NO: 1195), CAGguagaaa (SEQ ID NO: 1196), CAGguagaac (SEQ ID NO: 1197), CAGguagaag (SEQ ID NO: 1198), CAGguagaca (SEQ ID NO: 1199), CAGguagacc (SEQ ID NO: 1200), CAGguagaga (SEQ ID NO: 1201), CAGguagauu (SEQ ID NO: 1202), CAGguagcaa (SEQ ID NO: 1203), CAGguagcac (SEQ ID NO: 1204), CAGguagcag (SEQ ID NO: 1205), CAGguagcca (SEQ ID NO: 1206), CAGguagcgu (SEQ ID NO: 1207), CAGguagcua (SEQ ID NO: 1208), CAGguagcuc (SEQ ID NO: 1209), CAGguagcug (SEQ ID NO: 1210), CAGguagcuu (SEQ ID NO: 1211), CAGguaggaa (SEQ ID NO: 1212), CAGguaggac (SEQ ID NO: 1213), CAGguaggag (SEQ ID NO: 1214), CAGguaggca (SEQ ID NO: 1215), CAGguaggga (SEQ ID NO: 1216), CAGguagggc (SEQ ID NO: 1217), CAGguagggg (SEQ ID NO: 1218), CAGguagggu (SEQ ID NO: 1219), CAGguaggua (SEQ ID NO: 1220), CAGguagguc (SEQ ID NO: 1221), CAGguaggug (SEQ ID NO: 1222), CAGguagguu (SEQ ID NO: 1223), CAGguaguaa (SEQ ID NO: 1224), CAGguaguau (SEQ ID NO: 1225), CAGguaguca (SEQ ID NO: 1226), CAGguagucc (SEQ ID NO: 1227), CAGguaguga (SEQ ID NO: 1228), CAGguagugu (SEQ ID NO: 1229), CAGguaguuc (SEQ ID NO: 1230), CAGguaguug (SEQ ID NO: 1231), CAGguaguuu (SEQ ID NO: 1232), CAGguauaag (SEQ ID NO: 1233), CAGguauaca (SEQ ID NO: 1234), CAGguauaga (SEQ ID NO: 1235), CAGguauauc (SEQ ID NO: 1236), CAGguauaug (SEQ ID NO: 1237), CAGguauauu (SEQ ID NO: 1238), CAGguaucag (SEQ ID NO: 1239), CAGguaucau (SEQ ID NO: 1240), CAGguauccu (SEQ ID NO: 1241), CAGguaucga (SEQ ID NO: 1242), CAGguaucgc (SEQ ID NO: 1243), CAGguaucua (SEQ ID NO: 1244), CAGguaucug (SEQ ID NO: 1245), CAGguaucuu (SEQ ID NO: 1246), CAGguaugaa (SEQ ID NO: 1247), CAGguaugac (SEQ ID NO: 1248), CAGguaugag (SEQ ID NO: 1249), CAGguaugau (SEQ ID NO: 1250), CAGguaugca (SEQ ID NO: 1251), CAGguaugcc (SEQ ID NO: 1252), CAGguaugcg (SEQ ID NO: 1253), CAGguaugcu (SEQ ID NO: 1254), CAGguaugga (SEQ ID NO: 1255), CAGguauggg (SEQ ID NO: 1256), CAGguauggu (SEQ ID NO: 1257), CAGguaugua (SEQ ID NO: 1258), CAGguauguc (SEQ ID NO: 1259), CAGguaugug (SEQ ID NO: 1260), CAGguauguu (SEQ ID NO: 1261), CAGguauuau (SEQ ID NO: 1262), CAGguauuca (SEQ ID NO: 1263), CAGguauucu (SEQ ID NO: 1264), CAGguauuga (SEQ ID NO: 1265), CAGguauugg (SEQ ID NO: 1266), CAGguauugu (SEQ ID NO: 1267), CAGguauuua (SEQ ID NO: 1268), CAGguauuuc (SEQ ID NO: 1269), CAGguauuug (SEQ ID NO: 1270), CAGguauuuu (SEQ ID NO: 1271), CAGgucaaca (SEQ ID NO: 1272), CAGgucaaug (SEQ ID NO: 1273), CAGgucacgu (SEQ ID NO: 1274), CAGgucagaa (SEQ ID NO: 1275), CAGgucagac (SEQ ID NO: 1276), CAGgucagca (SEQ ID NO: 1277), CAGgucagcc (SEQ ID NO: 1278), CAGgucagcg (SEQ ID NO: 1279), CAGgucagga (SEQ ID NO: 1280), CAGgucagua (SEQ ID NO: 1281), CAGgucaguc (SEQ ID NO: 1282), CAGgucagug (SEQ ID NO: 1283), CAGgucaguu (SEQ ID NO: 1284), CAGgucaucc (SEQ ID NO: 1285), CAGgucaugc (SEQ ID NO: 1286), CAGgucauua (SEQ ID NO: 1287), CAGgucauuu (SEQ ID NO: 1288), CAGguccacc (SEQ ID NO: 1289), CAGguccacu (SEQ ID NO: 1290), CAGguccagu (SEQ ID NO: 1291), CAGguccauc (SEQ ID NO: 1292), CAGguccauu (SEQ ID NO: 1293), CAGgucccag (SEQ ID NO: 1294), CAGgucccug (SEQ ID NO: 1295), CAGguccuga (SEQ ID NO: 1296), CAGguccugc (SEQ ID NO: 1297), CAGguccugg (SEQ ID NO: 1298), CAGgucggcc (SEQ ID NO: 1299), CAGgucggug (SEQ ID NO: 1300), CAGgucguug (SEQ ID NO: 1301), CAGgucucuc (SEQ ID NO: 1302), CAGgucucuu (SEQ ID NO: 1303), CAGgucugag (SEQ ID NO: 1304), CAGgucugcc (SEQ ID NO: 1305), CAGgucugcg (SEQ ID NO: 1306), CAGgucugga (SEQ ID NO: 1307), CAGgucuggu (SEQ ID NO: 1308), CAGgucugua (SEQ ID NO: 1309), CAGgucuguc (SEQ ID NO: 1310), CAGgucugug (SEQ ID NO: 1311), CAGgucuguu (SEQ ID NO: 1312), CAGgucuucc (SEQ ID NO: 1313), CAGgucuuuc (SEQ ID NO: 1314), CAGgugaaag (SEQ ID NO: 1315), CAGgugaaau (SEQ ID NO: 1316), CAGgugaaca (SEQ ID NO: 1317), CAGgugaaga (SEQ ID NO: 1318), CAGgugaagg (SEQ ID NO: 1319), CAGgugaaua (SEQ ID NO: 1320), CAGgugaauc (SEQ ID NO: 1321), CAGgugaauu (SEQ ID NO: 1322), CAGgugacaa (SEQ ID NO: 1323), CAGgugacau (SEQ ID NO: 1324), CAGgugacca (SEQ ID NO: 1325), CAGgugaccc (SEQ ID NO: 1326), CAGgugaccg (SEQ ID NO: 1327), CAGgugaccu (SEQ ID NO: 1328), CAGgugacgg (SEQ ID NO: 1329), CAGgugacua (SEQ ID NO: 1330), CAGgugacuc (SEQ ID NO: 1331), CAGgugacug (SEQ ID NO: 1332), CAGgugagaa (SEQ ID NO: 1333), CAGgugagac (SEQ ID NO: 1334), CAGgugagag (SEQ ID NO: 1335), CAGgugagau (SEQ ID NO: 1336), CAGgugagca (SEQ ID NO: 1337), CAGgugagcc (SEQ ID NO: 1338), CAGgugagcg (SEQ ID NO: 1339), CAGgugagcu (SEQ ID NO: 1340), CAGgugagga (SEQ ID NO: 1341), CAGgugaggc (SEQ ID NO: 1342), CAGgugaggg (SEQ ID NO: 1343), CAGgugaggu (SEQ ID NO: 1344), CAGgugagua (SEQ ID NO: 1345), CAGgugaguc (SEQ ID NO: 1346), CAGgugagug (SEQ ID NO: 1347), CAGgugaguu (SEQ ID NO: 1348), CAGgugauaa (SEQ ID NO: 1349), CAGgugaucc (SEQ ID NO: 1350), CAGgugaucu (SEQ ID NO: 1351), CAGgugaugc (SEQ ID NO: 1352), CAGgugaugg (SEQ ID NO: 1353), CAGgugaugu (SEQ ID NO: 1354), CAGgugauua (SEQ ID NO: 1355), CAGgugauuc (SEQ ID NO: 1356), CAGgugauug (SEQ ID NO: 1357), CAGgugauuu (SEQ ID NO: 1358), CAGgugcaaa (SEQ ID NO: 1359), CAGgugcaag (SEQ ID NO: 1360), CAGgugcaca (SEQ ID NO: 1361), CAGgugcacg (SEQ ID NO: 1362), CAGgugcaga (SEQ ID NO: 1363), CAGgugcagg (SEQ ID NO: 1364), CAGgugcaua (SEQ ID NO: 1365), CAGgugcauc (SEQ ID NO: 1366), CAGgugcaug (SEQ ID NO: 1367), CAGgugccaa (SEQ ID NO: 1368), CAGgugccca (SEQ ID NO: 1369), CAGgugcccc (SEQ ID NO: 1370), CAGgugcccg (SEQ ID NO: 1371), CAGgugccua (SEQ ID NO: 1372), CAGgugccug (SEQ ID NO: 1373), CAGgugcgaa (SEQ ID NO: 1374), CAGgugcgca (SEQ ID NO: 1375), CAGgugcgcc (SEQ ID NO: 1376), CAGgugcgcg (SEQ ID NO: 1377), CAGgugcgga (SEQ ID NO: 1378), CAGgugcggu (SEQ ID NO: 1379), CAGgugcgua (SEQ ID NO: 1380), CAGgugcguc (SEQ ID NO: 1381), CAGgugcgug (SEQ ID NO: 1382), CAGgugcuag (SEQ ID NO: 1383), CAGgugcuau (SEQ ID NO: 1384), CAGgugcuca (SEQ ID NO: 1385), CAGgugcucc (SEQ ID NO: 1386), CAGgugcucg (SEQ ID NO: 1387), CAGgugcugc (SEQ ID NO: 1388), CAGgugcugg (SEQ ID NO: 1389), CAGgugcuua (SEQ ID NO: 1390), CAGgugcuuc (SEQ ID NO: 1391), CAGgugcuug (SEQ ID NO: 1392), CAGguggaac (SEQ ID NO: 1393), CAGguggaag (SEQ ID NO: 1394), CAGguggaau (SEQ ID NO: 1395), CAGguggaga (SEQ ID NO: 1396), CAGguggagu (SEQ ID NO: 1397), CAGguggauu (SEQ ID NO: 1398), CAGguggcca (SEQ ID NO: 1399), CAGguggcuc (SEQ ID NO: 1400), CAGguggcug (SEQ ID NO: 1401), CAGgugggaa (SEQ ID NO: 1402), CAGgugggac (SEQ ID NO: 1403), CAGgugggag (SEQ ID NO: 1404), CAGgugggau (SEQ ID NO: 1405), CAGgugggca (SEQ ID NO: 1406), CAGgugggcc (SEQ ID NO: 1407), CAGgugggcu (SEQ ID NO: 1408), CAGgugggga (SEQ ID NO: 1409), CAGguggggc (SEQ ID NO: 1410), CAGguggggg (SEQ ID NO: 1411), CAGguggggu (SEQ ID NO: 1412), CAGgugggua (SEQ ID NO: 1413), CAGguggguc (SEQ ID NO: 1414), CAGgugggug (SEQ ID NO: 1415), CAGguggguu (SEQ ID NO: 1416), CAGguggucu (SEQ ID NO: 1417), CAGguggugg (SEQ ID NO: 1418), CAGgugguug (SEQ ID NO: 1419), CAGguguaca (SEQ ID NO: 1420), CAGguguagg (SEQ ID NO: 1421), CAGguguauc (SEQ ID NO: 1422), CAGgugucac (SEQ ID NO: 1423), CAGgugucag (SEQ ID NO: 1424), CAGgugucca (SEQ ID NO: 1425), CAGguguccu (SEQ ID NO: 1426), CAGgugucua (SEQ ID NO: 1427), CAGgugucuc (SEQ ID NO: 1428), CAGgugucug (SEQ ID NO: 1429), CAGgugugaa (SEQ ID NO: 1430), CAGgugugac (SEQ ID NO: 1431), CAGgugugag (SEQ ID NO: 1432), CAGgugugau (SEQ ID NO: 1433), CAGgugugca (SEQ ID NO: 1434), CAGgugugcc (SEQ ID NO: 1435), CAGgugugcg (SEQ ID NO: 1436), CAGgugugcu (SEQ ID NO: 1437), CAGgugugga (SEQ ID NO: 1438), CAGguguggc (SEQ ID NO: 1439), CAGgugugua (SEQ ID NO: 1440), CAGguguguc (SEQ ID NO: 1441), CAGgugugug (SEQ ID NO: 1442), CAGguguguu (SEQ ID NO: 1443), CAGguguuua (SEQ ID NO: 1444), CAGguuaaaa (SEQ ID NO: 1445), CAGguuaaua (SEQ ID NO: 1446), CAGguuaauc (SEQ ID NO: 1447), CAGguuaccu (SEQ ID NO: 1448), CAGguuagaa (SEQ ID NO: 1449), CAGguuagag (SEQ ID NO: 1450), CAGguuagau (SEQ ID NO: 1451), CAGguuagcc (SEQ ID NO: 1452), CAGguuaggg (SEQ ID NO: 1453), CAGguuaggu (SEQ ID NO: 1454), CAGguuagua (SEQ ID NO: 1455), CAGguuaguc (SEQ ID NO: 1456), CAGguuagug (SEQ ID NO: 1457), CAGguuaguu (SEQ ID NO: 1458), CAGguuauca (SEQ ID NO: 1459), CAGguuaugu (SEQ ID NO: 1460), CAGguuauua (SEQ ID NO: 1461), CAGguuauug (SEQ ID NO: 1462), CAGguucaaa (SEQ ID NO: 1463), CAGguucaac (SEQ ID NO: 1464), CAGguucaag (SEQ ID NO: 1465), CAGguucaca (SEQ ID NO: 1466), CAGguucacg (SEQ ID NO: 1467), CAGguucagg (SEQ ID NO: 1468), CAGguucaug (SEQ ID NO: 1469), CAGguuccag (SEQ ID NO: 1470), CAGguuccca (SEQ ID NO: 1471), CAGguucccg (SEQ ID NO: 1472), CAGguucgaa (SEQ ID NO: 1473), CAGguucgag (SEQ ID NO: 1474), CAGguucuau (SEQ ID NO: 1475), CAGguucugc (SEQ ID NO: 1476), CAGguucuua (SEQ ID NO: 1477), CAGguucuuc (SEQ ID NO: 1478), CAGguucuuu (SEQ ID NO: 1479), CAGguugaac (SEQ ID NO: 1480), CAGguugaag (SEQ ID NO: 1481), CAGguugagu (SEQ ID NO: 1482), CAGguugaua (SEQ ID NO: 1483), CAGguuggag (SEQ ID NO: 1484), CAGguuggca (SEQ ID NO: 1485), CAGguuggcc (SEQ ID NO: 1486), CAGguugguc (SEQ ID NO: 1487), CAGguuggug (SEQ ID NO: 1488), CAGguugguu (SEQ ID NO: 1489), CAGguuguaa (SEQ ID NO: 1490), CAGguuguac (SEQ ID NO: 1491), CAGguuguau (SEQ ID NO: 1492), CAGguuguca (SEQ ID NO: 1493), CAGguuguga (SEQ ID NO: 1494), CAGguuguug (SEQ ID NO: 1495), CAGguuuaag (SEQ ID NO: 1496), CAGguuuacc (SEQ ID NO: 1497), CAGguuuagc (SEQ ID NO: 1498), CAGguuuagu (SEQ ID NO: 1499), CAGguuucuu (SEQ ID NO: 1500), CAGguuugaa (SEQ ID NO: 1501), CAGguuugag (SEQ ID NO: 1502), CAGguuugau (SEQ ID NO: 15...

Claims

CLAIMS 1. A compound of Formula (I):(I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1; X is C(R2a), O, S, N, or N(R2c); Y is C(R2a), C(R2a)(R2b), N, N(R2c), O, or S, wherein at least one of X and Y is N or N(R2c), and the bonds within the ring containing X and Y are single bonds or double bounds depending on valence; W is C, C(R2a), or N; Z1is C(R2d), C(R2d)(R2e), or N; Z2and Z3are each independently C or N; Z4is C(R2d) or N; Z5is C(R2d), C(R2d)(R2e), N, N(R2c), wherein the bonds within the ring containing Z1, Z2, Z3, Z4, and Z5are single bonds or double bounds depending on valence; L1and L2are each absent, C1-C6-alkylene, C1-C6-heteroalkylene, -O-, -S-, -C(O)-, - N(R3)-, -N(R3)C(O)-, or -C(O)N(R3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4; each R1is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6alkylene-aryl, C1-C6alkenylene-aryl, C1-C6alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –ORA, –NRBRC, – NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; ortwo R1groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R2a, R2b, R2d, and R2eare each independently hydrogen, deuterium, C1-C6-alkyl, C2-C6- alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, – C(O)ORD, –S(O)xRD, or -P(O)yRERF, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; or R2dand R2eare taken together with the carbon atom to which they are attached to form a carbonyl group; R2cis hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; R3is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, or C1-C6-haloalkyl; each R4is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; wherein each C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, and cycloalkyl is optionally substituted with one or more R9; each R5is independently hydrogen, deuterium, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, or –S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; each R6is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or –ORA; each RAis independently hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, aryl, heteroaryl, C1-C6alkylene-aryl, C1-C6alkylene-heteroaryl, cycloalkyl, heterocyclyl, –C(O)RD, or –S(O)xRD; wherein each alkyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7;each of RBand RCis independently hydrogen, C1-C6alkyl, C1-C6heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or –ORA1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; or RBand RCtogether with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7; each RD, RE, and RFis independently hydrogen, deuterium, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6heteroalkyl, C1-C6haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1- C6alkylene-aryl, C1-C6alkylene-heteroaryl, or –NRB1RC1, wherein each alkyl, heteroalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R7; each R7is independently hydrogen, deuterium, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, or oxo; each R9is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, oxo, –ORA, –NRBRC, –C(O)RD, or –C(O)ORD; each RA1, RB1, and RC1is hydrogen, deuterium, or C1-C6alkyl; x is 0, 1, or 2; and y is 1, 2, or 3.

2. The compound of claim 1, wherein each of A and B is independently heteroaryl or heterocyclyl, each of which is optionally substituted with one or more R1.

3. The compound of any one of the preceding claims, wherein one of A and B is independently a monocyclic heteroaryl or bicyclic heteroaryl, each of which is optionally substituted with one or more R1.

4. The compound of any one of the preceding claims, wherein one of A and B is independently a bicyclic heteroaryl optionally substituted with one or more R1.

5. The compound of any one of the preceding claims, wherein one of A and B is independently a nitrogen-containing heteroaryl optionally substituted with one or more R1.

6. The compound of any one of the preceding claims, wherein one of A and B is a 5-10 membered heteroaryl optionally substituted with one or more R1.

7. The compound of any one of the preceding claims, wherein one of A and B is8. The compound of any one of the preceding claims, wherein one of A and B is9. The compound of any one of the preceding claims, wherein one of A and B is independently selected fromwherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7.

10. The compound of any one of the preceding claims, wherein one of A and B is independently, wherein each R1ais independently C1-C6- alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7.

11. The compound of any one of the preceding claims, wherein one of A and B is independently , wherein whe1arein each R is independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7.

12. The compound of any one of the preceding claims, wherein A is selected from13. The compound of any one of the preceding claims, wherein B is selected from14. The compound of any one of the preceding claims, wherein A is selected from, wherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6- haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7.

15. The compound of any one of the preceding claims, wherein A is , whereinR1is as described in claim 1.

16. The compound of any one of the preceding claims, wherein A is, wherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7.

17. The compound of any one of the preceding claims, wherein A iswherein each R1ais independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7.

18. The compound of any one of the preceding claims, wherein one of A and B is independently selected from19. The compound of any one of the preceding claims, wherein one of A and B is independently selected from20. The compound of any one of the preceding claims, wherein one of A and B is independently21. The compound of any one of the preceding claims, wherein A is selected from22. The compound of any one of the preceding claims, wherein B is selected from23. The compound of any one of the preceding claims, wherein A selected from24. The compound of any one of the preceding claims, wherein A is , or25. The compound of any one of the preceding claims, wherein one of A and B is independently a monocyclic heterocyclyl or bicyclic heterocyclyl, each of which is optionally substituted with one or more R1.

26. The compound of any one of the preceding claims, wherein one of A and B is independently a nitrogen-containing heterocyclyl optionally substituted with one or more R1.

27. The compound of any one of the preceding claims, wherein one of A and B is independently a 4-8 membered heterocyclyl optionally substituted with one or more R1.

28. The compound of any one of the preceding claims, wherein one of A and B is independently selected from, wherein R1is as described in claim 1.

29. The compound of any one of the preceding claims, wherein one of A and B is independently selected from , wherein R1is asdescribed in claim 1.

30. The compound of any one of the preceding claims, wherein one of A and B is , wherein R1is as described in claim 1.

31. The compound of any one of the preceding claims, wherein one of A and B is , wherein R1is as described in claim 1.

32. The compound of any one of the preceding claims, wherein A is selected from, wherein R1is as described in claim 1.

33. The compound of any one of the preceding claims, wherein B is selected from, wherein R1is as described in claim 1.

34. The compound of any one of the preceding claims, wherein B is selected from, wherein R1is as described in claim 1.

35. The compound of any one of the preceding claims, wherein B is selected from , wherein R1is as described in claim 1.

36. The compound of any one of the preceding claims, wherein one of A and B is independently selected from37. The compound of any one of the preceding claims, wherein one of A and B is independently selected from38. The compound of any one of the preceding claims, wherein one of A and B is39. The compound of any one of the preceding claims, wherein one of A and B is40. The compound of any one of the preceding claims, wherein A is selected from ,41. The compound of any one of the preceding claims, wherein B is selected from ,42. The compound of any one of the preceding claims, wherein B is selected from43. The compound of any one of the preceding claims, wherein B is selected from44. The compound of any one of the preceding claims, wherein B is45. The compound of any one of the preceding claims, wherein each of L1and L2are each independently absent, C1-C6-alkylene, C1-C6-heteroalkylene, -N(R3)-, -O-, -C(O)-, and -S-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R4.

46. The compound of any one of the preceding claims, wherein L1is absent, C1-C6-alkylene, -N(R3)-, -S-, -N(R3)-, -C(O)-, or -O- wherein each alkylene is optionally substituted with one or more R4.

47. The compound of any one of the preceding claims, wherein L1is absent or N(R3)- (e.g., - NH or -NCH3).

48. The compound of any one of the preceding claims, wherein L2is absent, C1-C6-alkylene, C1-C6-heteroalkylene, -N(R3)-, -O-,-S-, or -C(O)- wherein each alkylene is optionally substituted with one or more R4.

49. The compound of any one of the preceding claims, wherein L2is absent, -N(R3)-, or -O-,.

50. The compound of any one of the preceding claims, wherein L1is -N(R3)- and L2is absent.

51. The compound of any one of the preceding claims, wherein X is C(R2a), N(R2c), or N.

52. The compound of any one of the preceding claims, wherein X is N.

53. The compound of any one of the preceding claims, wherein Y is C(R2a), N, N(R2c), O, or S.

54. The compound of any one of the preceding claims, wherein Y is C(R2a), N(R2c), or N.

55. The compound of any one of the preceding claims, wherein Y is N or N(R2c).

56. The compound of any one of the preceding claims, wherein W is C or N.

57. The compound of any one of the preceding claims, wherein W is C.

58. The compound of any one of the preceding claims, wherein W is N.

59. The compound of any one of the preceding claims, wherein at least one of Z1, Z2, Z3, Z4, and Z5is independently N.

60. The compound of any one of the preceding claims, wherein at least two of Z1, Z2, Z3, Z4, and Z5are independently N.

61. The compound of any one of the preceding claims, wherein Z1is N.

62. The compound of any one of the preceding claims, wherein Z2is N.

63. The compound of any one of the preceding claims, wherein Z3is N.

64. The compound of any one of the preceding claims, wherein Z4is N.

65. The compound of any one of the preceding claims, wherein Z5is N.

66. The compound of any one of the preceding claims, wherein Z1is N and each of Z2, Z3, Z4, and Z5is independently C or C(R2d).

67. The compound of any one of the preceding claims, wherein Z1, Z2, Z3, Z4, and Z5are each independently C or C(R2d).

68. The compound of any one of the preceding claims, wherein Z1is C(R2d), and R2dis C1- C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, –ORA, –NRBRC, –NRBC(O)RD, –NO2, –C(O)NRBRC, –C(O)RD, –C(O)ORD, – S(O)xRD, or -P(O)yRERF.

69. The compound of any one of the preceding claims, wherein Z1is C(R2d), and R2dis selected from:

70. The compound of any one of the preceding claims, wherein Z5is C(R2d), and R2dis C1- C6-alkyl, –ORA, S(O)xRD, or -P(O)yRERF.

71. The compound of any one of the preceding claims, wherein Z4is C(R2d), and R2dis C1- C6-alkyl, halo, heterocyclyl, or –ORA.

72. The compound of any one of the preceding claims, wherein Y is N(R2c) and R2cis hydrogen, C1-C6- alkyl, cycloalkyl, or heterocyclyl, each of which is optionally substituted with 1 or more R5.

73. The compound of any one of the preceding claims wherein, is selected74. The compound of any one of the preceding claims, wherein is75. The compound of any one of the preceding claims, whereinis selected from:

76. The compound of any one of the preceding claims, whereinis selected from:

77. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-a):(I-a), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, W, X, Y, Z1, Z2, Z3, Z4, Z5, L1, L2, and variables therein are as defined in claim 1.

78. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-ai):(I-ai), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, Y, Z1, Z2, Z3, Z4, Z5, L1, L2, and variables therein are as defined in claim 1.

79. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-b): (I-b), o ar a phrmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, X, Y, Z1, L1, L2, and variables therein are as defined in claim 1, and each R2dis hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, or –ORA1.

80. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-c):(I-c), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L1, L2, R2c, R2d, and variables therein are asdefined in claim 1, and each R2d is hydrogen, C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl,halo, or –ORA1.

81. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-d): (I-d), or a pahrmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, X, Y, Z1, Z2, L1, and variables therein are as defined in claim 1.

82. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-e):(I-e), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each R1ais independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7; and wherein B, X, Y, Z1, Z2, Z3, Z4, Z5, L1, L2, and variables therein are as defined in claim 1.

83. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-f):(I-f), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each R1ais independently C1-C6-alkyl, C1-C6- heteroalkyl, C1-C6-haloalkyl, halo, cyano, or –ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R7; and wherein B, X, Y, L1, Z1, and variables therein are as described in claim 1.

84. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-g):(I-g), or a pharmaceutically acceptable salt thereof, wherein A, B, X, L1, R2c, and R2dare as defined in claim 1.

85. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-h):(I-h), or a pharmaceutically acceptable salt thereof, wherein each of A, B, X, Y, L1, and R2dare as defined in claim 1.

86. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-i): or a pharmaceutically acceptable salt thereof, wherein each of A,B, X, Y, L1, and R2dare as defined in claim 1.

87. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-j):or a pharmaceutically acceptable salt thereof, wherein each of A, B, X, Y, L1, and R2dare as defined in claim 1.

88. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-k):or a pharmaceutically acceptable salt thereof, wherein each of A, B, X, Y, L1, and R2dare as defined in claim 1.

89. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-l):,(I-l), or a pharmaceutically acceptable salt thereof, wherein each of A, B, X, Y, L1, L2, and R2dare as defined in claim 1; and m is 0, 1, 2, 3, 4, 5, or 6.

90. The compound of any one of the preceding claims, wherein the compound is selected from a compound listed in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

91. A pharmaceutical composition comprising a compound of any one of claims 1-90 and a pharmaceutically acceptable excipient.

92. The compound of any one of claims 1-90 or the pharmaceutical composition of claim 91, wherein the compound alters a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

93. The compound of any one of claims 1-90 or the pharmaceutical composition of claim 91, wherein the compound binds to a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

94. The compound of any one of claims 1-90 or the pharmaceutical composition of claim 91, wherein the compound stabilizes a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

95. The compound of any one of claims 1-90 or the pharmaceutical composition of claim 91, wherein the compound increases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

96. The compound of any one of claims 1-90 or the pharmaceutical composition of claim 91, wherein the compound decreases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR %.

97. A method of modulating splicing of a nucleic acid (e.g., DNA, RNA, e.g., a pre-mRNA) comprising contacting the nucleic acid with a compound of Formula (I) or (II) as described in any one of claims 1-90 or the pharmaceutical composition of claim 91.

98. A method of forming a complex comprising a component of a spliceosome (e.g., a major spliceosome component or a minor spliceosome component), a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA), and a compound of Formula (I) as described in any one of claims 1-90, comprising contacting the nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) with a compound of Formula (I).

99. The method of claim 98, wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (I) as described in any one of claims 1- 90.

100. A method of altering the conformation of a nucleic acid (e.g., a DNA, RNA, e.g., a pre- mRNA) comprising contacting the nucleic acid with a compound of Formula (I) as described in any one of claims 1-90.

101. The method of claim 100, wherein the altering comprises forming a bulge in the nucleic acid.

102. The method of claim 100, wherein the altering comprises stabilizing a bulge in the nucleic acid.

103. The method of claim 100, wherein the altering comprises reducing a bulge in the nucleic acid.

104. The method of any one of claims 100-103, wherein the nucleic acid comprises a splice site.

105. A method of treating a disease or disorder in a subject comprising administering to the subject a compound of Formula (I) as described in any one of claims 1-90 or the pharmaceutical composition of claim 91.

106. The method of claim 105, wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).

107. The method of any one of claims 105-106, wherein the proliferative disease is cancer.

108. The method of claim 105, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

109. The method of claim 95, wherein the disease or disorder comprises neurological disease or disorder.

110. The method of claim 95, wherein the disease or disorder comprises Huntington’s disease.

111. A composition for use in treating a disease or disorder in a subject comprising a compound of Formula (I) as described in any one of claims 1-90 or the pharmaceutical composition of claim 91.

112. The composition for use of claim 111, wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).

113. The composition for use of any one of claims 111-112, wherein the proliferative disease is cancer.

114. The composition for use of claim 111, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

115. The composition for use of claim 114, wherein the disease or disorder comprises neurological disease or disorder.

116. The composition for use of claim 115, wherein the disease or disorder comprises Huntington’s disease.

Images